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Autoinflammatory diseases are a group of conditions (often monogenic) that are characterised 
by episodes of inflammation driven by the innate immune system. One example is pustular 
psoriasis, a rare and severe disorder that manifests with the eruption of sterile pustules on 
erythematous skin. The condition has been classified into three subtypes, (generalised pustular 
psoriasis, acrodermatitis continua of Hallopeau and palmoplantar pustulosis), which can be 
distinguished based on the localisation and extent of skin lesions, and on the presence or 
absence of general symptoms.  
Previous genetic studies have identified variants in IL36RN, AP1S3 and CARD14 in a proportion 
of affected individuals. Such patients, however, account for fewer than 30% of disease cases. 
Moreover, the growing use of IL36RN sequencing as a diagnostic tool has raised issues relating 
to the interpretation of discovered missense variants.  
In this context, the aim of the project was to improve our understanding of pustular psoriasis 
genetics and phenotypic variability. 
In the first stage of the study, the analysis of an extended patient cohort (n=863) revealed 
clinical, demographic and genetic factors that differentiated palmoplantar pustulosis from the 
other forms of the disease. A significant (P = 0.003), dose-dependent association between 
IL36RN status and age of onset was also observed. 
In the second part of the research, a set of in-vitro assays were designed to measure the impact 
of IL36RN missense changes on protein function. Comparison with predictions generated by 
online tools demonstrated the classification errors which can arise when in-silico methods alone 
are utilised to assess missense changes. 
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Finally, the study sought to identify new genetic determinants for pustular psoriasis, by the 
means of whole-exome sequencing. Two candidate genes were uncovered and followed-up in a 
larger dataset. This highlighted the genetic heterogeneity of the condition as well as the 
importance of analysing representative control populations.  
Taken together, these findings have improved our understanding of known pustular psoriasis 
genes and paved the way for the identification of novel genetic determinants for the disease.  
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1.1 Pustular psoriasis 
The term pustular psoriasis encompasses a group of rare and severe neutrophilic skin disorders 
with overlapping clinical and genetic features. Consensus diagnostic criteria were lacking until 
recently, but the European Rare and Severe Psoriasis Expert Network (ERASPEN) has sought to 
address this issue (1). 
1.1.1 Clinical presentation 
All forms of pustular psoriasis are characterised by the appearance of macroscopic neutrophil-
filled pustules on the skin. These are non-infectious and form as a primary lesion, distinguishing 
the condition from those where pustules are infected (e.g. bullous impetigo) or form as a 
secondary feature (e.g. pustules within pre-existing psoriasis plaques) (1).  
Three subtypes of pustular psoriasis can be defined based on the location of pustules and the 
disease course (Figure 1.1, panels a-c). These are generalised pustular psoriasis (GPP), 
acrodermatitis continua of Hallopeau (ACH) and palmoplantar pustulosis (PPP, also known as 
palmoplantar pustular psoriasis). 
In all three variants, histological staining of affected skin shows neutrophil infiltration into 
necrotic epidermis, forming spongiform pustules of Kogoj (2) (Figure 1.1, panel d). These are 
accompanied by intraepidermal micropustules, parakeratosis and elongation of rete ridges (3,4). 
As pustules dry they may form brown scabs which gradually slough off, with the potential for 
fresh pustules to appear on the skin beneath (1,3). 
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Patients with pustular psoriasis may also suffer from plaque psoriasis. This is a more common 
and less severe skin disease that presents with well demarcated scaly red plaques. It affects 2-
5% of the world population, although the prevalence identified in national studies varies widely 
(3,5). 
1.1.1.1 Generalised pustular psoriasis 
According to the ERASPEN criteria, generalised pustular psoriasis can be diagnosed based on the 
observation of macroscopically visible, sterile pustules on non-acral skin. These lesions, which 
typically appear on erythematous skin, may then expand and coalesce to form lakes of 
superficial pus (1).  
Affected individuals can experience a relapsing (>1 episode) or persistent (>3 months) course of 
disease. In the former, flares are often accompanied by systemic inflammation, with patients 
exhibiting malaise, fever, neutrophilia, elevated levels of C-reactive protein, a high erythrocyte 
sedimentation rate (ESR) and neutrophilic cholangitis (6–8). This may result in intensive care 
admission for  treatment of dehydration, secondary infections and monitoring of organ function 
(1,3). In addition, patients may continue to experience symptoms such as chronic skin lesions 
and fatigue between flares, blurring the line somewhat between ‘relapsing’ and ‘persistent’ 
patients (9). The condition is therefore responsible for significant morbidity and, if systemic 
inflammation is not managed, it is potentially fatal (10,11). 
Data on the prevalence of generalised pustular psoriasis is limited, but reports have ranged from 
2 to 7 cases per million (4,12). Incidence is estimated at around 0.6-0.7/million (2,4). While the 
disease certainly has a genetic component (section 1.1.3), flares can be triggered by a variety of 
environmental factors. These include infections, pregnancy, drug exposure, stress, 
hypocalcaemia and withdrawal of corticosteroid treatment. Pustular flares that occur solely 
during pregnancy and often resolve rapidly after birth were previously known as impetigo 
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herpetiformis (1,12,13), now simply referred to as ‘GPP in pregnancy’. This is a particularly 
dangerous presentation of GPP, threatening the life of both mother and foetus (8). 
It has been reported that the presence or absence of a history of plaque psoriasis can define two 
subsets of GPP patients with differing genetic backgrounds, mean age of onset and 
environmental triggers (14,15). 
The presentation of GPP is very similar to that of acute generalised exanthematous pustulosis 
(AGEP). This is an adverse drug reaction presenting with a pustular flare and signs of systemic 
inflammation after, generally within 48hrs of exposure to certain medications (common triggers 
include aminopenicillins, sulphonamides, quinolones and pristinamycin). The flare resolves after 
the culprit drug is withdrawn and, crucially, does not reoccur in the absence of the trigger (16). 
Thus, the lack of spontaneous relapse in AGEP differentiates it from GPP (1). 
1.1.1.2 Localised forms of pustular psoriasis 
The rarest form of pustular psoriasis is acrodermatitis continua of Hallopeau, where pustulation 
is localised to the distal regions of fingers and toes, primarily affecting the nail apparatus (1). 
The disease may also result in loss of nails, destruction of the nail apparatus and osteolysis of 
the distal phalanx. It is a chronic (>3 months), slowly developing condition which causes severe 
pain and morbidity, resulting in functional and occupational disability. Prevalence and incidence 
data are not available due to the rarity of the disease (17). 
Palmoplantar pustulosis is also a chronic and localised disease, but here the pustulation is 
restricted to the palms and/or soles (1). Affected skin also exhibits erythema, hyperkeratosis 
and scaling (17). Pustulation may also spread to the digits, but a secondary diagnosis of ACH is 
only made if the nail apparatus becomes involved (1). As in the case of ACH, the condition has a 
significant effect on the quality of life of patients but is not life-threatening. 
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The prevalence of palmoplantar pustulosis is higher than that of generalised pustular psoriasis. 
The condition is also more common in Asia than Europe, with a reported prevalence of 
1200/million in Japan verses estimates of 100-500 cases/million in populations of European 
descent (18–20). Patients are predominantly female, with onset most common in middle-age 
(8,17).  
Some of the environmental factors contributing to the development of palmoplantar pustulosis 
are the same as those seen in generalised pustular psoriasis: infections, stress and drug 
exposure. However, other triggers include trauma, metal sensitivity and thyroid dysfunction. 
One of the most widely recognised risk factors for PPP is smoking, with many studies finding a 
high or very high prevalence of the behaviour amongst patients. Symptoms also improve upon 
cessation of smoking (17,21).  
Arthralgia and arthritis are relatively common extracutaneous co-morbidities and in some cases 
may be present in the context of Sonozaki syndrome or SAPHO (synovitis, acne, palmoplantar 
pustulosis, hyperostosis, osteitis) syndrome (8,21). 
Historically, palmoplantar pustulosis has been viewed as a subtype of plaque psoriasis, as 
patients often present with both conditions and/or a family history of plaque psoriasis and 
psoriatic arthritis (21). However, more recent genetic and demographic studies have revealed 





Figure 1.1 Clinical and histological presentation of pustular psoriasis 
The figure illustrates the widespread pustulation seen in generalised pustular psoriasis (GPP, 
panel a), involvement of nail apparatus seen in acrodermatitis continua of Hallopeau (ACH, panel 
b) and palm lesions seen in palmoplantar pustulosis (PPP, panel c). Panel d shows a histological 
cross-section of affected epidermis, showing neutrophil infiltration and spongiform pustule of 





Pustular forms of psoriasis are extremely difficult to treat. This is due, at least in part, to the 
rarity of the disease and the resulting lack of research into potential therapies. While cases are 
typically managed with medications that are used to good effect in plaque psoriasis, patient 
response is variable as these agents have a much lower efficacy in the pustular forms of the 
disease (9,17). 
The severe nature of GPP flares necessitates systemic and fast-acting treatment. The common 
choices for first-line therapy are therefore acitretin, methotrexate, cyclosporin or the TNFα 
inhibitor infliximab, with the latter two predominating in the most serious cases due to their 
rapid onset of effect. Second-line treatments include PUVA (psoralen plus ultraviolet-A) 
phototherapy, topical corticosteroids and TNFα blockers (e.g. etanercept, adalimumab). A 
combination of first-line oral systemics with second-line biologics may also be used, such as 
cyclosporin and etanercept or methotrexate and infliximab (17,23).  
While systemic steroids are usually avoided in treatment of GPP, due to the risk of relapse upon 
drug cessation, they can be prescribed when the disease presents during pregnancy. Labour may 
also be induced, as symptoms often improve rapidly after delivery. Acitretin, in contrast, should 
not be used in pregnant women as it can disrupt development of the foetus and cause birth 
abnormalities  (17). 
More recently developed biological agents targeting IL-1 (anakinra), IL-12/23 (ustekinumab) or 
IL-17A (secukinumab) have been used to successfully treat some GPP patients. Here the 
literature is more substantial (6), enabling Boehner et al. to review case series, case reports and 
clinical trials. Their study found evidence for a therapeutic potential of biologics, with the most 
robust data obtained for IL-17A blockers (9). These conclusions are however limited by small 
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patient numbers, the single arm/open label design of trials and the self-remitting course of GPP, 
and so must be interpreted cautiously. 
Treatment of localised pustular psoriasis (ACH and PPP) may take the form of topical or systemic 
therapies, or a combination thereof. While topical agents, such as corticosteroids under 
occlusion, calcipotriol, fluorouracil or tacrolimus, may initially be successful, patients usually 
relapse.  Systemic treatment is then required. This takes a similar form to the systemic therapies 
used in GPP, including cyclosporine, acitretin, TNFα blockers and biologics (17,23). However, 
symptoms are often recalcitrant to these therapies.  
While the rarity of ACH is preventing the implementation of controlled studies, the picture is 
slightly more positive for PPP, where  two clinical trials are currently assessing the efficacy of the 
IL-1 blocker anakinra (EudraCT 2015-003600-23, NCT01794117) and a third has been 
investigating the IL-17A blocker secukinumab (NCT02008890). Results from the anakinra studies 
are expected in February 2019 and December 2021 respectively. The secukinumab trial 
completed in May 2017 but did not meet its primary endpoint and found only weak evidence 
that the drug could be more effective than a placebo (24). This in turn would suggest a limited 
role for IL-17A in pathogenesis of PPP. 
Finally, recent advances in understanding of the genetic basis of pustular psoriasis have revealed 
new potential therapeutic targets. Central among these is the IL-36 signalling pathway (25), 
which is now being targeted by drugs undergoing early phase clinical trials (26,27). 
1.1.3 Genetic basis of the disease 
Disease-associated alleles have been identified in three genes: IL36RN, AP1S3 and CARD14. 
However, these account for only a minority of cases and so further genetic determinants remain 
to be identified. While familial aggregation of pustular psoriasis is sometimes seen, disease 
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presentation can vary widely between individuals of the same family and associations with rare 
disease alleles of large effect have not been observed. 
1.1.3.1 IL36RN 
IL36RN encodes the IL-36 receptor antagonist, IL-36Ra. This is a soluble molecule which 
competes with three agonists (IL-36α, IL-36β and IL-36γ) for binding to the IL-1Rrp2 cell-surface 
receptor. Upon engagement with IL-36α/β/γ, the receptor dimerises with a membrane-bound 
accessory protein, IL-1RAcP, forming a heterodimer known as IL-36R. This is followed by 
activation of the NF-κB and mitogen-activated protein (MAP) kinase pathways and expression 
of a range inflammatory genes, including IL8, IL1, IL6 and TNFα (28–30). Binding of IL-36Ra to 
IL1-Rrp2 does not cause dimerization with IL-1RAcP and so signalling via the receptor is 
prevented. 
The IL-36 receptor antagonist and IL-36γ share a β-trefoil structure (12 β-sheets connected by 
11 loops) that is characteristic of IL-1 family cytokines (31–33). As there is a high degree of 
sequence homology between all three IL-36 agonists, it is reasonable to assume that IL-36α and 
β have similar 3D structures. The regions that differ most between IL-36Ra and IL-36γ are the 
loops connecting β-sheet 4 to β-sheet 5, β6 to β7 and β11 to β12. Indeed, by exchanging the 
β4/5 loop in IL-36Ra for that of IL-36γ, the antagonist is converted to an agonist, albeit a weaker 
one than IL-36γ. Conversely, the long β11/12 loop in IL-36Ra is likely to sterically hinder 
interaction with IL-1RAcP (31).  
All IL-36 cytokines are produced as inactive precursor proteins, requiring N-terminal cleavage by 
proteases. For example, Cathepsin S cleaves only IL-36γ, but Cathepsin G cleaves IL-36α at Lys3 




Both IL-1Rrp2 and IL-1RAcP consist of three extracellular immunoglobulin-like domains and an 
intracellular Toll-interleukin 1 receptor (TIR) domain. The extracellular domains of IL-1Rrp2 form 
the ligand-binding pocket and also interact with IL-1RAcP to form the IL-36R complex. Detailed 
in-silico modelling and in-vitro experimental work indicated that within the extracellular region 
IL-1Rrp2 residues (e.g. Asn-41, Cys-42 and Cys-118) allow for specific recognition of IL-36α, -β or 
-γ (35).  
The NF-κB and MAP kinase pathways are likely to be activated through the recruitment of 
MyD88 and the Tollip-IRAK complex to the two TIR domains in the receptor complex (36), as this 
is the mechanism underlying the activation of the IL-1 receptor, which also dimerises with IL-
1RAcP. Indeed, MyD88 and Tollip have both been implicated in IL-36 signal transduction (37).  
While IL-1Rrp2 and IL-1RAcP will co-precipitate in the absence of IL-36, the addition of IL-36γ 
more than doubled the level of co-immunoprecipitation. If modified to lack the intracellular TIR 
domains IL-1Rrp2 and IL-1RAcP are secreted rather than trafficked to the cell membrane. 
However, they are still able to bind IL-36α/β/γ and the co-receptor and so act as dominant 
negative regulators of IL-36 signalling (35). 
IL36RN variants were first discovered by Onoufriadis et al. and Marrakchi et al., by the analysis 
of isolated and familial cases of GPP respectively (28,29). These authors also demonstrated that 
the variants impair IL-36Ra function, thereby upregulating IL-36 mediated signalling (Figure 1.2) 
and leading to an over-expression of key inflammatory genes (28,29). This correlated well with 
earlier work in mice, where absence of IL-36Ra in combination with expression of IL-36α in basal 
keratinocytes led to the development of a severe psoriatic skin phenotype with the addition of 
intracorneal and intraepithelial pustules (38). 
Subsequent studies have identified additional disease-associated alleles. These include 
missense, stop-gain, splice site and deletion variants, with 20 disease alleles currently listed on 
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the Infevers database (39). Of note, while the patients described in the Onoufriadis and 
Marrakchi papers carried homozygous IL36RN variants, those same alleles and others have since 
been seen in patients in the heterozygous state. This raises the possibility that heterozygous 
variants may be sufficient to cause disease in some individuals, or that in those patients they 
exist alongside another (yet to be identified) disease allele. 
While disease associated IL36RN alleles have been seen in all major ethnic groups, the frequency 
of individual variants varies between populations. In Asians, the most prevalent change is the 
c.155+6T>G splicing variant, whereas the p.Ser113Leu change is the most common in patients 
of European descent. 
Generalised pustular psoriasis patients who carry one or more IL36RN disease alleles collectively 
account for approximately 30% of cases (40,41). These individuals suffer from a more severe 
form of the disease, presenting with increased risk of systemic inflammation and earlier age of 
onset. IL36RN variants have been seen less frequently in palmoplantar pustulosis (<5% of cases) 
than in GPP, which has led some authors to question the association with this form of the disease 
(41–43). Finally, variants have been seen in cases of ACH, but again the rarity of the condition 
means estimates of frequency have thus far been difficult to calculate (41,44). 
As IL36RN screening is increasingly used as a diagnostic test for pustular psoriasis, it is essential 
that variants identified in patients are correctly classed as disease alleles or benign changes. 
The ongoing development of drugs to target IL36RN deficiency (section 1.1.2) adds to this, as it 





Figure 1.2 Signalling through the IL-36 receptor complex activates NF-κB and MAP kinase 
pathways 
In (A) the receptor antagonist IL-36Ra binds to IL-36R, which remains monomeric and inactive. 
In (B), IL-36α/β/γ binds to the receptor, which forms a complex with IL-1RAcP. MyD88, Tollip 
and IRAK are recruited to TIR domains and the NFκB and MAP kinase pathways are activated. 
This leads to expression of inflammatory genes. In (C), IL-36Ra is absent and so signalling via the 




AP1S3 encodes APσ1C, a small subunit of the AP-1 intracellular trafficking complex (45). Setta-
Kaffetzi et al. identified two disease-associated variants, p.Phy4Ser and p.Arg33Trp, through 
whole-exome sequencing of eight ACH patients and targeted screening in a follow-up cohort 
(46).  
This association has since been confirmed in a larger patient group (47). In addition, three 
affected individuals have been identified as carrying heterozygous disease alleles in both IL36RN 
and AP1S3. Interestingly, one of these patients suffered from a very severe GPP phenotype, with 
paediatric onset, systemic inflammation and limited drug response. In contrast, a sibling who 
carried only the IL36RN change experienced a much milder form of the disease (41,47). This 
suggests that AP1S3 variants may act as a modifier in the presence of IL36RN disease alleles. 
Variants in AP1S3 destabilise AP-1 by preventing the interaction between the small and medium-
sized subunits of the complex. This disrupts the formation of autophagosomes from the trans-
Golgi network, a process in which AP-1 is essential. Impaired autophagy in turn leads to a 
cytoplasmic accumulation of p62 (Figure 1.3). This is an NF-κB adaptor protein involved in 
intracellular signalling downstream of toll-like receptor 2/6 and the IL-1 receptor. As a result of 





Figure 1.3 The effect of damaging variants in AP1S3 on production of IL-36α. 
AP1S3 disease alleles lead to a disruption of autophagosome formation. This in turn causes 
accumulation of the NF-κB adaptor protein p62, which results in upregulation of multiple 
inflammatory genes, including IL36A. As a cytokine, IL-36α is able to activate IL-36 receptor-






Caspase Recruitment Domain Family Member 14 (CARD14) is a scaffold protein, expressed in 
keratinocytes, that is required for BCL10-MALT1 mediated activation of NF-κB signalling. Most 
CARD14 variants map to the coiled coil domain, which keeps the protein in a ‘closed’, inactive, 
conformation. Disease alleles disrupt this autoinhibitory structure and result in abnormal 
protein oligomerisation (48), which causes abnormal activation of NF-κB signalling (49) (Figure 
1.4). 
A missense variant, p.Asp176His, was first identified in Japanese patients with generalised 
pustular psoriasis and plaque psoriasis (50). Berki et al. subsequently found the same allele in 
patients of Chinese descent and confirmed the association with pustular psoriasis through a 
meta-analysis (48). Of note, nearby residues are affected by changes seen in patients with 
monogenic plaque psoriasis and pityriasis rubra pilaris (PRP) (51,52). Interestingly, multiple 
studies have demonstrated that some CARD14 gain of function variants lead to elevated 





Figure 1.4 An overview of CARD14 signalling 
In its inactive form, the 3D conformation of CARD14 prevents the CARD domain from 
interacting with BCL10. Following signals from toll-like receptors (TLRs), the IL-17 receptor and 
intracellular organelles such as the endoplasmic reticulum (ER), CARD14 is converted into its 
active form. The CARD domain can then recruit the BCL10-MALT1 complex, which is able to 
activate the NF-κB pathway. This leads to expression of pro-inflammatory genes including 
IL36G. Mutated forms of CARD14, indicated here by the red star, are constitutively active, 
leading to excessive NF-κB activation. Figure adapted from (54,55). CARD: caspase recruitment 
domain; CC: coiled-coil; MAGUK: membrane-associated guanylate kinase; BCL10: B-cell 
lymphoma/leukemia 10; MALT1:  mucosa-associated lymphoid tissue lymphoma translocation 
protein 1.   
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1.1.4 Disease immunopathogenesis 
Gene identification studies have clearly demonstrated that IL-36 signalling is a key driver in the 
pathogenesis of pustular psoriasis; disease alleles are known to affect the receptor antagonist, 
cause accumulation of IL-36 or result in aberrant activation of a downstream target, the NF-κB 
pathway. Transcription profiling of patient skin supported this conclusion, highlighting the 
dominant role of IL-36 cytokines, and more generally the innate immune system, in the 
development of the disease (25,56).   
A significant overlap has been demonstrated between differentially expressed genes (DEGs) in 
lesional GPP skin and those in keratinocytes stimulated with IL-36α, -β or -γ. (25,56). In addition, 
genes that are differentially expressed in GPP and upregulated by IL-36 (e.g. IL8 and S100A7) 
preferentially map to pathways related to infiltration of granulocytes, a characteristic feature of 
pustular psoriasis (25,56).  
A number of mouse models also demonstrate a key role for the IL-36 pathway in psoriasiform 
inflammation. Firstly, transgenic mice overexpressing Il1f6 (the murine ortholog of IL36A) in 
basal keratinocytes develop skin lesions with histological features seen in psoriasis, such as 
hyperkeratosis and leukocyte infiltration of the dermis and epidermis. When the animals are 
bred with homozygous or heterozygous Il1f5 (ortholog of IL36RN) knockouts, intracorneal and 
intraepithelial pustules appear within the skin lesions (38).  
Secondly, the application of the TLR7 agonist imiquimod on mouse skin causes, over several 
days, the appearance of psoriasis-like lesions with infiltration of neutrophils and macrophages 
(57). However, the infiltrate is absent in mice lacking the IL-36 receptor, while it is increased 3-
fold in Il1f5 knockout littermates (58).  
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Finally, in wild-type mice, pre-treatment with an antibody neutralising the IL-36 receptor 
significantly reduced the severity of imiquimod-induced psoriasiform lesions (25). Similarly, 
when human lesional skin was transplanted onto severe combined immunodeficiency (SCID) 
mice and then treated with an antibody blocking the IL-36 receptor, the psoriasis phenotype 
improved (59). 
Returning to human biology, proteases derived from neutrophils are responsible for the 
processing of IL-36 cytokines into an active state (34,56). Thus, IL-36/IL-8 mediated neutrophil 
recruitment leads to an increase in IL-36 activity at the site of inflammation. Interestingly, IL-36 
also contributes to the activation of dermal dendritic cells (DCs) and keratinocytes, leading to 
Th17 cell polarization and chemokine production, respectively (33). Thus, IL-36 cytokines drive 




Figure 1.5 The IL-36/Th17 axis in psoriatic inflammation 
Figure outlines key cytokines and cell types in development of inflammation driven by IL-36. 
Keratinocytes (KC) express IL-36, which can upregulate its own expression in a paracrine fashion, 
but also induce the expression of CCL20, and S100A7 and IL-8. While the former attracts Th17 
lymphocytes to the site of inflammation, IL-8 and S100A7 recruit neutrophils. These secrete 
proteases that convert secreted IL-36 into its active state. Finally, IL-36 activates dendritic cells 
(DC), leading to IL-23 secretion and polarization of T lymphocytes towards a Th17 phenotype. 
Figure adapted from (25).  
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1.2 Gene identification by next generation sequencing 
While early advances in gene discovery were made through the use of Sanger sequencing, 
progress since the late-2000s has been driven by the development of next-generation 
sequencing (NGS) technology, which simultaneously generates multiple sequence reads from a 
single DNA molecule. While individual reads may contain errors, the compilation of multiple 
sequences covering the same region enables NGS platforms to overcome this problem.   
1.2.1 Forms of next generation sequencing 
The various platforms for NGS can be separated into two categories by the length of the reads 
they are able to produce. Approaches that produce short reads have historically been cheaper 
and less error-prone, but long reads are preferable when attempting to sequence repetitive or 
otherwise complex regions of the genome (60). A summary of the platforms outlined below can 
be found in Table 1.1. 
1.2.1.1 Short read technologies 
While there are several different approaches which fall within this category, they all share some 
similarities in how the DNA is prepared for sequencing. First, the genomic material is fragmented 
and ligated to adapters, which anchor the DNA to the relevant surface and enable its 
amplification. Next, large numbers of clonal templates are generated, so that each fragment can 
be sequenced multiple times simultaneously (60,61). 
The most widely used platforms in NGS, to the extent that the market is effectively monopolised, 
are those produced by Illumina. These employ a ‘sequencing by synthesis’ approach with some 
similarities to Sanger sequencing, where the fluorophore-labelled deoxynucleotides (dNTPs) are 
3’-modified such that a subsequent base cannot be added. In contrast to Sanger sequencing, 
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however, there are no unmodified dNTPs. In this way, only one new nucleotide can be 
incorporated into each fragment per cycle. Total internal reflection fluorescence (TIRF) 
microscopy is used to identify the newly incorporated nucleotide and both the fluorophore and 
the terminator modification are then removed, a second distinction from classical Sanger 
sequencing where the modification is not reversible. A new batch of labelled dNTPs are then 
provided. With Illumina platforms, reads of up to 300bp are possible, with an overall accuracy 
of >99.5% (60,62). 
The Qiagen GeneReader platform uses a very similar approach to Illumina but is mainly applied 
to the screening of cancer gene panels. DNA fragments are also bound to beads in an emulsion, 
rather than a solid-phase surface (60). 
An alternative version of sequencing by synthesis does not use fluorescently labelled dNTPs. 
Instead, the IonTorrent platform (ThermoFisher) detects the H+ ion released upon incorporation 
of a nucleotide. As this ion is, obviously, the same regardless of the type of nucleotide, each base 
must be provided individually, removed and replaced by another. If there are multiple adjacent 
nucleotides of the same type in the DNA fragment, multiple nucleotides will be incorporated in 
one cycle and the H+ signal will be stronger (60,63).  
In the Roche 454 pyrosequencing platform, the incorporated nucleotide triggered an enzymatic 
reaction that led to the production of light. These models, however, were discontinued in 2016 
(60). 
Finally, a different approach to generating short reads is ‘sequencing by ligation’. There are two 
platforms that use this: SOLiD (Life Technologies) and Complete Genomics. Their key feature is 
an oligonucleotide probe formed from one (Complete Genomics) or two (SOLiD) known bases 
attached to an anchor fragment (i.e. a series of universal or degenerate bases). When the probe 
hybridises with the DNA strand, the anchor fragment is ligated, and the known base(s) are 
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imaged by detection of fluorophore(s) (64,65). However, these platforms are unpopular, despite 
high accuracy, due to very short read length (maximum 75-100bp) (60).  
1.2.1.2 Long read technologies 
These are sometimes referred to as ‘third generation’ technologies, as they have only come onto 
the market in the past seven years (66).  
The first platform was developed by Pacific Biosciences (PacBio) and utilises a ‘single-molecule 
real-time’ (SMRT) approach. This is now capable of producing reads of up to 2kb and while the 
error rate is high (13%), the DNA molecules can be sequenced multiple times, increasing the 
overall accuracy. The technique still utilises fluorescently labelled nucleotides, but their 
incorporation is visualised in real time. In addition, epigenetic modifications can also be detected 
as they result in an extended interval between incorporations (60,66,67).  
Oxford Nanopore Technologies (ONT) have developed sequencers where there is (theoretically) 
no limit to the length of the DNA molecule that can be sequenced, if the template is of 
sufficiently high quality. Currently, reads of up to 1Mb have been achieved and so the technology 
is particularly useful for sequencing long, highly repetitive regions of the genome (66).  
The DNA is translocated through a protein nanopore, through which a current is also passed. As 
the molecule passes through the pore, it disrupts the current in a characteristic pattern. The 
instrument can distinguish between over 1000 different k-mers and, depending on the type of 
pore used, detect different epigenetic modifications (66,68). 
An issue with nanopore technology is the high error rate (around 15%), but this can be reduced 
by usage of specialised adaptors that allow the sequencing of both strands in one read (known 
as the 1D2 system). The downside of this is that it doubles the length of time required to 
sequence the molecule (60,66). 
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Synthetic long read (SLR) technology is a modification of more traditional short-read approaches 
that facilitates a more reliable assembly of adjacent fragments. Two companies have released 
SLR systems: Illumina and 10X Genomics. Briefly, large DNA fragments are partitioned into 
microtiter wells or an emulsion such that each sample contains very few fragments. Within the 
partition, the large fragments are sheared and barcoded. After sequencing on a typical short-
read platform, the barcodes are used to assemble reads originating from the same large DNA 
fragment. This method is high throughput and has higher accuracy than true long read 
approaches, but as it requires a PCR step it suffers from some of the biases (e.g. poorer coverage 










Table 1.1 Comparison of NGS technologies 
Platform1 Read length (base pairs) Throughput Accuracy Pros Cons 
Illumina Up to 300 Up to 900Gb >99.5% 
















200-400 10 – 15Gb 99% 
Read length, shorter run-
time 




400-700 35 – 700Mb 99% N/A: discontinued in 2016 
cPal 
(Complete Genomics) 
50-100 8 – 200Gb 99.99% High accuracy Short read length 
SOLiD 
(Life Technologies) 
75 80 – 320Gb 99.99% High accuracy Short read length 
PacBio  
(Pacific Biosciences) 
10-15Kb 5 – 10Gb 
~99.999% at 20 
passes 
Detects epigenetic 
modifications, high accuracy 
Expensive, large amount 
of DNA required 





Dependent on quality of 
template, current max 1Mb 
20Gb-6Tb 
~85%, up to ~97% 
with 1D2 system 
Detects epigenetic 
modifications, cost effective 
High error rate, large 
amount of DNA required 
TruSeq SLR (Illumina) ~10Kb synthetic length 650Gb – 1.5Tb >99.5% Uses pre-existing platforms 
PCR-based, same biases 
as classic short-read seq 
10X Genomics 
Up to 100Kb synthetic 
length 
800Gb – 1.8Tb >99.5% 
Small amounts of DNA 
required 
PCR-based, same biases 
as classic short-read seq 




1.2.2 Applications of next generation sequencing 
Next generation sequencing has numerous applications that are ideally suited to the study of 
gene regulation. ChIP-seq, for example, is a popular method of investigating DNA-protein 
interactions. This involves cross-linking DNA to relevant proteins (such as histones), shearing the 
DNA, capturing protein-bound fragments and then sequencing them (69). A more recently 
developed technique is the assay for transposase-accessible chromatin (ATAC-seq), which allows 
genome-wide profiling of chromatin accessibility. A modified transposase cuts the DNA in 
accessible regions and ligates sequencing adaptors, after which the resulting fragments undergo 
NGS. The ends of fragments therefore correspond to regions of accessible chromatin (70).  
NGS can also be used to profile global gene expression by means of RNA-seq, where RNA is 
converted to cDNA, sheared and sequenced. The number of reads per gene is normalised 
relative to reads per kilobase per million (RPKM) (71). By comparing these in treated and 
untreated cells or in cases vs. controls, it is possible to identify the genes that are differentially 
expressed between two groups of samples.  
However, the most common application of NGS is in the rapid and accurate sequencing of whole 
genomes or exomes. NGS has therefore massively increased the potential for identification of 
disease-associated variants, both in monogenic and complex conditions. It not only allows more 
comprehensive screening of patient DNA but has also enabled population-wide sequencing 
efforts (e.g. 1000 Genomes Project (72), Exome Aggregation Consortium (73), Genome 
Aggregation Database (73)).  
These have provided researchers with insights into human variation and allowed comparisons 
between the genomes or exomes of patients and those of healthy individuals of comparable 
ethnicity. While this can enhance the power of association studies, it is important to bear in 
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mind that allele frequencies derived from public databases may be biased as a result of 
population structure. The usage of different platforms and analytical pipelines in cases vs  
controls can also be a confounding factor, leading to artificially inflated P values (74,75).  
1.2.3 Processing next generation sequencing data 
Whole-exome sequencing (WES) has played an important role in the identification of both 
IL36RN and AP1S3 as genes that are associated with pustular psoriasis. WES analyses only the 
coding regions of the genome, which are captured by in-solution hybridisation of RNA probes.  
The raw data produced by WES must go through a series of processing and quality control steps 
before an attempt is made to prioritise candidate disease variants. As the data is generated, it 
is stored in FASTQ format files, which contain both the sequence of nucleotides and a quality 
score for each base (75). This is on the Phred scale (1-60) and is calculated as:  
-10log10(P(incorrect base call)) 
A quality control step is then undertaken using tools such as FastQC, which identifies any low-
quality bases (generally Phred <20, i.e. P(incorrect call) >1%) to be trimmed from the reads, 
together with the adapters (75–77). 
Next, the reads are aligned to a reference genome. Again, there are many available tools, 
including Bowtie2 and Novoalign. The data is then assessed and processed for a second time, to 
remove read duplicates (which may be PCR artefacts), improve alignments in regions containing 
insertions or deletions (INDELs) and recalculate the base quality scores (75). 
Finally, a programme such as SAMtools is used to call sequence variants by identifying 
nucleotides that differ from the reference genome in a sufficient number of reads. These 
changes are then annotated to known genes (e.g. with ANNOVAR). Additional information such 
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as the variant zygosity, its population frequency and predicted impact are added at this stage. 
This data can then be used, alongside prior knowledge of the disease or family history, to 
prioritise the changes that are most worthy of follow-up (75). 
For the purposes of identifying candidate disease alleles, the first step in variant prioritisation is 
generally to remove synonymous substitutions. Another key consideration is whether the mode 
of disease inheritance is likely to be dominant or recessive, and therefore whether the variant(s) 
of interest are likely to be heterozygous or homozygous. If there is sufficient evidence for one 
or the other, it may be appropriate to restrict the analysis to variants with the relevant zygosity 
(78). 
Next, changes with a minor allele frequency (MAF) that exceed a certain value are removed. 
While the most appropriate cut-off depends on the prevalence of the disease and the expected 
penetrance of the mutation, variants with MAF >1-5% are generally regarded as common and 
excluded from subsequent analysis (78). As described above, data from population-wide WES or 
WGS is normally used to provide control MAFs. The frequency of rare alleles, however, can vary 
widely between ethnic groups (79), so it is important that, where possible, MAFs from the 
appropriate population are used. 
Where applicable, subsequent filtering steps may include retaining only variants shared 
amongst affected family members or with other unrelated patients. A recent publication also 
demonstrated the value in removing variants commonly seen in private cohorts, even if ‘rare’ in 
publicly available datasets, as a method of reducing the number of non-pathogenic variants (80). 
It may also be useful to consider tissue-specific gene expression patterns or to prioritise variants 
based on the results of in-silico pathogenicity predictions (section 1.3) (75,78). However, such 
filtering steps must be carried out carefully as they rely on the accuracy of underlying 
assumptions and the performance of pathogenicity algorithms. 
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Finally, it is important to check the quality of reads covering the prioritised variants and perform 
Sanger sequencing of the region, to confirm that the variant base call is not an artefact 
introduced during the NGS process. 
1.2.4 Advantages and limitations of whole exome sequencing 
A major advantage of WES is that it is focussed on coding sequences. This makes the data easier 
and quicker to analyse, with candidate variant lists likely to be shorter. Additionally, there are 
now a multitude of in-silico tools which aim to predict the effects of coding variants (section 
1.3.3), allowing for the prioritisation of changes with pathogenic potential. In contrast, the 
consequences of variants located in non-coding regions covered by WGS can be much harder to 
decipher. Whole exome sequencing is also cheaper, so a greater number of samples can be 
sequenced for the same amount of money (60,74). 
However, the targeted nature of WES inevitably means that regulatory changes will be missed 
as these generally lie in non-coding regions. Whole exome sequencing is also inferior compared 
to WGS when it comes to identifying structural alterations such as copy number variants (CNVs). 
Reads from a duplicated locus, for example, would likely be mapped to the single copy in the 
reference sequence. In contrast, WGS data from the same region (particularly if generated on a 
long-read platform) would contain reads that cover both coding and intergenic regions, allowing 
detection of the two independent copies of the gene. 
Finally, a key variable in the process of WES is the step where the exome DNA is prepared for 
sequencing. Several hybridisation kits are commercially available, but none are able to capture 
100% of the exome. As a result, some target regions will be missing and others will be 
insufficiently covered (74).  
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Recently, Cummings et al. demonstrated that combining WES/WGS with RNA-seq of a disease 
relevant tissue (here skeletal muscle in muscular dystrophy or myopathy) can compensate for 
some of the limitations of WES and overcome some of the difficulties associated with the 
interpretation of non-coding changes. For example, they were able to detect an intronic variant 
within COL6A1 and demonstrate that it results in abnormal splicing. They also uncovered a 
substitution in a region of the NEB gene that had not been captured during WES sample 
preparation, and demonstrated that the change disrupted a canonical splice site, causing an 
extended exon (81). 
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1.3 Limitations of in-silico approaches to pathogenicity prediction 
The average human exome diverges from the reference sequence at 20,000 – 23,000 sites. 
Around half of these differences are non-synonymous, with loss-of function (LOF) changes 
(INDELs, variants disrupting canonical splice sites or introducing premature stop codons) 
affecting 250 – 300 genes (72). More stringent analysis has suggested that the typical exome 
harbours ~100 genuine LOF mutations, resulting in the full inactivation of ~20 genes (82). It is 
therefore clear that most of the variation affecting the human genome is not disease causing. 
This is especially the case for missense single nucleotide variants (SNVs). In fact, the average 
individual included in the Exome Aggregation Consortium (ExAC) carries 54 alleles which are 
reported as disease causing in the Human Gene Mutation Database and/or ClinVar. However, 
41 of these changes have an allele frequency greater than 1% in at least one ethnic group, 
suggesting that they are unlikely to be responsible for a rare Mendelian condition (73). As the 
genotyping of these sites was of high quality, the conclusion was reached that the inflated 
frequency of ‘disease causing’ variants was due to classification errors. 
1.3.1 Issues raised by variants of unknown significance 
Mutation screening may be utilised in clinical settings for the purposes of diagnosis, targeted 
treatment or genetic counselling. While this can be a rapid and powerful approach if the disease 
allele(s) have already been validated, interpreting newly identified changes is less 
straightforward (83,84). Even if a gene (such as IL36RN) has been robustly identified as disease-
associated, there is a risk that subsequent rare variants will be labelled as disease-causing on 
the basis of otherwise weak evidence. As NGS-based panels are more frequently used for 
diagnostic screening and the number of variants seen in a given patient has increased (85), this 
has become very significant problem. 
52 
 
Similar difficulties present themselves in research settings, where a cohort of patients may 
undergo whole exome/genome sequencing with a view to identifying disease-associated 
changes (see section 1.2.2).  While successful gene discovery can lead to a better understanding 
of disease pathogenesis (as has been demonstrated in pustular psoriasis (25,28,46,48)), the 
analysis of exome profiles is not straightforward. Pathogenicity predictions are key to the 
filtering of variants, so if the conclusions drawn from in-silico tools are inaccurate, the chances 
of identifying disease genes are severely compromised.  
A major question therefore presents itself: as NGS is increasingly used in diagnostic and research 
settings, and the number of variant alleles inevitably grows, how can the truly pathogenic 
variants be efficiently and reliably identified? 
1.3.2 Classification of variants of unknown significance 
In 2015 the American College of Medical Genetics and Genomics (ACMG) and the Association 
for Molecular Pathology (AMP) published an extensive set of guidelines designed to standardise 
the clinical interpretation of genetic changes (86). They recommended using a five-tier system 
whereby variants are classified as pathogenic, likely pathogenic, of uncertain significance, likely 
benign or benign. Changes are placed into one of these five categories on the basis of 28 
different criteria, outlined in Table 1.2 and Table 1.3. The tables also illustrate the range of 
information which may be accessed when attempting to classify a variant, from the results of 
functional studies, to those of familial segregation analysis and computational predictions.  
The ACMG-AMP guidelines were expanded upon two years later, when a more standardised 
approach to applying the classifications was proposed and formalised into the InterVar tool (87). 
This was deemed necessary due to discrepancies in the conclusions reached by different 
researchers applying the guidelines to the same variants. The discordance in classification is in 
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part due to the complexity of the guidelines themselves. There is also the issue of personal bias 





















 Same amino acid change as established pathogenic variant, 
regardless of nucleotide change 
 PS2  De novo in patient with no family history 
 
PS3 
 Well-established in-vitro/in-vivo functional evidence of 
damaging effect on gene/gene product 
 
PS4 
 Variant is significantly more prevalent in cases than 




 Located in mutational hotspot and/or critical functional 
domain that lacks benign variation 
 
PM2 
 Absent from controls in ESP4, 1000 Genomes or ExAC (or 
extremely low frequency if recessive) 
 
PM3 
 If recessive disorder: detected in trans with pathogenic 
variant 
 PM4  Protein length changed by in-frame INDEL/stop loss variant 
 
PM5 
 Novel missense change causing amino acid change at 
residue where different amino acid change is pathogenic 




 Variant gene known to cause disease cosegregates with 
disease in multiple affected family members 
 
PP2 
 Missense variant in gene where missense variants are 
common mechanism of disease and with low rate of benign 
variation 
 PP3  Multiple lines of supporting computational evidence 
 
PP4 




 Recently reported as pathogenic by reputable source, but 
independent evaluation not possible 
1Adapted from (86); 2Loss of function; 3Odds ratio; 4Exome Sequencing Project 
55 
 







Stand-alone  BA1  Frequency >5% in ESP2, 1000 Genomes or ExAC 
Strong 
 BS1  Frequency greater than expected for disorder 
 
BS2 
 Observed in healthy adult individual with relevant zygosity, 
when full penetrance expected at early age 
 
BS3 
 Well-established in-vitro/in-vivo functional evidence of no 
effect on gene/gene product 




 Missense variant in gene where truncating variants known 
to cause disease 
 
BP2 
 Seen with pathogenic variant in trans (dominant 
inheritance) or in cis (any inheritance) 
 
BP3 




 Multiple lines of computational evidence suggest no 
impact 
 BP5  Found in case with alternate molecular basis for disease 
 
BP6 
 Recently reported as benign by reputable source, but 
independent evaluation not possible 
 
BP7 
 Synonymous variant with no splicing impact and 
nucleotide is not highly conserved 
1Adapted from (86); 2Exome Sequencing Project  
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1.3.3 Commonly used pathogenicity prediction tools 
The authors of the ACMG-AMP guidelines noted that their recommendations are of limited 
utility when evaluating alleles identified in research settings, as the criteria assume that the gene 
in which the variant lies has already been associated with the condition under investigation (86). 
Where the disease gene is not known, or where the association is established but there is limited 
scope to generate in-vitro/vivo data on a new allele, pathogenicity prediction tools provide a 
relatively easy way to assess variants. 
Predicting the effect of variants in splicing regions is fairly simple, because there are known 
consensus sequences. Popular tools include Spliceman, MaxEntScan and Human Splicing Finder, 
all of which compare consensus and variant sites (88–90). If the difference between the two 
exceeds a certain threshold, the change is deemed to disrupt splicing. 
In contrast, determining the pathogenicity (or lack thereof) of missense changes is more difficult. 
A wide range of tools have been designed which attempt to predict the effect of these alleles, 
but all have weaknesses.  
One of the oldest, and still used, pathogenicity prediction tools is SIFT (Sorting Intolerant From 
Tolerant). This algorithm is based solely on evolutionary conservation, with the rationale that a 
change in a highly conserved amino acid is more likely to have a damaging effect. For a given 
protein sequence, a set of functionally related proteins is compiled using PSI-BLAST and the 
sequences aligned. SIFT then calculates the scaled probability of seeing any of the 20 possible 
amino acids at each position. Substitutions with a scaled probability value below a threshold 
(normally 0.05) are classed as damaging (91). 
Another tool based on a similar approach is PROVEAN (Protein Variation Effect Analyzer), 
although this algorithm also takes into account the conservation levels in the sequences flanking 
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the variant. It is therefore able to assess the effects of INDELs and multiple substitutions, in 
addition to SNVs. The PROVEAN score is an average of delta alignment scores from pairwise 
alignments between the variant sequence and the wild type and related sequences. It is then 
compared to a threshold (normally -2.5), with variants that have a score below this classed as 
deleterious (92). 
PolyPhen-2 is a more advanced tool, created using a naïve Bayes classifier. This is a simple 





This calculates the probability of A happening if B has already occurred, e.g. the probability of a 
variant being pathogenic given a set of information about that nucleotide change. The term 
naïve indicates that the algorithm assumes all conditions (sources of information about the 
variant) are independent. While this is not the case in reality, the algorithm is still sufficiently 
powerful to make valid predictions, especially as the input includes a wide range of features, 
including sequence alignments but also structural information and protein site/region 
annotation (93).  
PolyPhen-2 was created by training the algorithm on a dataset where both the input (data on 
conservation, protein annotation, etc) and the output (variant classification) was provided. Two 
versions of the tool are currently available. One (HumDiv) was trained on alleles annotated in 
UniProt as causing Mendelian diseases and affecting protein function or stability, while the other 
(HumVar) used all disease-causing mutations from UniProt. Both training sets also included 
several thousand variants that were assumed to be nondamaging. As a result, the HumDiv model 
is more appropriate for the analysis of variants in Mendelian diseases, while HumVar should be 
used when a more complex genetic aetiology is suspected (94). 
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MutationTaster is also built on a naïve Bayes classifier and integrates information from a range 
of sources. Unlike SIFT, PROVEAN and PolyPhen-2, it can also be used to assess variants affecting 
splicing consensus sequences. The tool uses one of three different prediction models, depending 
on whether the variant is synonymous/intronic, affects a single amino acid or causes more 
complex changes to the sequence (95). 
One of the more complex and commonly used tools is CADD (Combined Annotation-Dependent 
Depletion). In developing the program, annotations from a diverse range of sources (e.g. 
conservation measures, location of DNase I hypersensitivity regions, expression levels, results 
from other pathogenicity prediction tools) were collated for 14.7 million high-frequency human 
alleles and from the same number of simulated variants. The assumption was that damaging 
variants would be depleted from the set of common, naturally occurring alleles but present in 
the simulated dataset. A support vector machine was trained to differentiate between these 
two variant sets and a C score was then precomputed for all possible single nucleotide variants 
in the human exome (96). 
Clearly, all tools rely on assumptions about the effect of a variant, such as the importance of 
individual residues within a protein domain, or how a residue change may affect secondary and 
tertiary structures. Many are also reliant on the accuracy of pre-existing annotation and 
experimental data and most have a limited ability to predict the scale of the effect caused by a 
variant and are limited to analysing variants in isolation rather than taking into account the 
potential effect of multiple changes.  
Unsurprisingly, the more basic pathogenicity prediction algorithms have the most limitations. 
Primarily, those which only examine evolutionary conservation cannot exploit information on 
the structure or function of the protein region that is affected by the variant. Their reliability is 
also limited by the availability of evolutionarily related sequences. 
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However, newer machine-learning tools also have well-established weaknesses. Specifically, 
they are vulnerable to bias as a result of type 1 or type 2 circularity. The former occurs when a 
variant being examined by a tool was present in the training set, which may result in overfitting 
(the tool is well suited to the training dataset but performs poorly on novel variants). Type 2 
circularity occurs when a variant is assessed based on the annotated pathogenicity of other 
variants in the same genes. The problem with this approach is that the distribution of pathogenic 
variants in online databases is biased, with most damaging substitutions found within a relatively 
small number of genes. It is also common for all variants within a gene to be annotated with the 
same status. Therefore, tools will have limited ability to identify damaging variants in an 
unannotated gene and incorrectly classify variants that fall within a gene with mixed annotation 
(97,98).  
Machine-learning based tools also tend to periodically update their algorithms, which can lead 
to changes in variant classification. This can cause problems in both research and diagnostic 
settings and raise some important questions: How often should the classification be rechecked? 
At what point in the analysis should the results be considered ‘fixed’? 
1.3.4 Utility of existing pathogenicity prediction tools 
As described above, pathogenicity prediction tools are particularly vulnerable to biased usage 
and interpretation. There are many of these tools freely available online, and each promises 
advances in accuracy and precision over its predecessors. However, it is those that are easier to 
operate (e.g. SIFT, PolyPhen-2 and CADD) that tend to dominate in published research (98). 
Importantly some tools are based on shared assumptions and theoretical frameworks (e.g. both 
SIFT and PROVEAN predictions are solely based on conservation, data from PolyPhen-2 was used 
when training the CADD classifier). Thus, their results should not be considered as independent 
pieces of evidence (86). Nonetheless, computational predictions may be all that is readily 
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available to assess a newly identified variant and so efforts must be made, where possible, to 
mitigate some of their inherent biases and weaknesses. 
One option is to assess a variant with multiple, genuinely independent tools and build a 
consensus classification. However, a study by Ghosh et al found that the combination of tools 
that best differentiates pathogenic alleles from variants of unknown significance (VUS) performs 
less well in discriminating VUS from benign changes. The same authors also found that the 
discordance between tools can cause genuinely benign or pathogenic variants to be erroneously 
classed as VUS (98). 
Another approach that has been explored is to tailor thresholds for pathogenicity within 
individual algorithms to the gene being examined. In fact, a study of the Human Gene Mutation 
Database (HGMD) demonstrated very limited overlap between CADD scores associated with 
disease alleles in different genes (99). This suggests that using a fixed cut-off to determine 
pathogenicity will result in increased rates of false-positives or false-negatives, depending on 
the gene in question. The difficulty with designing gene-specific thresholds is that a set of true 
mutations and benign variants in the gene must already be known.  
Ultimately, however, the conclusions that can be drawn from pathogenicity prediction tools 
alone are limited. The addition of even simple functional assays allows for far more reliable 
variant classification. Guidugli et al used this approach to assess the clinical relevance of 
missense variants in the DNA binding domain (DBD) of BRCA2, combining a homology-directed 
DNA repair (HDR) assay with in-silico predictions. This enabled them to build a classifier that 
could be used to predict the effect of new missense variants affecting the DBD (100). In another 
study, a PPARG variant classifier was built after assessing the effects of all possible amino acid 
substitutions (101), using a high-throughput assay.  
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It is therefore clear that the integration of functional and computational methods is the best 






Pustular psoriasis is a rare disease. As a result, patient cohorts and the conclusions drawn from 
them are limited to some degree by size. Moreover, while IL36RN screening is increasingly used 
as a diagnostic test, its clinical utility is limited by the genetic heterogeneity of the disease and 
the difficulty of predicting the impact of newly identified sequence variants. 
In this context, the study pursued three key objectives, with a view to improving our 
understanding of pustular psoriasis and facilitating its genetic diagnosis: 
1.  To identify phenotypic and genetic features that can be used for the 
stratification of patient cohorts. This was achieved through the systematic analysis of 
clinical and genetic data collated from a large study resource. 
2. To characterise functionally all published IL36RN missense changes, using in-
silico and in-vitro methods. A selection of rare substitutions of uncertain significance 
was also included in this analysis, to determine whether the results obtained from 
known disease alleles could be used to predict the status of as-yet unclassified variants.  
3. To identify novel candidate genes for the disease, by analysing whole exome 
data from patients with a rare phenotype (acrodermatitis continua of Hallopeau) or 






2 Materials and Methods 
2.1 Materials 
Reagent Manufacturer Catalogue number 
100bp DNA Ladder New England BioLabs N3231S  
10X DreamTaq buffer Thermo Scientific EP0703 
Acrylamide mix Geneflow Limited EC-890 
Agarose Severn Biotech 30-10-60 
Amersham ECL Western Blotting 
System 
GE Healthcare RPN2232 
Ammonium acetate Sigma-Aldrich A2706 
Ammonium persulfate Sigma-Aldrich A3678 
Ampicillin Sigma-Aldrich A0166 
Autoradiography film Fujifilm 12715325 
Bacto-Agar BD Diagnostics 214010 
Bacto-Tryptone BD Diagnostics 211705 
Bacto-Yeast BD Diagnostics 212750 
BigDye Terminator Sequencing buffer Applied Biosystems 4336697 
BigDye Terminator v3.1 Applied Biosystems 4337454 
Bromophenol blue Sigma-Aldrich B5525 





cOmplete™, Mini, EDTA-free Protease 
Inhibitor Cocktail 
Sigma-Aldrich 11836170001 
DMSO Sigma-Aldrich D8418 
dNTP nucleotides Fisher Scientific 10520651 
DreamTaq DNA polymerase Thermo Scientific EP0703 
Dulbecco’s Modified Eagle Medium 





EDTA VWR/BDH  
Ethanol VWR 20821.330 
Ethidium bromide Sigma-Aldrich E1510 
Foetal Bovine Serum (FBS) Gibco 10500064 
GeneJET RNA Purification Kit Thermo Scientific K0731 
Glycerol Sigma-Aldrich G7893 
Guanidinium hydrochloride Sigma-Aldrich G7294 
Hi-DiTM Formamide Applied Biosystems 4311320 
HiSpeed Plasmid Maxi Kit QIAGEN 12663 
HiSpeed Plasmid Midi Kit QIAGEN 12643 
Human B2M (Beta-2-Microglobulin) 
Endogenous Control (VIC™/MGB™ 
probe, primer limited) 
Applied Biosystems 4326319E 
Human IL-8/CXCL8 DuoSet ELISA kit R&D Systems DY208 
Human PPIA (Cyclophilin A) 
Endogenous Control (VIC™/MGB™ 
probe, primer limited) 
Applied Biosystems 4326316E 
IGEPAL Sigma-Aldrich I3021 
illustra ExoProStar 1-Step GE Healthcare/Fisher 
Scientific 
11961411 
Isopropanol   
Kanamycin Sigma-Aldrich K1377 
KAPA SYBR qPCR Master Mix Sigma-Aldrich KK4604 
Laemli dye 0.375 M Tris-HCl (pH 6.8) 
9% (v/v) SDS 
50% (v/v) Glycerol 
5% (w/v) β-mercaptoethanol 
0.03% Bromophenol Blue 
n/a 
LB agar 1% (w/v) NaCl 
1% (w/v) Bacto-Tryptone 
0.5% (w/v) Bacto-Yeast 
1.5% (w/v) Bacto-Agar 
n/a 
LB medium 1% (w/v) NaCl n/a 
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1% (w/v) Bacto-Tryptone 
0.5% (w/v) Bacto-Yeast 
Lipofectamine™ 2000 Transfection 
Reagent 
Invitrogen 11668027 
Loading buffer 3% Glycerol 
2.5% (w/v) Bromophenol blue 
ddH20 
n/a 
Monoclonal Anti-β-actin antibody Cell Signalling Technologies 4967S 
Monoclonal Anti-c-Myc antibody Santa-Cruz 9E10 
PVDF transfer membrane Roche 03010040001 





PBS Gibco 10010015 
pcDNA3 vector Professor Asma Smahi n/a 
pCMV6 entry vector Origene n/a 
Penicillin-Streptomycin Gibco 15140122 
Polyclonal Anti-Mouse antibody Agilent/Dako P0447 
Polyclonal Anti-Rabbit antibody GE Healthcare NA934V 
Ponseau S red dye Sigma-Aldrich P3504 
Precipitation solution 95% Ethanol 
0.12M NaOAc (pH 4.6) 
n/a 
Precision nanoScript2 Reverse 
Transcription kit 
PrimerDesign n/a 
PrecisionPlus SYBR and ROX qPCR Mix PrimerDesign n/a 
Proteinase K Sigma-Aldrich P2308 
QIAPrep Spin Mini Kit QIAGEN 27104 
QuikChange Lightening Site-Directed 
Mutagenesis Kit 
Agilent 210518 
Recombinant Human IL-36 alpha/IL-
1F6 (aa 6-158) Protein 
R&D Systems 6995-IL-010 
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RNaseZap™ RNase Decontamination 
Solution 
Invitrogen AM9780 
RPMI 1640 Medium Gibco 21875034 




SDS Sigma-Aldrich L4509 
Skimmed milk powder Tesco n/a 
Sodium acetate Sigma-Aldrich S8625 
Sodium chloride (NaCl) VWR chemicals 27810.295 
TaqMan™ Universal Master Mix II Applied Biosystems 4440040 
Tris-buffered saline (TBS) 1.5 M NaCl 
0.2 M Trizma-base 
n/a 
TEMED Sigma-Aldrich T9281 
Transfer buffer 250mM Trizma-Base 
1.92M Glycine 
n/a 
Tris-EDTA (TE) 0.1 mM EDTA 
10 mM Tris-HCl 
n/a 
Tris-HCL Sigma-Aldrich T2569 
TrypLE™ Express Enzyme (1X) Gibco 12605010 
Tween 20 Sigma-Aldrich P7949 
β2M PrimerDesign probe PrimerDesign 54684 
β-mercaptoethanol Sigma-Aldrich M-3148 
Trizma-Base Sigma-Aldrich T1503 
Glycine Sigma-Aldrich G7126 
10X Tris-Borate-EDTA (TBE) Geneflow Limited B9-0020 





2.2 Study resource 
2.2.1 Ethical approval 
This study was carried out in accordance with the Declaration of Helsinki. Patients were 
recruited as part of the FAP (Functional Annotation of Psoriasis susceptibility alleles) study, 
which was approved by the London - Chelsea Research Ethics Committee (reference 
14/LO/2169, 20th January 2015) or the PLUM (Pustular psoriasis: eLucidating Underlying 
Mechanisms) study, which was approved by the London - London Bridge Research Ethics 
Committee (reference 16/LO/2190, 30th January 2017). A small subset of PPP patients were 
ascertained through the APRICOT (Anakinra for Pustular psoriasis: Response in a COntrolled 
Trial) clinical trial, which was granted ethical approval on 1st April 2016 and assigned EudraCT 
number 2015-003600-23. The ethics committees of collaborating institutions also granted the 
required approvals for this study. All patients provided informed written consent for the use of 
their DNA and clinical data. 
2.2.2 Patient ascertainment  
This study examined a total of 947 cases of pustular psoriasis, including 6 families, each with two 
affected individuals. Table 2.1 displays summary information on the isolated cases and further 
information on familial cases is provided in Table 2.2. Differing subsets of patients were utilised 
throughout in the study; the demographics of these groups are outlined alongside the relevant 
results. 
All patients were assessed by trained dermatologists and clinical information was recorded in a 
standardised case report form, included in Appendix 1. Pustular psoriasis was diagnosed and 
classified based on clinical examination, with the criteria set out by the European Rare And 
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Severe Psoriasis Expert Network (ERASPEN) (1) used in 581 cases. Subject ethnicity was self-
declared. 
2.2.2.1 British and Irish pustular psoriasis patients 
A total of 329 patients (39 GPP, 7 ACH, 264 PPP and 19 with multiple forms of the disease) were 
recruited through British or Irish centres (St John’s Institute of Dermatology, London; University 
of Manchester; Glasgow Western Infirmary; St Mary’s Hospital, Portsmouth; Our Lady’s 
Children’s Hospital, Dublin; St Luke’s Hospital, Bradford; University Hospital of North Durham; 
Royal Victoria Infirmary, Newcastle; Basildon Hospital; University Hospital of Wales, Cardiff; 
Poole Hospital; Worthing Hospital; Russell’s Hall Hospital, Dudley; The Royal Shrewsbury 
Hospital; Whipps Cross University Hospital; Birmingham Children’s Hospital; University Hospital, 
Galway; Leicester Royal Infirmary; Peterborough City Hospital; Ninewells Hospital, Dundee; 
Broadgreen Hospital, Liverpool; Bristol Royal Infirmary). DNA was available from 325 of these 
patients. 
2.2.2.2 European Rare And Severe Psoriasis Expert Network patients 
Clinical information for 416 patients (58 GPP, 17 ACH, 338 PPP, 3 with multiple disease forms) 
was provided by recruiting centres affiliated with the European Rare And Severe Psoriasis Expert 
Network (Medical University of Vienna; Tartu University Hospital; Beni Suef University; 
University Hospital Zurich; University Medical Center, Schleswig-Holstein, Kiel; Hospital 
Germans Trias I Pujol, Barcelona; Hospital Universitario Virgen Macarena, Seville; Complejo 
Asistencial Universitario de León; Hospital 12 de Octubre, Madrid; Universitari Vall d’Hebron, 
Barcelona).  For a subset of these (63 patients) we also received DNA. 
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2.2.2.3 Other European recruiting centres 
An additional 39 patients (11 GPP, 3 ACH, 25 PPP) were ascertained independently of ERASPEN 
by multiple centres across Europe (University of Szeged; European Registry of Severe Cutaneous 
Adverse Reactions; Helsinki University Central Hospital; IMAGINE Institute, Necker-Enfants 
Malades Hospital, Paris; Radboud University Medical Centre, Nijmegen; Universitari Vall 
d’Hebron, Barcelona; Geneva University Hospital). All provided DNA samples. 
2.2.2.4 Non-European recruiting centres 
Outside of Europe, 163 patients (156 GPP, 1 ACH, 6 with multiple disease forms) were 
ascertained at multiple North American, Australian and Asian institutions (Hospital Sultanah 
Aminah, Johor Bahru, Malaysia; National Skin Centre, Singapore; Royal Prince Alfred Hospital, 
Camperdown, Australia; Hacettepe University, Turkey; University of Washington, Seattle, USA; 
National Institutes of Health, Bethesda, USA). All provided blood for DNA isolation. Five GPP 
kindreds, comprising 10 individuals in total, were identified at the Hospital Sultanah Aminah, 
Johor Bahru, Malaysia. An additional pair of siblings affected by GPP were identified in Australia. 
Details of familial cases can be found in Table 2.2.  
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Table 2.1 Summary of isolated pustular psoriasis cases 
Disease form 
 



















 Mean: 31.3yrs 
Min: 1mth 
Max: 87yrs 
 African (n = 53); East Asian (n = 45); 
European (n = 48); Malay (n = 88); 















African (n = 3); East Asian (n = 1);  










 Mean: 43.8yrs 
Min: 4yrs 
Max: 81yrs 
 African (n = 23); East Asian (n = 3); 
European (n = 558); South Asian (n = 











 Mean1: 31.8yrs 
Min: 2yrs 
Max: 61yrs 
 East Asian (n = 4); European (n = 20);  
Malay (n = 1); South Asian (n = 2);  
Other (n = 1) 
mth: month; PV: psoriasis vulgaris; yrs: years; 1 Age data based on patient age at the onset of first form of pustular psoriasis
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Table 2.2 Summary of familial GPP cases 
Patient ID 
 







Female 32 Y 
8GPP2  Female 19 N 
16GPP1  
Aunt and niece Chinese 
Female 25 Y 
16GPP2  Female 17 Y 
23GPP1  First cousins 
once removed 
Malay 
Female 52 Y 
23GPP2  Female 28 Y 
38GPP1  Father and 
daughter 
Malay 
Male 72 Y 
38GPP2  Female 30 Y 
41GPP1  
Sisters Malay 
Female 52 Y 
41GPP2  Female 53 N 
OVS0015  
Sisters European 
Female 0.9 N 




2.2.3 Control populations 
Control populations were utilised at several stages throughout this study. For initial whole 
exome data filtering, global allele frequencies derived from the Exome Aggregation Consortium 
(ExAC) database (n=61,406) were used. For gene association tests, allele frequencies from 
relevant ethnic groups were required. The populations represented were: British (3,781 
individuals), Non-Finnish Europeans (63,369 individuals), Malays (96 individuals), South Asians 
(15,391 individuals) and East Asians (9,435 individuals). Details of control populations are 
outlined in Table 2.3. 
2.2.4 DNA extraction and storage 
DNA was extracted from 10ml whole blood by technical employees at St John’s Institute of 
Dermatology. Briefly, ice cold distilled water was added to the sample to lyse red blood cells, 
and the sample tubes were spun at 1250g for 20min at 4°C. The supernatant was removed and 
the pellet resuspended in 0.1% IGEPAL. After a second spin under the same conditions, the pellet 
was resuspended in 6M guanidinium hydrochloride and 7.5M ammonium acetate. The solution 
was vortexed, supplemented with 10mg/ml proteinase K and vortexed again. After incubation 
at 60°C for 90min, 96% ethanol was added, and the DNA spooled out on a Pasteur pipette tip. 
The DNA was immediately placed in 1X TE buffer and allowed to dissolve overnight. Finally, the 
DNA was reprecipitated with 3M sodium acetate (pH 5.5) and 96% ethanol before being spooled 
out as before, allowed to dry and dissolved again in 1X TE buffer. Duplicate aliquots of isolated 
DNA were stored in 1X TE buffer at -20°C. Prior to storage the concentration of DNA was 
measured on a NanoDrop ND-1000 Spectrophotometer. Working solutions (25ng/µl) were 
diluted in ddH2O and stored at -20°C in 96-well plates.  
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Table 2.3 Sources of control populations 
Ethnicity  Dataset  Reference 
Multiple ethnicities 
 Exome Aggregation Consortium (n=60,706) 
Exomes sequenced in-house (n=674) 
 
Lek, et al, 2016 (73) 
British  UK10K (n=3,781)  UK10K Consortium, 2015 (102) 
Non-Finnish European 
 Exome Aggregation Consortium: Non-Finnish Europeans (n = 33,370) 
Genome Aggregation Database: Non-Finnish Europeans (n = 63,369) 
 
Lek, et al, 2016 (73) 
Malay  Singapore Sequencing Malay Project (n = 96)  Wong, et al, 2013 (103) 
South Asian  Genome Aggregation Database: South Asians (n = 15,391)  Lek, et al, 2016 (73) 
East Asian  Genome Aggregation Database: East Asians (n = 9,435)  Lek, et al, 2016 (73) 
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2.3 Genotyping by Sanger sequencing 
2.3.1 Polymerase chain reaction (PCR) 
2.3.1.1 Primer design 
Primers were designed using Primer3 (104,105) with template sequences taken from the 
Ensembl genome browser (106). The possible location of primers within the template sequence 
was restricted such that they would amplify both the relevant exon and exon/intron boundaries. 
Where possible, overlap with single nucleotide polymorphisms was avoided by comparing 
potential primer sequences to the target region on Ensembl. Oligonucleotides were also 
examined with Primer-BLAST (107) to ensure there were no off-target binding sites.  
In the case of ZNF33A, primers for exon 5 (6 pairs) were designed manually due to very high 
levels of coding sequence similarity between ZNF33A and ZNF33B. The two sequences were 
aligned using T-coffee (108) and primers then designed in regions where the most 3’ bases were 
specific to ZNF33A. These primer pairs also fulfilled the following conditions, where possible: 
primer length: 18-22nt; Tm: 50-65°C; GC%: 40-60; product length: <500bp. All primer sequences 
are listed in Appendix 2. 
Oligonucleotides were purchased from Eurofins Genomics or Sigma-Aldrich and upon arrival 
were reconstituted in ddH2O to a concentration of 100μM. For use in PCR and Sanger 
sequencing, primers were diluted to a working concentration of 10μM. Both stock and working 
solutions were stored at -20°C. 
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2.3.1.2 PCR conditions 
Reactions were carried out with 25ng DNA in a final volume of 15μl, using reagents as listed in 
Table 2.4. Optimal primer annealing temperatures (Tm) were determined by gradient PCR and 





Table 2.4 Components of PCR reaction mix 
Reagent  Volume (µl) 
ddH2O  9.85 
10X Polymerase buffer  1.5 
10µM Forward primer  0.5 
10µM Reverse primer  0.5 
2µM dNTPs  1.5 
5U/µl Taq polymerase  0.15 
25ng/µl DNA template  1 
Total  15 
 
Table 2.5 Cycling conditions for PCR reaction 
Step Temperature Time 





Annealing Tm1 30sec 
Extension 72°C 30sec 
Final extension 72°C 10min 




2.3.2 Agarose gel electrophoresis 
Samples of PCR product (3.5µl) were diluted in 1.5µl 5X loading buffer and loaded into a 2% 
agarose gel, which also contained 0.5mg/ml ethidium bromide. Hyperladder II was used as a 
molecular weight marker. After amplification products were separated by electrophoresis, the 
gel was visualised under UV light and bands checked to confirm success and specificity of the 
PCR reaction. 
2.3.3 Sanger sequencing 
A clean-up reaction removed unincorporated primers and nucleotides from a 2µl sample of PCR 
product. illustra ExoProStar 1-Step (0.125µl diluted in 2.875μl ddH20) was added to the PCR 
sample, in a 96 well plate, and the mixture incubated at 37°C for 30min then 80°C for 15min. 
The full volume of cleaned PCR product was then used for Sanger sequencing, with addition of 
the reagents listed in Table 2.6 and under cycling conditions displayed in Table 2.7. In the 
majority of cases, the primer used for sequencing was one of the pair used for the preceding 
PCR reaction, but in three cases primers internal to the PCR product were used to obtain cleaner 
sequences (Appendix 2). 
Sequencing products were purified by ethanol precipitation. A precipitation solution (26µl/well, 
50ml 95% EtOH + 2ml 3M NaOAc, pH 4.6) was added to each product. The plate was incubated 
at room temperature for 10min and then centrifuged at 3000rpm for 30min. Supernatants were 
removed by inversion and pellets washed in 100μl 70% ethanol before being centrifuged at 
3000rpm for 10min. The supernatant was removed as before, and the pellet allowed to air dry. 
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Finally, the pellet was resuspended in 10μl formamide and denatured by heating to 96°C for 
2min. Samples were run on a 3730xl DNA Analyzer (Applied Biosystems) and visualised with 
Sequencher v.4.9 (Gene Codes, section 2.8.3).  
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Table 2.6 Components of Sanger sequencing reaction 
Reagent  Volume (µl) 
BigDye Terminator sequencing buffer  1.25 
10µM Primer  0.25 
BigDye Terminator v3.1  0.25 
Cleaned PCR product  5 
Total  6.75 
 
Table 2.7 Cycling conditions for Sanger sequencing  





Annealing 50°C 15sec 





2.4 Plasmid DNA manipulation 
2.4.1 Plasmids used 
Mutagenesis was carried out on a pCMV6 entry vector that contained a wild type IL36RN insert 
(obtained from Origene). In addition, three pcDNA3 vectors, each containing a mutated form of 
IL36RN, were kindly provided by Professor Asma Smahi of the Imagine Institute, Necker-Enfants 
Malades Hospital, Paris, France. 
2.4.2 Expansion and purification 
E. coli containing the desired plasmid were grown on LB agar plates or in LB medium, where 
necessary supplemented with the required antibiotic (Ampicillin, 100μg/ml, or Kanamycin, 
50μg/ml). Components of LB medium and agar are listed in section 2.1. Transformed bacteria 
were stored as glycerol stocks (250µl sterilised 70% glycerol and 750µl bacteria culture) at -80°C. 
Suspensions of E. coli were spread onto LB agar either to expand from a glycerol stock or after 
transformation (see below). After overnight incubation at 37°C, single colonies were picked 
and propagated in LB medium as outlined in Table 2.8. To recover purified plasmid, QIAGEN 
HiSpeed Plasmid Midi and Maxi Kits, or the QIAPrep Spin Mini Kit, were used as described in 




Table 2.8 Expansion of E. coli colonies 
Application  LB medium  Source of E. coli  Incubation 
Mini-prep with QIAPrep 
Spin Mini Kit 
 
5ml 
 Colony picked from 
LB agar plate 
 
12-16hrs 
Inoculation of large 
cultures and/or creation 




Colony picked from 
LB agar plate 
 
8hrs 
Midi-prep with QIAGEN 
HiSpeed Plasmid Midi Kit 
 
50ml 




Maxi-prep with QIAGEN 
HiSpeed Plasmid Maxi Kit 
 
150ml 








2.4.3 Transformation of E. coli  
Ultra-competent E. coli (XL10-Gold strain) were transformed by heat shock. For each 
transformation, 20ng plasmid DNA was added to a 50μl aliquot of competent cells and incubated 
on ice for 30min. Aliquots were then heat-shocked at 42°C for 45sec and returned to ice for a 
further 5min. After addition of 500μl antibiotic-free LB medium, bacterial cultures were 
incubated at 37°C for at least 1hr before being pelleted by centrifugation at 9000rpm for 5min. 
The pellet was resuspended in 100μl LB medium and spread onto an agar plate containing the 
relevant antibiotic, then incubated at 37°C overnight. 
2.4.4 Site-directed mutagenesis 
Mutagenesis primers were designed using the QuikChange Primer Design Program and then 
compared to the relevant plasmid sequence to ensure absence of off-target binding sites. 
Primers were ordered from Sigma-Aldrich and reconstituted in ddH2O to a stock concentration 
of 100μM. All primer sequences are listed in Appendix 2. The QuikChange Lightening Site-
Directed Mutagenesis Kit was used according to the manufacturer protocol. Briefly, a plasmid 
containing a wild type construct was combined with mutagenesis primers and amplification 
reagents then incubated under prescribed cycling conditions. Next, the parental plasmid was 
digested with DpnI before the mutated vector was transformed into XL10-Gold ultracompetent 
cells by heat-shock.  
After incubation in antibiotic-free medium at 37°C for 1hr, bacteria were spread onto agar plates 
containing the relevant antibiotic and incubated at 37°C overnight. Isolated colonies were 
picked, propagated and purified as described in section 2.4.2. The CMV promoter, cDNA insert 
and polyadenylation regions of the plasmid were Sanger sequenced (as outlined in section 2.3.3, 
excluding the initial clean-up reaction) to confirm only the desired mutation was present. 
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2.5 Cell culture 
2.5.1 Cell lines 
Two cell lines were used, both grown in a NuAire Air-Jacketed Automatic CO2 Incubator (NU-
5500). This provides a humidified atmosphere at 37°C, with 5% CO2. Cell cultures were handled 
aseptically under a laminar flow hood.  
HEK293 (human embryonic kidney) cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 2mM L-Glutamine, 25mM D-glucose, 10% Foetal Calf Serum (FCS), 
50U/ml of penicillin and 50µg/ml of streptomycin. HeLa-IL-36R cells (stably transfected with the 
IL-36 receptor, kindly provided by Prof Seamus Martin, Trinity College Dublin, Ireland) were 
cultured in RPMI 1640 Medium, supplemented with 11mM D-glucose, 5% Foetal Calf Serum 
(FCS), 50U/ml of penicillin and 50µg/ml of streptomycin. 
For long-term storage, 1-2x106 pelleted cells were suspended in 1ml freezing medium (90% FCS 
and 10% DMSO, filter sterilised), placed in a Mr. Frosty container for 24hr at -80°C then 
transferred to liquid nitrogen. When removed from storage, aliquots were thawed for 2min at 
37°C then combined with 4ml complete medium. Cells were pelleted by centrifugation at 
1500rpm for 5min, the supernatant aspirated and the pellet resuspended in an appropriate 
volume of complete medium. After 24hrs growth in a T25 or T75 flask (dependent on the 
number of cells that had been frozen), cells were split into a new flask. 
To split cells, the medium from a confluent (80-90%) T75 flask was removed and the cells briefly 
washed with 5ml PBS. To detach cells, 3ml of TrypLE was added and the flasks incubated either 
at room temperature for 3min (HEK293) or at 37°C for 5min (HeLa-IL36R). Complete medium 
(7ml) was added to deactivate TrypLE and the cells pelleted by centrifugation at 1500rpm for 
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5min. Finally, the supernatant was aspirated, the pellet resuspended in 10ml complete medium 
and a 1ml aliquot transferred to a new T75 flask with 9ml complete medium. If splitting cells 
from a T25 flask into another of the same size, the same procedure was followed, but volumes 
were halved. If moving cells from a T25 flask to a T75 flask, cells were split at a 1:3 dilution. 
2.5.2 Transfection 
Cells (HEK293 or HeLa-IL36R) were transfected with plasmid DNA using Lipofectamine2000. Cells 
were seeded at a density of 0.6x106/well, in 3ml complete DMEM, in a 6-well plate. Twenty-four 
hours after seeding, the medium was removed and replaced with 2ml antibiotic-free DMEM. 
Lipofectamine2000 was then used according to the manufacturer protocol, by diluting plasmid 
DNA at a final concentration of 2.5µg/well and Lipofectamine2000 at a final concentration of 
5µl/well, both in serum- and antibiotic-free medium. Cells were harvested for protein 
purification or Western blot 24hrs after transfection (section 2.7.1 and section 2.7.3).  
2.5.3 Stimulation with IL-36α 
HeLa-IL-36R cells were seeded in a 48-well plate at a density of 0.1x106 cells/well, in 500µl 
complete RPMI medium. After 24hrs, the medium was removed. For each IL-36Ra construct 
(wild-type or mutagenised), a 150µl master mix including 600ng purified protein in complete 
medium was split equally between two wells. The plate was incubated for 30min at 37°C, then 
25µl of IL-36α (20ng/ml) was added to each well for a final concentration of 5ng/ml. Elution 
buffer from the protein purification kit (section 2.7.1) was diluted in complete medium and 
added to both negative and positive control wells in each plate. The negative control was not 
stimulated with IL-36α, while the positive control was stimulated as described above. 
Supernatants were harvested 4hrs after stimulation, spun at 1500rpm for 10min to pellet cell 
debris and stored at -80°C. 
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2.6 RNA expression studies 
2.6.1 RNA extraction 
RNA was extracted using the GeneJET RNA Purification Kit, according to manufacturer’s 
instructions, and eluted in 30µl RNase-free water. Steps involving β-mercaptoethanol were 
carried out under an extraction hood and all surfaces and equipment were cleaned with 70% 
ethanol and RNaseZap prior to use. Eluted RNA was quantified on a NanoDrop ND-1000 
Spectrophotometer then stored at -80°C.  
2.6.2 cDNA synthesis 
The Precision nanoScript2 Reverse Transcription kit was used, with oligo-dT primers, to generate 
cDNA from 500ng total RNA. Primers were annealed to RNA during a 5min incubation at 65°C, 
then cDNA was synthesised during a 20min incubation at 42°C. The reaction was heat-
inactivated at 75°C for 10min and 30µl RNase-free water was added for a final volume of 50µl. 
cDNA was stored in the short-term at -20°C and for the long-term at -80°C. 
2.6.3 Real-time PCR 
Multiple kit/probe combinations were used to measure transcript levels by real-time PCR. A 
TaqMan probe and mastermix were used for the housekeeping gene PPIA. A second 
housekeeping gene, β2M, was measured with either a TaqMan probe and mastermix or a 
PrimerDesign probe and PrecisionPLUS SYBR qPCR Master Mix. Transcripts of interest were 
measured with the KAPA SYBR FAST Master Mix (ARFGAP2, IL8) or the PrecisionPlus SYBR qPCR 
Master Mix (IL36RN, IL1RL2). The primers amplifying these target genes were designed in-house. 
The sequences (listed in Appendix 2) were required to span an exon-exon junction and to have 
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similar melting temperatures within each pair (maximum 3°C difference). Primer specificity was 
validated by agarose gel electrophoresis, which was also used to exclude the formation of primer 
dimers. 
Reagent volumes for all real-time PCR reactions are shown in Table 2.9, and cycling conditions 
are listed in Table 2.10. All reactions used 2µl cDNA, were set up in duplicate and run on a 
7900HT Fast Real-Time PCR System.  
Gene expression relative to the housekeeping gene was calculated using the ΔΔCt method (109). 
Detection threshold cycle (Ct) values were averaged across technical duplicates and then the 
ΔCt calculated for each sample [1 in the equations below]. This was then normalised to a 
selected calibrator sample [2] and, finally, the relative gene expression level (RQ) was calculated 
[3]. 
ΔCt = Ct[sample] – Ct[housekeeping]  [1] 
ΔΔCt = ΔCt[sample] – ΔCt[calibrator]  [2] 





Table 2.9 Components of real-time PCR reaction mixes 
Real-time PCR kit  Reagent  Volume (µl) 
TaqMan 
 TaqMan Universal Master Mix II   10 
 Probe  1 
 cDNA  2 
 Nuclease-free water  7 
PrecisionPlus 
(housekeeping gene) 
 PrecisionPlus SYBR and ROX qPCR Mix  10 
 Gene probe  1 
 cDNA  2 
 Nuclease-free water  7 
KAPA SYBR FAST 
 KAPA SYBR qPCR Master Mix  10 
 Forward Primer (1μM)  2.8 
 Reverse Primer (1μM)  2.8 
 cDNA  2 
 Nuclease-free water  2.4 
PrecisionPlus 
(transcript of interest) 
 PrecisionPlus SYBR and ROX qPCR Mix  10 
 Forward Primer (1μM)  2.8 
 Reverse Primer (1μM)  2.8 
 cDNA  2 





Table 2.10 Cycling conditions for real-time PCR 
Real-time PCR kit  Temperature Time 
TaqMan/KAPA 
SYBR FAST 
 95°C 10min 
 95°C 15sec 
x40 cycles 
 60°C 1min 
PrecisionPlus 
 95°C 2min 
 95°C 10sec 
x40 cycles 





2.7 Protein analysis 
2.7.1 Protein purification 
Myc-tagged IL-36Ra proteins were isolated with the MBL c-Myc tagged Protein Mild Purification 
Kit. The manufacturer’s protocol was scaled down to take into account the lower number of 
transfected cells (3.6x106 instead of the suggested 8.8x106). Briefly, each myc-tagged cDNA 
construct was transfected in triplicate in HEK293 cells, using the protocol reported in 2.5.2. 
Twenty-four hours later, the medium was removed, the cells detached in PBS (2ml/well, 5min 
incubation at room temp) and centrifuged for 5min at 1500rpm. The cell pellet was washed in 
PBS and re-centrifuged as described above. Cells were resuspended in 500µl non-denaturing 
lysis buffer (section 2.1), supplemented with protease inhibitor (EDTA-free). After incubation on 
ice for 30min, the cell lysate was transferred to a spin column and 20µl Anti-c-Myc bead 
suspension was added. The spin column was incubated for 1hr at 4°C with end-over-end mixing 
then centrifuged for 10sec at high speed. After three washes with wash concentrate diluted 1:10 
in ddH2O, the purified protein was eluted with 20µl elution peptide solution. A second elution 
step was carried out, re-using the 20µl eluate. The concentration of the purified protein was 
measured on a NanoDrop ND-1000 Spectrophotometer, using the Protein A280 mode with user-
entered molar extinction coefficient and molecular weight values (calculated using BioMol.net 
online calculator (110)). Proteins were then used the same day for a stimulation assay (section 
2.5.3). 
2.7.2 ELISA 
The R&D Human IL-8/CXCL8 DuoSet ELISA kit was used to assay IL-8 levels after stimulation with 
IL-36α (section 2.5.3). Samples were diluted 1:80 in 0.1% BSA and the ELISA carried out according 
to the manufacturer’s instructions. The absorbance of each sample was then measured at 
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450nm and 540nm on a BMG Labtech FLUOstar Omega microplate reader. The raw data was 
processed with BMG Labtech MARS software, using a four-parameter fit to create the standard 
curve. 
2.7.3 Protein expression assay 
2.7.3.1 Gel preparation 
A 15% separating gel was used as the protein of interest was small (17kDa), in addition to a 5% 
stacking gel. Components of both gels are listed in Table 2.11. The separating gel was poured 
first, then 1ml isopropanol added on top to remove any bubbles that had formed. After the 
separating gel had polymerised the isopropanol was removed, and the stacking gel poured on 
top. A comb was carefully inserted and, once all had set, the gel was stored at 4°C soaked in 
running buffer. 
2.7.3.2 Western blotting 
Twenty-four hours after transfection, HeLa cells were detached in TryplE (1ml/well), centrifuged 
for 5min at 1500rpm, washed in ice-cold PBS and re-centrifuged. The cell pellet was resuspended 
in non-denaturing lysis buffer (section 2.1) supplemented with protease inhibitor (EDTA-free) 
and incubated on ice for 30min. 
Samples were combined with 6X Laemli dye and denatured at 95-98°C for 5min, then loaded 
onto the prepared gel. Electrophoresis was carried out for 2hr in 1X running buffer, at 100V. 
Separated proteins were transferred to a PVDF membrane in a Biorad Mini Trans-Blot 
Electrophoretic Transfer Cell filled with transfer buffer and run for 2.5hr at 200mA. Transferred 
proteins were visualised by soaking the membrane in Ponseau S red dye and the membrane 
then blocked in 5% milk-1X TBS-0.1% Tween 20 for 1hr at room temperature. 
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The membrane was then incubated overnight at 4°C with the primary antibody (Monoclonal 
Anti-c-Myc or Monoclonal Anti-β-actin, diluted 1:1000 in milk). After three washes of 5min in 1X 
TBS-0.1% Tween 20, the membrane was incubated 1hr at room temperature with an HRP-
conjugated secondary antibody (Polyclonal Anti-Mouse or Polyclonal Anti-Rabbit, diluted 
1:10000 in milk). The membrane was then washed as before. 
Finally, to visualise the protein of interest, the membrane was treated with the Amersham ECL 
Western Blotting System for 5 minutes. Autoradiography films were exposed to the membrane 
and developed using an automated film developer (KONICA MINOLTA SRX-101A). The developed 
film was then scanned, and densitometry analysis performed with ImageJ (111,112).  
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Table 2.11 Components of Western blot gels 
Gel  Component  Volume (ml) 
Separating 
(15% gel) 
 H2O  2.3 
 30% acrylamide mix  5 
 1.5M Tris (pH 8.8)  2.5 
 10% SDS  0.1 
 10% ammonium persulfate  0.1 
 TEMED  0.004 
 Total  10 
Stacking 
(5% gel) 
 H2O  1.4 
 30% acrylamide mix  0.33 
 1.5M Tris (pH 6.8)  0.25 
 10% SDS  0.02 
 10% ammonium persulfate  0.02 
 TEMED  0.002 





2.8 Whole exome sequencing 
2.8.1 Sample selection and preparation 
One hundred and thirteen samples were exome sequenced in the Capon lab between 2011 and 
2018. Samples selected for exome sequencing originated from well-phenotyped patients that 
also fulfilled one of the following criteria: early age of onset, familial disease, rare disease 
subtype (namely acrodermatitis continua of Hallopeau) or inclusion within the PLUM 
study/APRICOT trial. 
Genomic DNA samples were diluted in 1X TE buffer to a final concentration of 30ng/μl, with 
concentration confirmed using a Qubit 2.0 Fluorometer. 
2.8.2 Whole exome sequencing 
All steps of the whole exome sequencing procedure were undertaken by technicians of the Guy’s 
and St Thomas Hospital Biomedical Research Centre (BRC) core genomics facility. 
Genomic DNA samples were diluted in 1X TE (3µg in 130µl) then sheared by sonication into 150-
200bp fragments. These fragments were purified with AMPure XP beads and repaired with the 
SureSelect XT Library Prep Kit, which generates blunt 5’-phosphorylated ends. Following a 
second purification step, the 3’ ends were polyadenylated and the sample purified a third time. 
After ligation of paired end adaptors, each sample was amplified with the Herculase II Fusion 
DNA Polymerase Kit. Amplification products were assessed for quality using an Agilent 2100 




Exome capture was carried out with the Agilent SureSelect Human All Exome Kit v.4 (pre-2017) 
or v.6 (2017 onwards), according to the manufacturer’s protocol. Sequencing libraries were 
hybridised with the capture library for 24hrs at 65°C. The hybridised DNA was then captured by 
streptavidin-coated magnetic beads and amplified with indexing primers.  After purification, the 
amplified DNA was analysed with the Bioanalyzer High Sensitivity DNA Assay. Finally, samples 
were pooled for multiplex sequencing and prepared for cluster amplification. Sequencing was 
carried out on a HiSeq1000 (pre-2017) or HiSeq3000/4000 (2017 onwards). 
Raw data was annotated by a pipeline established by Prof Michael Simpson and now managed 
by the Guy’s and St Thomas’ Hospital BRC core genomics facility. Novoalign (Novocraft 
Technologies) was used to align paired-end reads to the reference genome (hg19), before the 
removal of duplicates and poor-quality reads with MarkDuplicates and SAMtools (113). The 
efficiency of capture was assessed with BEDtools (114). Variants were called by SAMtools where 
covered by 5 or more reads, then annotated with Annovar (115). 
2.8.3 Analysis of Sanger sequencing data 
Sanger sequencing data was visualised with Sequencher v4.9 and aligned to reference 
sequences obtained from the Ensembl genome browser (release 91). Detected sequence 
changes were also annotated by querying Ensembl. Data from the Exome Aggregation 
Consortium (ExAC) was used to determine the allele frequency of variants. 
2.8.4 Pathogenicity predictions 
Five tools were used to assess the pathogenicity of variants located in coding regions. These 
were: PROVEAN (92), SIFT (91), PolyPhen-2 (93), MutationTaster (95) and CADD (96). Variants 
within splicing regions were assessed with MutationTaster, CADD, Spliceman (88) and Human 
Splicing Finder (90) (which includes data from MaxEntScan (89)). Sequence changes that were 
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classified as deleterious by at least two (splicing variants) or three (coding variants) of these 
algorithms were considered as potentially pathogenic (Table 2.12). Stopgain variants were an 
exception, as they qualified automatically. 
When pathogenicity predictions were required from a wider range of tools, or when information 
on evolutionary conservation (such as the GERP++ score) was needed, the dbNSFP database 




Table 2.12 Interpretation of in-silico pathogenicity prediction tools 
Tool  Output  Score1 
SIFT 
 Tolerated  0 
 Damaging  1 
PROVEAN 
 Neutral  0 
 Deleterious  1 
PolyPhen-2 
 Benign  0 
 Possibly damaging  0.5 
 Probably damaging  1 
MutationTaster 
 Disease causing  0 
 Polymorphism  1 
CADD 
 <10  0 
 10 – 20  0.5 
 >20  1 
Spliceman 
 <50%  0 
 50-75  0.5 
 >75%  1 
Human Splicing Finder2 
 Probably no impact  0 
 Potentially affecting splicing  0.5 
 Probably affecting splicing  1 
1A combined score of at least 3 meant a variant was considered pathogenic, 
except for stop-gain alleles which qualified automatically; 2Result based on 




2.8.5 Filtering of whole exome data 
Annotated whole exome data (section 2.8.2) was imported into Microsoft Excel and analysed by 
filtering and prioritisation of variants based on a number of criteria. First, synonymous variants 
and those annotated as having an unknown effect were removed. Subsequent analysis differed 
according to the cases included.   
2.8.5.1 Multiple unrelated cases 
When analysing data combined from multiple unrelated ACH patients, variants were split into 
two groups: heterozygous and homozygous/compound heterozygous. Both groups were then 
filtered according to the minor allele frequency (MAF) of individual variants. In the heterozygous 
group, only variants with a MAF <0.01 were retained. A more relaxed threshold of <0.05 was 
used for the homozygous/compound heterozygous group. The sources for minor allele 
frequency were the Exome Aggregation Consortium (73), the 1000 Genomes Project (72), the 
Exome Variant Server (119) and 700 exomes sequenced in-house. 
Next, variants found in only one individual were discarded, along with those likely to be artefacts 
and those in genes that are very commonly seen in public exome datasets (120). The remaining 
variants were annotated with pathogenicity predictions as described in section 2.8.4 and those 
classified as damaging by a majority of tools were retained. An RNAseq dataset generated from 
unstimulated keratinocytes (25) was used to highlight variants within genes with a reads per 




2.8.5.2 Isolated case with related parents 
For the analysis of a paediatric onset case of GPP, it was assumed that the causative variant 
would be homozygous as the parents of the proband were first cousins. Therefore, only 
homozygous variants with a MAF <0.05 were retained; the sources of minor allele frequency 
were the same as listed in the previous section. Next, variants that, in the original unfiltered 
data, lay within a homozygosity block of at least 2Mb were retained. This increased the 
likelihood that the remaining homozygous variants were identical by descent.  
As described above, pathogenicity prediction tools were used to prioritise genes containing 
damaging variants and these genes were then filtered on the basis of their expression in 
keratinocytes. 
2.8.6 Visual validation of whole exome reads 
Whole exome sequencing reads relating to the variants that had passed the above filtering steps 
were visualised with the Integrative Genome Viewer (IGV) (121). The position of each variant of 
interest was assessed for coverage and quality of reads. Variants covered by fewer than 10 reads 
or that were in a region containing numerous mismatches were labelled as artefacts and 




2.9   Statistical analyses 
2.9.1   Comparative and association tests 
When examining clinical traits in pustular psoriasis, a binomial test was used to compare the sex 
distribution amongst patients with that observed in the general population. The distribution of 
the data for age of onset was assessed with the D'Agostino-Pearson normality test in GraphPad 
Prism 7. A Kruskal-Wallis test, followed by Dunn’s multiple comparisons test, was used to 
analyse differences in age of onset between forms of pustular psoriasis. 
To assess for association between clinical traits (e.g. plaque psoriasis) and the disease, or genetic 
variants and the disease, a Fisher’s exact test or chi-squared test were used. The choice of test 
was dependent on sample size and the number of factors being assessed. A Yates correction for 
continuity was used with chi-squared tests with one degree of frequency. When examining the 
association between genetic variants and pustular psoriasis, a one-tailed Fisher’s exact test was 
applied.  This was justified as rare deleterious variants would be strongly expected to be 
enriched amongst patients, not reduced.  
When combining ethnicity-specific data on association between genetic variants and pustular 
psoriasis, a meta-analysis was carried out in Comprehensive Meta-Analysis Version 3 (122). A 
weighted pooled odds ratio and Z score was calculated. 
When comparing densitometry measurements and ELISA readouts between mutant and wild 
type IL-36Ra, Dunnett’s multiple comparisons test was carried out in GraphPad Prism 7. 




2.9.2 Power calculations 
The Genetic Power Calculator (125) was used to assess whether components of the study had 
sufficient power to detect disease-associated variants of a realistic frequency and genotype 
relative risk. The disease prevalence was set at 0.09% and D-prime as 1, with the required power 
threshold defined as 80%. 
2.9.3   Regression analyses 
Genotype-phenotype correlations were assessed using a linear (age of onset) or logistic (sex, 
psoriasis vulgaris concurrence) regression analysis. The disease subtype was included as a 
covariate. Analysis of rates of smoking in PPP and GPP was done using a logistic regression 
with age of onset and nationality as covariates. All regression analyses were carried out in R. 
2.9.4   Significance thresholds 
In the case of tests addressing clinical data, P values of less than 0.05 were considered 
significant. The same threshold was used for the analysis of ELISA, Western blot and real-time 
PCR data. When examining the association between sequence variants and the disease, an 
exome-wide threshold of P<2.5x10-6 was used to compensate for the issue of multiple testing. 
This value is reached by applying a Bonferroni correction to 20000 independent tests (one test 




3  Clinical and genetic analysis of an extended patient 
cohort 
The majority of published findings regarding the clinical presentation or genetic basis of pustular 
psoriasis are based on the analysis of small patient groups. To address the limitations associated 
with small sample size, the study collated clinical information from 863 affected individuals, 
generating a dataset that exceeds by almost 3-fold the size of largest cohort reported to date (n 
= 323 (41)). A representative patient subset (n = 473) was also screened for variants in known 
disease-associated genes. 
3.1 Cohort selection and demographics 
A total of 863 patients were examined (Table 3.1). These individuals suffered from generalised 
pustular psoriasis (GPP, n = 251), acrodermatitis continua of Hallopeau (ACH, n = 28), 
palmoplantar pustulosis (PPP, n = 560) or multiple forms of pustular psoriasis (n = 24). 
Case report forms based on the ERASPEN diagnostic criteria (1) (Appendix I) were used to 
phenotype 506/863 of the individuals. The remaining patients were included in the study based 
on the assessment of an experienced dermatologist and the availability of data on at least one 
of the following: age of onset, sex or plaque psoriasis concurrence. Ethnicity was self-declared. 
Clinical ascertainment occurred at 41 locations. When grouped by country of origin, 95% of 
patients (823/863) fell into one of eight regional cohorts: UK/Ireland, Malaysia, Austria, Estonia, 
Egypt, Switzerland, Germany or Hungary (Table 3.2). The majority (n = 591, 68.5%) were of 
European descent, with substantial numbers also originating from Asia (n = 161, 18.7%) and 
Africa (n = 78, 9.0%). The distribution of pustular psoriasis subtypes was not the same across all 
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ethnicities: the majority of Asian participants suffered from GPP, while most European patients 
had PPP (Table 3.1, Table 3.2). However, this was largely due to ascertainment bias (e.g. some 




Table 3.1 Summary description of the patient cohort 
 
 Ethnicity  Sex  Clinical diagnosis   








Total  591 161 78 33  620 233 10  28 251 560 9 4 11  863 
1Includes unknown ethnicity (n = 19), mixed ethnicity (n = 4), Middle Eastern (n = 4), Finnish (n = 2), Filipino (n = 1), Hispanic (n = 1), Jamaican (n = 1), Romani 




Table 3.2 Breakdown of patient cohorts by ethnicity and diagnosis 
  Clinical Diagnosis  







(St John’s Institute of 
Dermatology, London) 
European 6 31 169 15   
Asian - 3 9 -   
Other 1 2 19 - 221 255 
Malaysia 
(Hospital Sultanah 
Aminah, Johor Bahru) 
Asian - 130 - 6   





European - - 118 -   
Asian - - 1 -   
Other - - 1 - - 120 
Egypt 
(Beni Suef University)  
African 1 51 22 - - 74 
Switzerland 
(University Hospital of 
Zurich) 





European 2 - 33 2 - 37 
Hungary 
(University of Szeged) 




European - - 103 -   
Other - - 1 - - 104 
Europe – other European - 7 6 1   
 Asian - 2 - -   
 Other 3 6 - - 14 25 
Asia – other Asian 1 9 - -   
 Other - 1 - - 11 11 
Australia/USA European - 4 - - 4 4 




3.2 Comparisons of clinical features 
The study first focussed on three key clinical features: age of onset, sex and plaque psoriasis 
concurrence. The distribution of these parameters was comparable between different 
ascertainment centres (Table 3.3), with the exception of the rate of concurrent plaque psoriasis 
in GPP, which was much higher in patients ascertained in Malaysia compared to the rest of the 
cohort (77.3% vs 26.4% in non-Malay GPP).  
The 24 individuals with multiple forms of pustular psoriasis were excluded from further analysis, 
as they could not be unambiguously assigned to a single clinical group. 
3.2.1 Age of onset 
The earliest age of onset recorded within the cohort was just one month, whereas the latest was 
87 years. The mean age of onset was 40yrs, with the median slightly higher at 42yrs. A 
D'Agostino-Pearson test revealed that the data was not normally distributed (P < 0.0001) and so 
non-parametric tests were used in subsequent analysis.  
While paediatric (<10yrs) and very late onset (>70yrs) cases were present in all three disease 
subtypes, a highly significant difference in median age of onset was observed (Figure 3.1, panel 
A). Symptoms manifested, on average, earlier in GPP (31.0 ± 19.7 years) than PPP (43.7 ± 14.4; 
P = 9.3x10-19) or ACH (51.8 ± 20.4; P = 1.2x10-7).  
3.2.2 Concurrent plaque psoriasis 
It is well known that patients with pustular psoriasis may also develop plaque psoriasis during 
their lifetime (1,8,21). Indeed, 29.1% (238/817) of individuals in the cohort suffered from this 
condition, a much higher prevalence than the 2-5% seen in the general population (P<2.2x10-16). 
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However, when patients were separated by disease subtype, plaque psoriasis concurrence rates 
differed significantly. Specifically, plaque psoriasis had a lower prevalence in PPP (15.8%) than 
GPP (54.4%; P <2.2x10-16) or ACH (46.2%; P = 0.0004) (Figure 3.1, panel B). This difference 
remained significant (P = 0.013) even after removing the 132 Malaysian GPP patients who had a 
very high rate of plaque psoriasis. 
3.2.3 Sex ratio 
Of the 853 patients for whom the sex was known, 620 (72.7%) were female. A significant bias in 
female to male ratios was observed among GPP and PPP cases (1.7:1; P = 3.95x10-6 and 3.5:1; 
P<2.2x10-16 respectively). The difference between the ratios observed in the two conditions was 
significant (P = 5.84x10-5) (Figure 3.1, panel C), highlighting PPP as the disease with the most 
pronounced sex bias. An unequal sex distribution was also seen amongst ACH cases (1.5:1) but 
was not statistically significant. 
3.2.4 Smoking status 
It is well established that a history of smoking is a risk factor in PPP (17,21). Indeed, 80.7% 
(264/327) of PPP patients for whom data was available here were current or ex-smokers, 
compared to 29% (27/93) in the GPP group. The data is difficult to analyse outside of the 
aggregate as samples become comparatively small. Also, individual resources tend to be heavily 
skewed towards GPP (e.g. Malay dataset) or PPP cases (e.g. Austrian dataset), hindering a more 
granular comparison. Despite this caveat, the significance of smoking on PPP patient numbers 
cannot be overlooked in the aggregate. A logistic regression analysis reveals smoking to be 
significant when analysed alone (P < 2.2x10-16), and still the only significant factor (P < 0.005; no 
other factors had p < 0.05) when analysed along with age and nationality. Thus, while the drop 
in significance suggests that other factors contribute to the probabilistic weightings in the 
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aggregate, smoking remains the most important factor. This is consistent with data published 
by many others (126–128). 
Interestingly, the concurrence of plaque psoriasis was higher among PPP patients who smoked, 
compared to their non-smoking counterparts (12.4% vs. 1.6%, P = 0.009). This suggests that 
smoking not only increases the risk of PPP but may also affect other manifestations of the 
disease. A larger dataset, allowing us to control for potentially confounding variables, would be 




Table 3.3 Phenotype characteristics of the major cohorts1 
   Sex  PV status  Age of onset (yrs) 
Cohort   Female Male Unknown  Has PV No PV Unknown  Mean SD 












 31.8 26.3 














 42.4 15.9 














 33.3 17.1 










-  42.8 13.0 










-  27.9 18.4 










-  37.0 14.2 












 42.4 15.9 
109 
 














 42.2 16.1 










-  49.5 12.4 












 47.0 10.9 




Figure 3.1 Key demographics and clinical features observed in the patient cohort 
(A) Disease onset differed significantly across disease subtypes as demonstrated by a Kruskal-
Wallis test followed by Dunn’s multiple comparison test. (B) Plaque psoriasis prevalence was 
lowest in PPP. Differences in disease concurrence were analysed with a chi-square test. (C) The 
ratio of females to males was higher in PPP than in GPP. Differences in the proportion of affected 
females were assessed using a chi-square test. The dashed line indicates the percentage of 
females in general population. **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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3.3 Genetic analysis 
The next stage of the study aimed to assess the relationship between key clinical characteristics 
and patient disease allele status. Within the cohort, DNA was available for 473 of the 863 (54.8%) 
individuals. Importantly the demographics and clinical features observed in this patient subset 
were representative of the cohort as a whole (Table 3.4). 
3.3.1 Patient screening 
The 473 affected individuals included 358 cases who had been previously screened by the Capon 
group (28,44,46–48) and 115 newly recruited patients. Among the latter, 59 were sequenced in-
house and 56 were analysed by members of the Navarini group at University Hospital Zurich, 
Switzerland. In the majority of cases (397/473), variant screening was carried out by Sanger 
sequencing of coding regions and exon/intron junctions. While there are newer and more 
advanced technologies available (e.g. the Nextera XT DNA Library Preparation Kit combined with 
the MiSeq sequencer), the limited number and small size of candidate genes here allowed for 
the use of Sanger. This remains one of the most accurate screening protocols. If new candidate 
genes are discovered, the use of NGS-based techniques will likely prove more advantageous and 
cost-efficient. The status of the remaining 76 patients was determined by querying whole exome 
sequencing data previously generated by the Capon group.  
3.3.2 Analysis of IL36RN variants 
The coding region of IL36RN extends across four exons and is 468bp in length. Here, IL36RN 
variants were identified in 66/467 (14.1%) patients (45 GPP, 4 ACH, 12 PPP, 5 multiple diagnoses) 
(Table 3.5), with a combined disease allele frequency of 0.11. While the majority of IL36RN-
positive patients (36/66, 54.5%) harboured biallelic (homozygous or compound heterozygous) 
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changes, monoallelic changes were observed in 30/66 individuals. The most common disease 
alleles were the missense p.Ser113Leu (c.338C>T) variant (n = 42/102) and the c.115+6T>C 
splicing change (n = 53/102). A previously unreported c.115+5G>A substitution was also 
identified. This affects a highly conserved residue within the donor splicing motif of intron 3-4 
(129) and so is predicted to be deleterious (Figure 3.2). All remaining changes had already been 
described in the literature. 
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Table 3.4 Clinical and demographic features of the 473 patients who were screened for variants 
   Sex  PV status  Age of onset (yrs) 








































































































 43.7 14.4 
1 The features observed in the broader dataset are shown for reference
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Table 3.5 Variants observed in IL36RN positive patients1 
  
Sample ID2  Diagnosis  Ethnicity 




















































































27GPP1  GPP  Malay 





































74GPP1  GPP  Malay 































































































































OVS0018  GPP  European 













































































1Patient is classified as IL36RN positive if they carry at least one variant in the examined locus; 2Patients highlighted in orange have not previously 
been reported; 3As per GRCh38 genome build and IL36RN transcript NM_012275; 4When a patient carries both c.115+6T>C and p.Pro76Leu, they 
are found on the same allele. While in this study a single Sanger sequencing fragment did not span both loci, this allele has been demonstrated 
in other publications (44,130) and is self-evident in those patients carrying homozygous c.115+6T>C in addition to heterozygous c.227C>T. 












































Figure 3.2 Consensus sequence of a donor splice site 
A: Sequence logo displaying the frequency of different nucleic acids within a donor splice site. 
The box highlights the position affected by the c.115+5G>A variant, illustrating that in 80% of 
splice sites this residue is a guanine. In contrast, adenine is seen in fewer than 10% of sites. 
Image generated using WebLogo 3 (131,132) with data from (129). B: Chromatogram shows 







3.3.2.1 The frequency of IL36RN alleles differs between disease subtypes and ethnicities 
The prevalence of IL36RN-positive patients was much lower in PPP (5.1%) compared to GPP 
(23.7%) or ACH (17.4%). In addition, GPP and ACH patients were more likely to harbour bi-allelic 
changes. The prevalence of IL36RN variants was therefore significantly lower in PPP (0.03) than 
GPP (0.19; P = 1.9x10-14)) or ACH (0.15; P = 0.0018) (Table 3.6). Comparisons involving ACH 
should however be interpreted with caution, because of the small number of subjects. 
As the association between PPP and IL36RN variants has previously been questioned (14,41,42), 
the frequency of the recurrent p.Ser113Leu change was compared in British patients, (the 
largest geographically homogeneous group within the PPP cohort) vs. population-matched 
controls. This showed a very significant association between the disease allele and PPP 
(P=9.3x10-8; OR: 10.8; 95% CI: 5.3-22.0) (Table 3.7). 
While deleterious IL36RN alleles were seen in most ethnic groups, the genetic landscape varied 
between cohorts of different origin. In the East Asian and Malay datasets, the most common 
disease allele was the c.115+6T>C splicing variant, with MAFs of 0.238 and 0.098 respectively. 
In contrast, the most prevalent variant among Europeans was p.Ser113Leu, which had a MAF of 
0.29 in our sample. Previous work by the Capon group and others has produced evidence that 
both variants spread in their respective populations as the result of founder effects 
(40,44,130,133). 
Overall, the highest number of disease alleles was seen in European and East Asian patients 
(Figure 3.3, panel A). No IL36RN variants were detected in South Asian individuals, but this might 
reflect the small size of this particular cohort (n = 28), as a p.Leu21Pro (c.62T>C) change has 
been reported in two Pakistani siblings with paediatric GPP (134). 
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3.3.2.2 IL36RN disease alleles are associated with an earlier age of onset 
Next, the frequency of Il36RN variants were compared in patients with different phenotypic 
features (Table 3.8), using regression analysis. This method was utilised as the number of ACH 
cases carrying an IL36RN variant was too small for pairwise comparisons with GPP and/or PPP 
patients to be valid. No significant results were obtained when investigating the relationship 
between IL36RN status and plaque psoriasis concurrence. Conversely, a strong association 
between IL36RN variants and early disease onset was observed (P = 0.003). The presence of a 
dose-response was also apparent, with patients harbouring biallelic variants tending to develop 




Table 3.6 IL36RN variant frequency across disease types 
 ACH  GPP  PPP  Multiple diagnoses 
 Positive1 Negative  Positive1 Negative  Positive1 Negative  Positive1 Negative 









































1Patients were classified as ‘Positive’ if they were carrying at least one IL36RN variant 
Table 3.7 Association between IL36RN-p.Ser113Leu and PPP 
 p.Ser113Leu Wild type 
Cases1 11 (3.6%) 291 (96.4%) 
Controls2 26 (0.4%) 7402 (99.6%) 




Figure 3.3 Features of IL36RN variants within the cohort 
(A) There are significant differences in the combined frequency of alleles seen in patients of 
European, East Asian, Malay and South Asian descent. Comparison of allele frequencies across 
multiple groups was carried out by chi-squared test. Comparisons between two groups were 
implemented with Fisher’s exact test. Other mutations: alleles seen only once in the cohort. The 
notation c.115+6T>C;p.Pro76Leu refers to patients carrying the two variants on the same 
haplotype (44,130).  (B) Patients carrying variants in IL36RN have earlier disease onset. Statistical 
significance was assessed by linear regression.  **P < 0.01; ***P < 0.001.
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Table 3.8 Influence of IL36RN genotype on disease phenotype 
































































































3.3.3 Analysis of AP1S3 disease alleles 
To date, only two AP1S3 disease alleles (p.Phe4Cys (c.11T>G) and p.Arg33Trp (c.97C>T)) have 
been identified, both of which fall within the second exon of the gene (46,47). Therefore, while 
249 patients were screened for the entire coding region, the remaining 74 were only sequenced 
for exon 2. This identified 24 individuals who carried an AP1S3 variant (2 ACH, 4 GPP, 14 PPP and 
4 with multiple diagnoses) (Table 3.9). In keeping with published findings (41,44,47), these 
changes were only seen in the heterozygous state and in individuals of European descent. The 
frequency of disease alleles was similar in GPP (0.05), ACH (0.05) and PPP (0.03) (Table 3.10), 
although the small number of ACH and GPP cases means caution is required when comparing 
these groups. Of note, three patients (2 GPP, 1 PPP) carried both AP1S3 and IL36RN disease 
alleles (Table 3.11).  
While the analysis of genotype-phenotype correlations did not yield significant results, it is 
noteworthy that almost all patients with AP1S3 variants were female (23/24) (Table 3.12). The 
distortion of sex ratios does not reach statistical significance (P=0.06), but this may simply reflect 
the small number of AP1S3-positive individuals, raising the possibility that sex-specific factors 










 AP1S3 genotype3 
cDNA; protein 
OVS0021  ACH  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
OVS0024  ACH  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0111  GPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
SCAR1690  GPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
OVS0014  GPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GYFAP0163  GPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
025HHE49  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
100IRU41  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
PUS-06  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0029  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0052  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0056  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GBR0073  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0078  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GBR0082  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GBR0122  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GYFAP0019  PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GBR0140  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0149  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
P020022  PPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GYFAP0014  ACH + GPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0007  ACH + GPP  chr2:g.223777776  c.97C>T/-; p.Arg33Trp/- 
GBR0126  GPP + PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
GBR0009  GPP + PPP  chr2:g.223777862  c.11T>G/-; p.Phe4Cys/- 
1Patients highlighted in orange have not previously been reported; 2As per GRCh38 




Table 3.10 AP1S3 variant frequency across disease types1 
 ACH  GPP  PPP  Multiple diagnoses 
 Positive2 Negative  Positive2 Negative  Positive2 Negative  Positive2 Negative 



































1The p.Phe4Cys and p.Arg33Trp variants have no frequency in East-Asian populations and therefore were not screened in patients from 
this ethnic group. 2Patients were classified as ‘Positive’ if they were carrying at least one variant at the examined locus  
 




 IL36RN genotype 
cDNA; protein 
 AP1S3 genotype 
cDNA; protein 
SCAR1690  GPP  c.338C>T/c.130G>A; p.Val44Met/p.Ser113Leu  c.11T>G/-; p.Phe4Cys/- 
OVS0014  GPP  c.338C>T/-; p.Ser113Leu/-  c.11T>G/-; p.Phe4Cys/- 
ERS0251  PPP  c.338C>T/-; p.Ser113Leu/-  c.11T>G/-; p.Phe4Cys/- 
1Patients highlighted in orange have not previously been reported  
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Table 3.12 Influence of AP1S3 genotype on disease phenotype 
































































































3.3.4 CARD14 and pustular psoriasis 
Genetic studies of CARD14 have identified a clear disease allele hotspot spanning exons 3 and 4 
of the gene (40,48,51). The full coding region (21 exons) was therefore only screened in 106 
patients, whereas the remaining were only sequenced for exons 3 and 4.  
In addition to three previously reported Chinese cases carrying a heterozygous p.Asp176His 
(c.526G>C) change (48),  five British PPP patients were found to harbour rare variants in the 
gene (Table 3.13, Figure 3.4). These alleles were predicted to have damaging potential by online 
tools. Interestingly, three of the four variants were not located within the hotspot, illustrating 
the importance of continuing to explore regions outside of those of established interest. While 
six of the eight patients also suffered from plaque psoriasis, the small size of the dataset meant 
there was insufficient power to detect genotype-phenotype correlations. 
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1Patients highlighted in orange have not previously been reported; 2As per GRCh38 genome build; 3CARD14 transcript NM_024110; 
4A CADD score greater than 15 is indicative of pathogenicity 
 
Sample ID1  Diagnosis  Ethnicity  Chromosomal location2  
CARD14 genotype3 
cDNA; protein 
 CADD score4 
16GPP1  GPP  Chinese  chr17:g.80184089  c.526G>C/-; p.Asp176His/-  
26.7 81GPP1  GPP  Chinese  chr17:g.80184089  c.526G>C/-; p.Asp176His/-  
108GPP1  GPP  Chinese  chr17:g.80184089  c.526G>C/-; p.Asp176His/-  
GYFAP0018  PPP  European  chr17:g.80198512  c.1772C>T/-; p.Thr591Met/-  28.1 
GYFAP0023  PPP  Unknown  chr17:g.80184107  c.544C>T/-; p.Arg182Cys/-  24.3 
POPLM0002  PPP  European  chr17:g.80182675  c.234G>T/-; p.Lys78Asn/-  28.2 
POPLM0008  PPP  European  chr17:g.80202245  c.2044C>T/-; p.Arg682Trp/-  
35 




Figure 3.4 IGV visualisations of CARD14 variants 
Screenshots of IGV visualisation of variants seen in CARD14 by whole exome sequencing.  
A: c.234G>T; p.Lys78Asn. B: c.544C>T; p.Arg182Cys. C: c.1772C>T; p.Thr591Met. D: c.2044C>T; 
p.Arg682Trp. The recurrent c.526G>C; p.Asp176His variant is not shown as this is well 




This work aimed to analyse a large, multi-ethnic pustular psoriasis cohort for the purposes of 
identifying demographic, clinical and genetic distinctions between the disease subtypes. 
Previous studies have generally examined patients of only one ethnicity and/or been restricted 
by smaller cohort sizes (28,41,42,44,46,48). 
A high degree of heterogeneity was present within our dataset. However, there were clear 
differences between features of GPP and PPP. Generalised pustular psoriasis patients are on 
average 13 years younger when the disease manifests than those with PPP, and paediatric onset 
is not uncommon. Although both disease subtypes displayed a sex ratio skewed towards 
females, the bias was much greater in PPP. In contrast, while higher than the general population, 
the prevalence of plaque psoriasis was lower in PPP than GPP. Finally, an extremely high 
proportion of PPP patients had a history of smoking, and this was associated with increased 
rates of concurrent plaque psoriasis.   
The analysis of patient clinical and demographic characteristics therefore indicates that PPP 
largely affects middle-aged women with a history of smoking. These features have been 
reported by others (18,21,22,126,135), but this is the first demonstration that they are specific 
to PPP and differentiate the disease from other forms of pustular psoriasis.  
It is widely known that there are differences in the immune response that correlate with sex: 
females mount a stronger challenge to pathogens and also account for 80% of autoimmune 
disease cases (136,137). One of the more extreme sex biases is seen in systemic lupus 
erythematosus (SLE), where 90% of sufferers are female. A recent study has revealed that the 
gene encoding toll-like receptor 7 (TLR7), which drives a key pathway in SLE pathogenesis, 
escapes X chromosome inactivation in immune cells (138) and is therefore more active in 
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females. Meanwhile, transcriptomic analyses of human skin have identified the transcription 
factor VGLL3 (which is itself expressed more highly in females) as a key regulator of other 
female-biased targets that are associated with autoimmune diseases (139). Finally, examples of 
hormonal effects on the immune system include the numerous aspects of immunity that are 
affected by oestradiol, including monocyte differentiation, neutrophil proliferation and 
expression of pro-inflammatory cytokines (137).  It is therefore unsurprising to find a sex bias in 
pustular psoriasis, but in-depth functional studies will be needed to determine whether this 
phenomenon is mediated by any of the general mechanisms described above (skewed 
inactivation of X-linked genes, sex-specific differences in gene expression, hormonal influences). 
One hypothesis to explain the relationship between smoking and PPP is that the disease is the 
result of an excessive response to nicotine (127,140). To explore this possibility, a study 
examined the expression and distribution of nicotinic acetylcholine receptors (nAChRs, of which 
nicotine is an agonist) in the skin of healthy non-smokers, healthy smokers and PPP patients. 
Both α3 and α7 nAChRs exhibited abnormal distribution and elevated expression in lesional PPP 
skin. In addition, healthy smokers had higher nAChR levels than healthy non-smokers and 
atypical patterns of α7 nAChR staining were seen in non-lesional patient biopsies. This led the 
authors to suggest that smoking modulated nAChR expression and that the potential for 
abnormal nicotine responses exists in the skin of patients prior to the onset of inflammation 
(140).  
More recently, a link between smoking, the aryl hydrocarbon receptor (AhR) and psoriatic 
inflammation has emerged. Signalling via AhR downregulates expression of genes related to 
psoriasis, reducing levels of inflammation (141). The region encoding the repressor of the AhR 
pathway (AHRR) contains multiple CpG islands that are differentially methylated in smokers. In 
particular, smoking causes AHRR to become hypomethylated, which results in an increase in 
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gene expression. This is likely to downregulate the AhR pathway and impair its anti-
inflammatory function in skin (142,143). 
It is notable that PPP also appears distinct from GPP and ACH at the genetic level, with a much 
lower prevalence of IL36RN variants. Evidence for divergent immunopathogeneses was also 
observed in a study that profiled the transcriptome of GPP and PPP lesions, vs. that of normal 
skin. This revealed a number of differentially expressed genes (DEG) that were unique to each 
disease. Of note GPP-specific DEGs tended to cluster to very specific cellular processes (e.g. 
protein ubiquitination), while PPP-only DEGs showed significant enrichment for pathways 
related to T-cell signalling (144). Thus, PPP may be a disease driven by a dysfunction of adaptive 
immunity, caused by abnormalities in cytokines other than IL-36. Given that the IL-36 pathway 
has also been implicated in the pathogenesis of plaque psoriasis (25,33), it is possible that the 
lower rates of this condition in PPP may be linked to the relative rarity of IL36RN disease alleles.  
The association between IL36RN alleles and earlier disease onset has been previously reported 
in GPP (15) but here is robustly demonstrated in all disease forms. This work therefore suggests 
that patients with symptoms that appear before the age of 30 (GPP) or 40 (PPP/ACH) should be 
prioritised for IL36RN screening, in addition to GPP patients presenting with systemic 
inflammation (15).  
While it was not possible to detect statistically robust correlations between AP1S3 genotype and 
patient phenotype, an interesting trend was identified: almost all carriers of AP1S3 disease 
alleles are female. The screening of additional patients may help to bring statistical significance 
to this observation, which would then merit investigation into the sex-specific modifiers 
underlying the association. As described above, these could take the form of hormonal effects 
or interactions with proteins with sex-biased expression. 
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It was also difficult to draw conclusions from the results of the CARD14 screening, but a number 
of new alleles with pathogenic potential were identified. One of these variants (c.544C>T; 
p.Arg182Cys) lies within a known disease allele hotspot, in a region that encodes a coiled-coil 
domain. This has an autoinhibitory function, as it maintains the protein in a close conformation 
that prevents its oligomerisation in the absence of inflammatory stimuli. Disease alleles disrupt 
the regulatory function of the coiled-coil domain, leading to constitutive protein 
oligomerisation, which in turn causes abnormal NF-kB activation (48). However, other changes 
observed in this study were located outside of the coiled-coil region and so further work would 
be needed to experimentally validate their pathogenic potential. One variant, p.Lys78Asn 
(c.234G>T), maps to the caspase recruitment domain (CARD) region, while the remaining two 
(c.1772C>T; p.Thr591Met and c.2044C>T; p.Arg682Trp) are within a PDZ domain (145,146). 
Interestingly, a study found that, in CARD11, deletion of the wider region containing the PDZ 
domain resulted in elevated NFκB signalling (147). 
More broadly, the genetic analysis of the cohort emphasises the fact that known disease genes 
account for only a fifth of pustular psoriasis cases. There is therefore still a real need to identify 
new genes involved in disease pathogenesis, particularly in PPP where fewer than 10% of 
individuals harbour a known disease allele.  
Key to expediting the process of gene identification is the standardised ascertainment of 
patients, a task that has been facilitated by the work of the ERASPEN consortium (1,148). This 
work expands on the consensus diagnostic criteria outlined by ERASPEN and further 





4 Improving the classification of IL36RN variants 
4.1 The variant landscape of IL36RN 
In the seven years since IL36RN variants were first associated with pustular psoriasis, patient 
screening has revealed additional variants in the gene. As of October 2018, there are 20 alleles 
listed on Infevers (a registry of variants associated with hereditary auto-inflammatory disorders) 
(39), with an additional five awaiting upload. There are in total 18 missense substitutions, four 
stop-gain variants, one splicing change, and two deletions (Table 4.1). However, as the only 
requirement for inclusion on Infevers is that the variant has been seen in a patient, it is possible 
that there are benign variants included in the registry. Indeed, one allele listed on Infevers 
(c.140A>G; p.Asn47Ser) has a frequency of 5.4% in East Asians, suggesting it is unlikely to be 
disease-causing. This highlights the importance of examining population-specific data. 
It is not always practical for functional work to be promptly carried out to assess the effect of a 
new nucleotide change. Moreover, there is not a single in-vitro assay that has been applied to 
the analysis of all known variants and is considered as a gold standard in the field. In these 
circumstances, researchers and clinicians generally turn to one or more of a diverse range of in-
silico pathogenicity prediction tools. However, different algorithms have been used to assess 
the effects of different variants. 
This lack of consistency has important clinical implications, as IL36RN screening is increasingly 
used as a diagnostic test for generalised pustular psoriasis. Furthermore, it is likely that as the 
gene is sequenced in more patients, additional variants will be uncovered. There is therefore a 
clear need to achieve a better understanding of IL36RN alleles and their effects on protein 
function. Here, this goal was pursued by attempting a systematic characterisation of IL36RN 
missense variants, based on the integration of in-vitro and in-silico approaches.
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Table 4.1 Published variants in IL36RN  
Variant1 Type ExAC MAF (min – max)2 Original publication Chromosomal location; cDNA change3 
p.Val2Phe Missense NA4 Bal et al (149) chr2:g.113059442; c.4G>T 
p.Arg10X Stop-gain 0 – 1.156x10-4 Sugiura et al (150) chr2:g.113059466; c.28C>T 
p.Ser14X Stop-gain NA Tauber et al (151) chr2:g.113060863; c.41C>A 
p.Leu21Pro Missense NA Ellingford et al (134) chr2:g.113060884; c.62T>C 
p.Leu27Pro Missense 0 – 0.002611 Marrakchi et al (29) chr2:g.113060902; c.80T>C 
p.His32Arg Missense NA Korber et al (152) chr2:g.113060917; c.95A>G 
p.Lys35Arg Missense 0 – 4.97x10-4 Setta-Kaffetzi et al (44) chr2:g.113060926; c.104A>G 
c.115+5G>A Splicing motif disrupted 0 – 6.046 x10-5 This study (section 3.3) chr2:g.113060942; c.115+5G>A 
c.115+6T>C Splicing motif disrupted 0 – 0.01383 Farooq et al (133) chr2:g.113060943; c.115+6T>C 
p.Ile42Asn Missense 0 – 1.528x10-5 Takeichi et al (153) chr2:g.113062133; c.125T>A 
p.Val44Met Missense NA Mössner et al (41) chr2:g.113062138; c.130G>A 
p.Asn47Ser Missense 8.731x10-5 – 0.05405 Li et al (130) chr2:g.113062148; c.140A>G 
p.Arg48Trp Missense 0 – 0.001143 Onoufriadis et al (28) chr2:g.113062150; c.142C>T 
p.Pro76Leu Missense 0 – 0.001157 Korber et al (152) chr2:g.113062235; c.227C>T 
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p.Pro82Leu Missense 0 – 0.004636 Takahashi et al (43) chr2:g.113062454; c.245C>T 
p.Glu94X Stop-gain NA Korber et al (152) chr2:g.113062489; c.280G>T 
c.295_300del Non-frameshift deletion NA Mössner et al (41) chr2:g.113062504_113062508; 
c.295_300del 
p.Arg102Trp Missense 0 – 2.313x10-4 Setta-Kaffetzi et al (44) chr2:g.113062513; c.304C>T 
p.Arg102Gln Missense 0 – 1.501x10-5 Li et al (130) chr2:g.113062514; c.305G>A 
p.Arg103Gln Missense 0 – 1.515x10-4 Mössner et al (41) chr2:g.113062517; c.308G>A 
p.Glu112Lys Missense 0 – 1.502x10-5 Hayashi et al (154) chr2:g.113062543; c.334G>A 
p.Ser113X Stop-gain 0 – 1.502x10-5 Mössner et al (41) chr2:g.113062547; c.338C>A 
p.Ser113Leu Missense 0 – 0.006505 Onoufriadis et al (28) chr2:g.113062547; c.338C>T 
p.Thr123Arg Missense NA Farooq et al (133) chr2:g.113062577; c.368C>G 
p.Thr123Met Missense 0 – 6.056x10-5 Kanazawa et al (155) chr2:g.113062577; c.368C>T 
c.420_426del Frameshift deletion NA Arostegui et al (156) chr2:g.113062629_ chr2:g.113062634; 
c.420_426del 
1Name most commonly used in literature; 2Smallest and largest minor allele frequencies, taken from the Exome Aggregation 




4.2 Surveying the effects of IL36RN variants  
While the splicing, deletion and stop-gain alleles found on Infevers are very likely to have 
deleterious effects on the IL-36Ra protein, missense changes are not so easily classified. This 
study therefore assessed all 18 missense variants that have been observed in pustular psoriasis 
cases (patient set, Table 4.2). To further explore the relationship between in-silico predictions 
and functional impact, a further 12 non-synonymous SNVs were selected, so as to represent 
variation that affects various protein segments and is associated with a broad range of CADD 




Table 4.2 IL36RN variants selected for study: patient set 
Variant rs ID Location; cDNA change1 
p.Val2Phe rs1292126146 chr2:g.113059442; c.4G>T 
p.Leu21Pro rs1285007154 chr2:g.113060884; c.62T>C 
p.Leu27Pro rs387906914 chr2:g.113060902; c.80T>C 
p.His32Arg NA chr2:g.113060917; c.95A>G 
p.Lys35Arg rs187015338 chr2:g.113060926; c.104A>G 
p.Ile42Asn rs775349262 chr2:g.113062133; c.125T>A 
p.Val44Met rs776622427 chr2:g.113062138; c.130G>A 
p.Asn47Ser rs28938777 chr2:g.113062148; c.140A>G 
p.Arg48Trp rs151325121 chr2:g.113062150; c.142C>T 
p.Pro76Leu rs139497891 chr2:g.113062235; c.227C>T 
p.Pro82Leu rs144182857 chr2:g.113062454; c.245C>T 
p.Arg102Trp rs199932303 chr2:g.113062513; c.304C>T 
p.Arg102Gln rs371819085 chr2:g.113062514; c.305G>A 
p.Arg103Gln rs542606182 chr2:g.113062517; c.308G>A 
p.Glu112Lys rs143724424 chr2:g.113062543; c.334G>A 




p.Thr123Met chr2:g.113062577; c.368C>T 
1As per GRCh38 genome build and IL36RN transcript NM_012275  
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Table 4.3 IL36RN variants selected for study: population set 
Variant rs ID Location; cDNA change1 
ExAC MAF 
(min – max)2 
CADD 
Score3 
p.Gln25Arg rs867378394 chr2:g.113060896; c.74A>G NA4 23.4 
p.Glu41Gln rs771984756 chr2:g.113062129; c.121G>C 0 – 1.1174x10-4 23.5 
p.Ala52Thr rs755465505 chr2:g.113062162; c.154G>A 0 – 1.158x10-4 16.7 
p.Cys70Arg rs375718709 chr2:g.113062216; c.208T>C 0 – 1.926x10-4 24.0 
p.Thr77Ile rs372880215 chr2:g.113062238; c.230C>T 0 - 0.001114 1.2 
p.Lys93Glu rs746109701 chr2:g.113062486; c.277A>G 0 - 1.156x10-4 0.07 
p.Tyr101Phe rs769214649 chr2:g.113062511; c.302A>T 0 – 3.853x10-4 12.3 
p.Glu138Lys rs750580815 chr2:g.113062621; c.412G>A 0 - 1.505x10-5 9.5 
p.Gly141Asp rs758533837 chr2:g.113062631; c.422G>A 0 - 1.508x10-5 0.03 
p.Ala144Thr rs780261792 chr2:g.113062639; c.430G>A 0 - 6.047x10-5 0.17 
p.Ile146Val rs202059991 chr2:g.113062645; c.436A>G 0 – 2.576x10-4 13.0 
p.Gln153Arg rs771496493 chr2:g.113062667; c.458A>G 0 - 1.559x10-5 9.5 
1As per GRCh38 genome build and IL36RN transcript NM_012275; 2Smallest and largest minor 
allele frequencies, taken from the Exome Aggregation Consortium; 3Correct as of Jan 2018; 4NA: 





4.2.1 In-silico pathogenicity predictions 
Table 4.4 and Table 4.5 display the output for all assessed variants from three commonly used 
pathogenicity prediction tools (correct as of October 2018). These were selected to ensure there 
was no overlap in the annotations used in the respective training sets. Two popular in-silico 
predictors (SIFT and PolyPhen-2) are not shown here, because they formed part of the training 
data for CADD (96). It should be noted that the work in the following chapter was carried out 
prior to the analysis described here, and utilised aspects of a pre-established pipeline where 
annotations from SIFT, PolyPhen-2 and CADD were examined in parallel. As such, the variant 
scoring system outlined in Materials and Methods (Table 2.12) does not apply here. 
The most conservative tool was PROVEAN, which classified most variants (8/18 in the patient 
set and 11/12 in the population set) as ‘Neutral’. In contrast, CADD predicted that virtually all 
changes (18/18 in the patient set and 9/12 in the population set) would have an effect on protein 
function. The output of MutationTaster was between that of PROVEAN and CADD with half of 
the changes labelled as “Polymorphism” (5/18 in the patient set and 10/12 in the population 
set) and the other half as “Disease Causing”. As a result of these discrepancies, the majority of 
variants (8/18 in the patient set and 8/12 in the population set) were associated with discordant 
predictions, highlighting the need for functional characterisation.  
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Table 4.4 Pathogenicity predictions for variants in the patient set 
Variant PROVEAN MutationTaster CADD1 
c.4G>T; p.Val2Phe  Neutral Disease causing 25.4 
c.62T>C; p.Leu21Pro  Deleterious Disease causing 27.3 
c.80T>C; p.Leu27Pro  Deleterious Disease causing 23.3 
c.95A>G; p.His32Arg  Neutral Polymorphism 19.17 
c.104A>G; p.Lys35Arg  Neutral Disease causing 22.8 
c.125T>A; p.Ile42Asn  Deleterious Disease causing 26.9 
c.130G>A; p.Val44Met  Neutral Polymorphism 18.35 
c.140A>G; p.Asn47Ser  Neutral Polymorphism 22.2 
c.142C>T; p.Arg48Trp  Deleterious Disease causing 25.4 
c.227C>T; p.Pro76Leu  Deleterious Disease causing 22.7 
c.245C>T; p.Pro82Leu  Neutral Disease causing 21.6 
c.304C>T; p.Arg102Trp  Deleterious Disease causing 22.9 
c.305G>A; p.Arg102Gln  Neutral Polymorphism 25.2 
c.308G>A; p.Arg103Gln  Neutral Polymorphism 21.5 
c.334G>A; p.Glu112Lys  Deleterious Disease causing 27.1 
c.338C>T; p.Ser113Leu  Deleterious Disease causing 22.8 
c.368C>G; p.Thr123Arg  Deleterious Disease causing 23.4 
c.368C>T; p.Thr123Met  Deleterious Disease causing 23.6 




Table 4.5 Pathogenicity predictions for variants in population set 
Variant PROVEAN MutationTaster CADD1 
c.74A>G; p.Gln25Arg  Neutral Polymorphism 23 
c.121G>C; p.Glu41Gln  Neutral Disease causing 24.5 
c.154G>A; p.Ala52Thr  Neutral Polymorphism 19.1 
c.208T>C; p.Cys70Arg  Deleterious Disease causing 23.9 
c.230C>T; p.Thr77Ile  Neutral Polymorphism 10.63 
c.277A>G; p.Lys93Glu  Neutral Polymorphism 7.538 
c.302A>T; p.Tyr101Phe  Neutral Polymorphism 18.54 
c.412G>A; p.Glu138Lys  Neutral Polymorphism 11.99 
c.422G>A; p.Gly141Asp  Neutral Polymorphism 1.371 
c.430G>A; p.Ala144Thr  Neutral Polymorphism 3.766 
c.436A>G; p.Ile146Val  Neutral Polymorphism 18.7 
c.458A>G; p.Gln153Arg  Neutral Polymorphism 18.36 
1CADD scores>15 are considered as evidence of pathogenicity; here 
CADD scores between 10 and 15 were classed as intermediate in order 
to avoid missing variants of moderate effect.  
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4.2.2 Protein expression 
As missense changes may affect protein expression, the results of pathogenicity predictions 
were followed up by investigating the effects of IL36RN variants on IL-36Ra expression. HeLa 
cells were transfected with wild-type and myc-tagged IL36RN constructs and the lysates were 
analysed by western blotting, using an anti-myc antibody. In this system, the intensity of the 
band visible on the Western blot serves as a proxy for protein expression.  
The assay confirmed that well-characterised disease-causing alleles (p.Leu27Pro and 
p.Ser113Leu) result in a marked reduction in protein expression. Conversely, the p.Asn47Ser 
variant, which has high frequency in East Asian populations, did not appear to affect IL-36Ra 
levels. Thus, control samples behaved as expected. 
A third (5/15) of the remaining missense changes from the patient set exhibited reduced 
expression (p.Ile42Asn, p.Pro76Leu, p.Glu112Lys, p.Thr123Arg, p.Thr123Met; Figure 4.1).  
Many of the alleles from the population set had little effect on protein expression (Figure 4.2). 
There were, however, some exceptions. The p.Glu41Gln and p.Glu138Lys, p.Gly141Asp changes 
were associated with reduced IL-36Ra levels and p.Cys70Arg severely disrupted expression, such 
that no protein was visible in the blot.  
Thus, reduced protein expression is a relatively common effect of IL36RN alleles. However, there 
are other mechanisms whereby amino acid changes can affect protein activity. For example, it 
has been shown that the p.Val2Phe change disrupts the processing step which activates IL-36Ra 
(149). Similarly, it has been suggested that p.His32Arg may impair the interaction between IL-
36Ra and the IL-36 receptor (151). It was therefore important to examine whether the variant 





















Figure 4.1 The expression of variant forms of IL-36Ra, patient set 
(A) Image displays representative Western blot, with variants in order seen in graph. (B) 
Densitometry measurements were derived with ImageJ and the ratio of myc-tagged IL-36Ra to 
β-actin was calculated for each lane. Plots show mean ratios observed in at least two 
independent transfections. Error bars show standard error; the red line indicates the mean ratio 
for wild type IL-36Ra. The mean ratio for each variant was compared to wild type by Dunnett’s 





L-R: Wild type, p.Val2Phe, p.Leu21Pro, 
p.Leu27Pro, p.His32Arg, p.Lys35Arg, 
p.Ile42Asn, p.Val44Met, p.Asn47Ser, 
p.Arg48Trp, untransfected control  
L-R: Wild type, p.Pro76Leu, p.Pro82Leu, 
p.Arg102Trp, p.Arg102Gln, p.Arg103Gln, 











Figure 4.2 The expression of variant forms of IL-36Ra, population set 
(A) Image displays representative Western blot, with variants in order seen in graph. (B) 
Densitometry measurements were derived with ImageJ and the ratio of myc-tagged IL-36Ra to 
β-actin was calculated for each lane. Plots show mean ratios observed in at least two 
independent transfections. Error bars show standard error; the red line indicates the mean ratio 
for wild type IL-36Ra. The mean ratio for each variant was compared to wild type by Dunnett’s 





L-R: Wild type, p.Gln25Arg, p.Glu41Gln, p.Ala52Thr, 
p.Cys70Arg, p.Thr77Ile, p.Lys93Glu, p.Tyr101Phe, 




4.2.3 Protein activity 
The biological activity of a subset of IL-36Ra alleles was investigated by assaying the effects of 
wild type or variant IL-36Ra on IL-36 signal transduction. The examined variants included three 
that were predicted to be pathogenic and were found to reduce protein expression (p.Leu27Pro, 
p.Pro76Leu,p.Ser113Leu), four that were predicted to be benign and did not affect protein 
expression (p.Thr77Ile, p.Lys93Glu, p.Ala144Thr, p.Gln153Arg), three for which the results of 
pathogenicity predictions and western blots were contradictory (p.Arg102Trp, p.Glu138Lys, 
p.Gly141Asp) and two where the expression assay was inconclusive (p.Leu21Pro, p.Arg48Trp). 
Wild type or variant forms of IL-36Ra were generated by transfecting HEK293 cells with myc-
tagged constructs and then purifying the recombinant protein from whole cell lysates. HeLa cells 
which stably over-expressed the IL-36 receptor (HeLa-IL-36R) were then incubated with purified 
IL-36Ra, before stimulation with IL-36α. Finally, IL-8 induction was measured by ELISA (Figure 
4.3). In the presence of functional IL-36Ra, IL-8 up-regulation is limited as the receptor 
antagonist will be competing with IL-36α for binding to IL-36R. If the antagonist is not functional, 
IL-8 production will be elevated. 
The assay showed a clear distinction between the activity of wild type IL-36Ra and that of 
proteins harbouring the p.Leu27Pro or p.Ser113Leu disease alleles. In fact, the latter were 
associated with IL-8 levels that were comparable to those observed in the positive control, 
where no IL-36Ra was added (Figure 4.4). The damaging effect of the variants p.Pro21Leu, 
p.Arg48Trp, Pro76Leu and p.Glu138Lys was also confirmed, along with the benign nature of 
p.Thr77Ile and p.Gln153Arg. However, a reduced level of antagonist activity was seen with three 





Figure 4.3 Outline of protein activity assay 
Flowchart describes key steps of the procedure to assess biological 





Figure 4.4 Most IL36RN variants affect IL-36 signal transduction 
The plot shows mean IL-8 production observed in at least two stimulation experiments, each 
carried out with a different batch of recombinant IL-36Ra. Error bars show standard error, red 
line indicates mean IL-8 production in presence of wild type IL-36Ra. The mean for each variant 
was compared to wild type by Dunnett’s multiple comparisons test. Pos: positive control (no IL-
36Ra); ** P < 0.01; **** P < 0.0001
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4.3 The relationship between in-silico predictions and the results of 
in-vitro assays 
There were interesting parallels between the pathogenicity predictions and the outcome of the 
western blot expression assay, with consistent results obtained for 22 out of 30 alleles (Table 
4.6). However, it is evident that in-silico tools do not perform well with the variants that disrupt 
the function of the protein but not the expression. For instance, p.Lys93Glu and p.Ala144Thr 
appeared benign on the basis of pathogenicity predictions, and did not affect protein levels, but 
nonetheless resulted in increased IL-8 production. The functional assay was therefore key in 
revealing the damaging effect of these variants. It also confirmed the pathogenicity of 
p.Arg102Trp, which appeared benign when analysed by western blotting (Table 4.6).  
Since the activity assay was only implemented on a subset of variants, unresolved discrepancies 
remain between in-silico and in-vitro findings (e.g. for p.Val2Phe and p.Pro82Leu). However, as 
previously mentioned, in the case of p.Val2Phe the discrepancy can be explained by the detailed 
functional work carried out by Bal et al. This demonstrated that the effect of this variant was to 
prevent removal of the N-terminal methionine, which is essential for protein activity, while 
having no effect on protein expression (149,157).  
In this context, the analysis of the 12 alleles that were fully characterised indicates that a 
consensus pathogenicity prediction based on the prevailing outcome from PROVEAN, 
MutationTaster and CADD would have 60% sensitivity and 100% specificity in differentiating 
IL36RN disease alleles from benign changes.  
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Table 4.6 Summary of variant assessment results 
Variant  In-silico tools Expression assay Activity assay 
p.Val2Phe  Damaging Benign  
p.Leu21Pro  Damaging Intermediate Damaging 
p.Gln25Arg  Benign Benign  
p.Leu27Pro  Damaging Damaging Damaging 
p.His32Arg  Benign Benign  
p.Lys35Arg  Damaging Intermediate  
p.Glu41Gln  Damaging Damaging  
p.Ile42Asn  Damaging Damaging  
p.Val44Met  Benign Benign  
p.Asn47Ser  Benign Benign  
p.Arg48Trp  Damaging Intermediate Damaging 
p.Ala52Thr  Benign Benign  
p.Cys70Arg  Damaging Damaging  
p.Pro76Leu  Damaging Damaging Damaging 
p.Thr77Ile  Benign Benign Benign 
p.Pro82Leu  Damaging Benign  
p.Lys93Glu  Benign Benign Damaging 
p.Tyr101Phe  Benign Benign  
p.Arg102Trp  Damaging Benign Damaging 
p.Arg102Gln  Benign Benign  
p.Arg103Gln  Benign Benign  
p.Glu112Lys  Damaging Damaging  
p.Ser113Leu  Damaging Damaging Damaging 
p.Thr123Arg  Damaging Damaging  
p.Thr123Met  Damaging Damaging  
p.Glu138Lys  Benign Damaging Damaging 
p.Gly141Asp  Benign Damaging Damaging 
p.Ala144Thr  Benign Benign Damaging 
p.Ile146Val  Benign Benign  




Over the past seven years, IL36RN variants have been assessed with a variety of in-silico tools 
and, in some cases, in-vitro methods. Prior to this work, the most comprehensive study was 
published in 2016 and included 9 of the 18 missense alleles listed in Table 4.1 (151). The 
expression of these variants was investigated in a similar way as has been utilised here, but 
protein activity levels were explored through a luciferase reporter assay. Other in-vitro methods 
used to assess the impact of changes in IL-36Ra include mass spectrometry (149), stimulation of 
patient cells (28,29), thermostability assays (29) and immunohistochemistry in patient skin 
(133,150).  
These disparate means of assessment make it difficult to compare the effects of all published IL-
36Ra variants on protein function. However, it is also important to note that in some instances 
(e.g. p.Val2Phe) a more unusual method of investigation (e.g. mass spectrometry) may be 
necessary to characterise the precise outcome of a missense substitution. Therefore, any future 
IL36RN-specific classifier should take into account the fact that such ‘outlier’ variants may not 
be fully described by an integration of more basic assay techniques. 
Despite concerns over the reliability of pathogenicity prediction tools, this study has shown that 
by integrating the results from three independent tools (PROVEAN, MutationTaster and CADD) 
a good degree of correlation between in-silico and in-vitro findings can be achieved. 
Applying the same three in-silico tools to all the 64 IL36RN missense changes reported on ExAC 
suggests that 60.9% (39/64) would be pathogenic. However, it is likely that the true proportion 
is even greater, given that the prediction tools do not perform as accurately for variants that 
impact protein activity but do not reduce expression. Of note, 63 of the 64 variants are rare 
(MAF<0.5%), which is also consistent with the notion of a damaging effect.   
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Therefore, it seems that the IL-36Ra protein is sensitive to missense changes, with the majority 
likely to reduce protein levels and/or render it inactive. This contrasts with the IL36RN constraint 
metrics that are reported on ExAC, which suggest broad tolerance to missense changes (negative 
z score) and nonsense alleles (probability of being loss-of-function intolerant = 0). As the coding 
region of IL36RN is only 468 nucleotides in length it seems likely that the power of the ExAC 
calculations has been reduced by the small size of the gene and resulting low number of possible 
variants (158).  
It is also possible that variants in IL36RN are not always disadvantageous, particularly if they 
occur in the heterozygous state. A moderate reduction in antagonism of the IL-36 receptor, 
causing a small rise in the expression of IL-36 target genes, could increase the immune response 
within a safe and beneficial range. 
Beyond these general considerations, however, it is evident that popular pathogenicity 
prediction tools are not sufficiently robust for use in a diagnostic setting, even when the outputs 
of different programs are combined in a consensus score.  
As previously described, the greatest weakness of the in-silico approach was in assessing 
variants that likely affect the binding of IL-36Ra to the IL-36 receptor. Thus, the identification of 
the residues which are key to this interaction could improve the accuracy of pathogenicity 
predictions.  
A recent study mapped the structure of mouse IL-36Ra onto that of human IL-36γ and found 
that the greatest structural differences between the two were found in the β4/5, β6/7 and 
β11/12 loops, which connect the β sheets found within the protein. More specifically, in mouse 
IL-36Ra β4/5 was shorter and β11/12 was longer. Subsequent experiments, utilising modified 
human IL-36Ra, indicated that loop β4/5 was particularly important for antagonist activity (31).   
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Examination of the residues in IL-1β that interact with IL-1RaCP (an accessory protein mediating 
both IL-1 and IL-36 signalling) also suggests that other key residues lie in IL-36Ra β sheets 8 and 
9 (31). Interestingly, these include p.Arg103, which does not destabilise protein folding when 
mutated into a Gln (Table 4.6, Figure 4.5).  
If the IL-36Ra/IL-36R interaction can be accurately reconstructed in 3D, it should be possible to 
integrate the location of key residues into an improved prediction model. Detailed examination 
of both the crystal structure of murine IL-36Ra (148) and the available human ‘loop-swapped’ 
models (147) may also reveal the residues most likely to disrupt the folding of the protein into 
its β-trefoil tertiary structure. These analyses are ongoing in the Capon lab and hold the promise 





Figure 4.5 Schema of IL-36Ra showing the  location of assayed variants within the protein secondary structure 
Figure displays the locations of variants assayed in this study, alongside key secondary structures within IL-36Ra. Colouring of variants reflects that used in 
Table 4.6, with red indicating damaging, green benign and orange intermediate. Location of β-sheets (blue) and α-helices (pink) taken from Dunn et al and 
Gunther et al (31,32). Lighter blue highlighting indicates residues identified as being within a β-sheet by only one of these publications.
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5 Identification of new candidate genes by whole exome 
sequencing 
5.1 Analysis of eight acrodermatitis continua of Hallopeau cases 
Gene discovery was initially pursued through the analysis of a tightly phenotyped dataset, 
comprising eight isolated ACH cases. None of the patients carried rare variants in IL36RN, AP1S3 
or CARD14; all were European and most suffered from adult-onset disease. Two affected 
individuals also presented with other forms of pustular psoriasis, and three had a history of 
plaque psoriasis (Table 5.1).  
5.1.1 Preliminary data filtering 
Because the cases were isolated, it was not possible to infer whether the causative variant would 
be likely to be homozygous or heterozygous. The data was therefore analysed twice: first 
assuming a recessive and then a dominant inheritance pattern (Figure 5.1). 
In total the eight exomes contained 196,859 variants, an average of 24,607 changes per patient. 
All synonymous variants were removed, along with variants annotated as ‘unknown’. Of the 
remaining alleles only those with an ExAC (159) global MAF ≤ 0.05 were retained (the disease 
itself is rare and so it was expected that the causative mutation would also occur with low-
















S0655  ACH  F  European  51  Y 
S0657  ACH  F  European  82  N 
S0658  ACH  M  European  49  N 
S0660  ACH  F  European  56  Y 
S0661  ACH  F  European  42  N 
S1948  ACH, GPP  F  European  49, 55  N 
S1953  ACH, PPP  F  European  17, 17  Y 




5.1.2 Analysis of homozygous and compound heterozygous variants 
If a disease allele is recessive, it will be seen in patients in the homozygous or compound 
heterozygous state. Starting from the set of non-synonymous variants with a MAF ≤0.05, 
homozygous alleles were therefore combined with potentially compound heterozygous variants 
for the recessive analysis. This generated a dataset of 6,316 variant calls (~790 per patient). 
The data was next filtered to remove alleles with a MAF greater than 0.05 in ExAC, 1000 
Genomes (72) or in-house sequencing datasets, and insertions or deletions (INDELs) of more 
than three bases. This step aimed to reduce the number of sequencing artefacts and left 1,928 
variants. HLA alleles were also filtered out, because the coding regions have high levels of 
sequence similarity and so it is difficult for alignment algorithms to map exome sequencing reads 
to the correct gene reliably. 
Any change affecting the 100 genes most frequently mutated in public exomes was also 
excluded, based on the work of Shyr et al., who found that rare variants in these genes are less 
likely to be disease-associated (120). At each filtering stage, the data set was re-examined: genes 
that were mutated in only one patient and heterozygous variants for which the compound 
partner had been removed were excluded from subsequent analysis. 
In total, 462 variant calls (298 unique changes) were carried forward for assessment by 
pathogenicity prediction software. The exome sequencing coverage of those classified as 
damaging by a majority of tools (at least 3/5), and that of stop-gain substitutions was also 
reviewed with the Interactive Genome Viewer (IGV) (121).  
At the conclusion of this analysis, no gene was found which harboured rare, damaging 
homozygous changes in more than one exome. One gene (TLN2, NM_015059) was identified 
where the same combination of heterozygous alleles was present in two affected individuals: 
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c.196G>A (chr15:g.62650143; p.Ala66Thr) and c.197C>A (chr15:g.62650144; p.Ala66Glu). 
However, closer examination of the sequencing reads revealed that these variants exist as a 
haplotype, and so could not be acting as compound heterozygotes (Figure 5.2).  
Therefore, it is unlikely that the causative gene exhibits a recessive mode of inheritance, unless 





Figure 5.1 Filtering process for ACH exomes 
Diagram describes the steps taken to prioritise variants seen in the 8 ACH exomes, for both 




Figure 5.2 Screenshot from IGV showing the two TLN2 variants affecting p.Ala66 
The c.196G>A (p.Ala66Thr) and c.197C>A (p.Ala66Glu) changes are always seen in the 
same read and so are found on the same chromosome. The actual amino acid change here 
is therefore p.Ala66Lys.  
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5.1.3 Analysis of heterozygous variants 
A filtering process similar to that utilised for the recessive analysis was applied when assuming 
dominant inheritance. The key differences were the expected zygosity of the disease allele and 
the lower MAF requirement (ExAC MAF of ≤0.01). Using these criteria, the original 196,859 
variants were reduced to 9,166 non-synonymous heterozygous changes (1,146 per exome, on 
average). After examination with pathogenicity prediction tools and review of sequencing 
coverage, 230 variant calls in 110 genes remained.  
Previous studies have shown that the known pustular psoriasis genes (IL36RN, AP1S3 and 
CARD14) are all strongly expressed in keratinocytes (51,160,161). It was therefore hypothesised 
that this would also apply to the disease gene under investigation. RNA sequencing data, 
previously generated by the Capon group in primary keratinocytes (25), was examined to assess 
the expression pattern of the genes harbouring potentially pathogenic variants. Sixty-five loci 
(harbouring a total of 136 variant calls) were retained in the analysis, as they had greater than 7 
reads per kilobase per million (RPKM), placing them in the top 75% of expressed genes. 
The majority of the 65 genes that passed all previous stages were only mutated in two patients. 
However, there were three genes which showed variants in three different individuals 
(ARFGAP2, JADE1 and NPHP3) (Table 5.2). These loci were examined in a further 104 pustular 
psoriasis exomes, previously generated by the Capon group (Table 5.3). This identified rare and 
potentially pathogenic alleles in all three genes. Among these, one ARFGAP2 variant (c.1036G>A; 
p.Asp346Asn) was shared by two affected relatives (a Malay father and daughter, who both 
suffered from GPP) (Table 5.4, Figure 5.3). As the other two genes were not mutated in familial 




Of note, there are two translated isoforms of ARFGAP2 (NM_032389 and NM_001242832), the 
shorter of which is a splicing variant lacking exon 5. However, real-time PCR undertaken in 
biologically relevant cell types (primary keratinocytes, HaCaT immortalised keratinocytes and 
peripheral blood mononuclear cells) indicated that the full-length isoform was the dominant 
transcript in all examined samples (Figure 5.4). Thus, no pathogenicity predictions were 
implemented to assess the impact of the variants on the shorter isoform. 
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Table 5.2 Candidate alleles observed in the original 8 patients 








































































































Disease causing 24.9 
1As per GRCh38 genome build; 2A CADD score over 15 is normally deemed pathogenic 
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Table 5.3 Summary demographics for the 104 exome sequenced patients in follow-up whole cohort 
 Diagnosis Sex Ethnicity Plaque psoriasis? Mean age 
of onset 
(yrs) 



































1Includes two patients with ACH + GPP and one with GPP + PPP  
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Table 5.4 Rare damaging variants in prioritised genes in follow-up exomes 

























































































































Figure 5.3 IGV visualisations of ARFGAP2 WES variants 
IGV visualisation of ARFGAP2 variants seen in whole exome sequencing. Note that ARFGAP2 lies 
on the reverse strand. A: c.308A>G; p.Asn103Ser. B: c.958G>A; p.Val320Met. C: c.1036G>A; 




Figure 5.4 Relative expression of long (NM_032389) and short (NM_001242832) isoforms 
of ARFGAP2 
Mean expression levels from two separate RNA samples are plotted with ±SD bars. The 
β2M housekeeping gene was used as an internal control. PKC: primary keratinocytes; 




5.1.4 Candidate gene follow up  
The ARFGAP2 variants seen in the original eight patients and the familial case were confirmed 
by Sanger sequencing (Figure 5.5).  Next, the 16 ARFGAP2 coding exons were screened in an 
additional dataset, including 96 Asian GPP patients (Table 5.5). No rare variants were observed 
in the 39 affected individuals of Chinese and Indian descent. Conversely, two rare substitutions 
(c.674T>C; p.Leu225Pro and c.1036G>A; p.Asp346Asn) with pathogenic potential were found in 





Table 5.5 Summary demographics for the Asian GPP patients screened for ARFGAP2 








































33.9 5 78 
 





































Neutral Tolerated Possibly damaging Disease causing 27.5 
1As per GRCh38 genome build and transcript NM_032389; 2Variants predicted damaging by at least 3 algorithms were considered pathogenic; 3A CADD 




Figure 5.5 Examples of variants in ARFGAP2 confirmed by Sanger sequencing 
Chromatograms displaying heterozygous changes seen in ARFGAP2. A: c.308A>G; p.Asn103Ser. 






5.1.5 Comparison to control populations 
The association between a disease and a set of rare variants affecting a given locus can be 
assessed using a burden test. In its simplest form, this is implemented by comparing the 
combined frequency of rare alleles in cases vs controls, using a one-tailed Fisher’s exact test 
(162). 
Here, the Singapore Sequencing Malay Project (SSMP) dataset (103), which includes whole 
genome sequences from 96 healthy Malay individuals, was used as a control dataset for the 
Malay population The analysis of this cohort uncovered four individuals, each carrying a rare 
heterozygous and potentially damaging ARFGAP2 change (Table 5.7). The comparison with the 
allele frequency measured in Malay cases returned P = 0.376 (Table 5.8), indicating that 
ARFGAP2 variants are not associated with the disease in Malay patients. 
For the 112 European cases (including the 8 original ACH cases and the 104 exomes in the follow-
up dataset) the control population were the Non-Finnish Europeans reported in ExAC (159), 
where a total of 621 rare, pathogenic, alleles (135 independent variants) were seen in 32,649 
individuals. Here the burden test demonstrated a significant enrichment for ARFGAP2 variants 
in cases compared to controls (P = 0.009, Table 5.9). This data does not, however, reach the 





Table 5.7 ARFGAP2 variants found in Malay controls 









































































1As per GRCh38 genome build and transcript NM_032389; 2From a total of 96 individuals from the Singapore Sequencing Malay Project; 
3Variants predicted damaging by at least 3 algorithms were considered pathogenic; 4A CADD score over 15 is normally deemed pathogenic 
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Table 5.8 Burden association test for ARFGAP2 in Malay cases 
Allele counts in cases1  Allele counts in controls2  P value3 
Alt/All Frequency  Alt/All Frequency   
4/124 0.0323  4/192 0.1484  0.376 
1Familial cases counted as if a single individual; 2Control data from SSMP; 3One-sided P value 
from Fisher’s exact test 
 
Table 5.9 Burden association test for ARFGAP2 in European cases 
Allele counts in cases  Allele counts in controls1  P value2 
Alt/All Frequency  Alt/All Frequency   
6/186 0.0322  621/65298 0.0095  0.009 
1Control data from ExAC Non-Finnish Europeans; 2One-sided P value from Fisher’s exact test 
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5.2 Analysis of a paediatric-onset generalised pustular psoriasis 
case 
5.2.1 Case selection 
A female paediatric case of generalised pustular psoriasis (disease onset at 9yrs) was whole 
exome sequenced prior to the onset of the study. The individual belonged to a population 
enriched for parental relatedness (Roma travellers) (163,164), and was the offspring of first 
cousins. Thus, a recessive mode of disease inheritance was assumed, where the proband was 
expected to have inherited two copies of the same variant, lying on identical haplotypes.  
5.2.2 Filtering of the exome profile 
The exome of this proband contained 24,581 variants, of which 10,441 (42.5%) were 
homozygous and 5,582 were also non-synonymous. Filtering to remove common changes (ExAC, 
1000 Genomes or in-house MAF ≥0.05) left 101 to be investigated in more detail (Figure 5.6).  
First, the haplotype background of these alleles was assessed. As it was assumed that the 
pathogenic variants would be identical by descent, it followed that they should map to a wider 
region of homozygosity. Changes were therefore retained if they lay within a homozygosity 
block of at least 2Mb. This was a low threshold, as stretches of homozygosity <3Mb in length are 
commonly found even in outbred populations (165). Following this step, 41 variants remained; 
30 were single nucleotide variants (SNVs), 6 were splicing changes and 5 were insertions or 
deletions (INDELs).  
Pathogenicity prediction software suggested that 11 SNVs could be damaging. As in the analysis 
of heterozygous variants in the ACH profiles, genes with low expression in keratinocytes (RPKM 
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Figure 5.6 Filtering process for exome from paediatric case 




Table 5.10 Candidate alleles identified in the paediatric GPP patient 
  
 
























































































































5.2.3 Screening prioritised genes in additional exomes 
To establish whether any of the prioritised genes also contained variants in other affected 
individuals, the 112 whole exome profiles described in the previous section (Table 5.1 and Table 
5.3) were queried. Low-frequency (MAF <0.02) alleles were found in 6 of the 7 genes (Table 
5.11).  
The largest number of changes was found in ZNF33A, where 21 alleles were identified (Figure 
5.7). These included a c.720G>C (p.Glu240Asp) substitution found in 11 unrelated European 
patients and a c.806C>T (p.Pro269Leu) allele detected in 2 Asian affected relative pairs (two 
siblings and two first cousins once removed). All changes were predicted to be deleterious by at 
least one algorithm.  
The gene harbouring the second highest number of variants was WWOX, with 17 changes. 
However, one of these substitutions (c.646C>G; p.Leu103Val) was predicted to be benign by all 
algorithms and none of the others were shared by affected family members.  
From this analysis, ZNF33A therefore emerged as the most promising candidate disease gene.
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Table 5.11 Low-frequency variants in detected in the follow-up of candidate genes1 



































































































0.0064 Tolerated Deleterious 
Possibly 
damaging 




















































0.0035 Tolerated Neutral Benign Polymorphism 4.645 










S2651, S2653, S2701, 
S2745, S2751, S2764 




















































































S0129, S0661, S1058, 
S1953, S2628, S2631, 
S2652, S2698, S2708, 
S2752, S2815 





S1056, S1412, S1413, 
S1414, S2706 





























Figure 5.7 IGV visualisations of ZNF33A WES variants 
Representative examples of IGV visualisations of ZNF33A variants seen in whole exome 
sequencing. A: c.354A>C; p.Gln118His. B: c.627T>A; p.His209Gln. C: c.720G>C; p.Glu240Asp. D: 




5.2.4 Candidate gene screening 
The original c.1076G>A (p.Cys359Tyr) change and the recurrent c.720G>C (p.Glu240Asp) and 
c.806C>T (p.Pro269Leu) variants were confirmed by Sanger sequencing (Figure 5.8). To further 
investigate the association with ZNF33A, the gene was next screened in an additional 372 
pustular psoriasis patients (201 European, 78 Malay, 42 East Asian, 24 South Asian and 27 other) 
(Table 5.12). Given that p.Glu240 and p.Pro269 accounted for the majority of alleles identified 
in affected individuals, the screening prioritised these two variants. All cases were sequenced 
for the genomic segment encompassing the two changes, with a subset of 43 screened for the 
entire gene locus. 
This analysis identified 41 additional patients carrying rare or low-frequency variants with 
pathogenic potential (Table 5.13). Of particular interest were the 19 European and 14 Asian 










Figure 5.8 Examples of WES variants in ZNF33A confirmed by Sanger sequencing  
Chromatograms displaying alleles seen in paediatric case and examples of recurrent variants. 
A1: Homozygous c.1076G>A (p.Cys359Tyr); A2: Wild-type c.1076G (p.Cys359); B: Heterozygous 








Table 5.12 Summary demographic information for the ZNF33A validation cohort 
 Diagnosis Sex Ethnicity 
 GPP  ACH PPP 
Multiple 
diagnoses 





































Table 5.13 ZNF33A variants seen in validation cohort 
















33GPP1, 88GPP1, GBR0019, 
GBR0047, GBR0056, GBR0057, 
GBR0058, GBR0059, GBR0063, 
GBR0064, GBR0083, GBR0086, 
GBR0137, GYFAP0163, GYPLM0036, 
OVS0016, OVS0020, OVS0026, 
POPLM0018, PUS-04, PUS-08, PUS-
17,PUS-19 

















101GPP1, 127GPP1, 12GPP1, 26GPP1, 
30GPP1, 3GPP1, 37GPP1, 50GPP1, 
5GPP1, 67GPP1, 69GPP1, 6GPP1, 
70GPP1, 76GPP1, LCPLM0002, 
LCPLM0005 









1As per GRCh38 genome build and transcript NM_006954; 2A CADD score greater than 15 is normally deemed pathogenic
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5.2.5 Comparison to control populations 
The frequency of the recurrent c.720G>C (p.Glu240Asp) and c.806C>T (p.Pro269Leu) variants 
was compared in patients and relevant control populations. A Fisher’s exact test revealed that 
the frequency of p.Pro269Leu was not significantly increased in East Asian, Malay or South Asian 
patients, compared to healthy controls (P>0.05 in all datasets and in the meta-analysis of the 
three cohorts) (Table 5.14, Figure 5.9).  
However, p.Glu240Asp was associated with pustular psoriasis in both the British/Irish and Non-
British European populations (P = 0.006 and P = 0.018) (Table 5.15), with a meta-analysis of the 
two datasets yielding a P value of  0.46x10-4 (Odds ratio: 1.984, Figure 5.10).  
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Table 5.14 Association test for c.806C>T (p.Pro269Leu) allele in Asian patient populations 
 











































0.58 – 4.43 
1Data from East Asians in gnomAD; 2Data from Singapore Sequencing Malay 









Figure 5.9 Meta-analysis of c.806C>T (p.Pro269Leu) in Asian patients 
Forest plot displaying data from three Asian populations. The weights of the populations in the 
meta-analysis are 42.9%, 35.8% and 21.4% respectively. The squares indicate the effect size for 
each subgroup and the horizontal lines through the squares show the length of the confidence 
interval. The black diamond represents the effect size and confidence intervals when the three 
populations are combined. MH: Mantel-Haenszel method of meta-analysis. Generated using 
Comprehensive Meta-Analysis Version 3 (122). 
Statistics for each study MH odds ratio and 95% CI Weight (Fixed)
MH odds Lower Upper Relative Relative Std Std Std 
ratio limit limit Z-Value p-Value weight weight Residual Residual Residual
East Asian 0.786 0.288 2.147 -0.469 0.639 42.86 1.66
Malay 1.144 0.443 2.951 0.278 0.781 35.78 2.74
South Asian 1.597 0.576 4.428 0.900 0.368 21.36 3.50
1.087 0.616 1.919 0.289 0.773
0.1 0.2 0.5 1 2 5 10












Table 5.15 Association test for c.720G>C (p.Glu240Asp) allele in European patient populations 
 
































1.4 – 8.7 












Figure 5.10 Meta-analysis of c.720G>C (p.Glu240Asp) in European patients 
Forest plot displaying data from two European populations. The weight of the British/Irish 
population in the meta-analysis is 90.1% and for the Other European group is 9.9%. The squares 
indicate the effect size for each subgroup and the horizontal lines through the squares show the 
length of the confidence interval. The black diamond represents the effect size and confidence 
intervals when the two populations are combined. MH: Mantel-Haenszel method of meta-
analysis. Generated using Comprehensive Meta-Analysis Version 3 (122). 
Study name Statistics for each study MH odds ratio and 95% CI Weight (Fixed)
MH odds Lower Upper Relative Relative Std Std Std 
ratio limit limit Z-Value p-Value weight weight Residual Residual Residual
British/Irish 1.817 1.193 2.767 2.782 0.005400093 90.11 12.76
Other European 3.508 1.410 8.726 2.699 0.006960585 9.89 6.69
1.984 1.353 2.910 3.506 0.000455429
0.1 0.2 0.5 1 2 5 10













5.3.1 Analysis of acrodermatitis continua of Hallopeau cases 
The attempt to identify a new disease gene through the analysis of ACH cases further highlights 
the genetic heterogeneity of pustular psoriasis. No gene had biallelic variants in more than one 
case and no gene was mutated in heterozygosity in more than three individuals. In these 
circumstances, power to detect a disease-associated allele was reduced and the analysis of the 
prioritised gene (ARFGAP2) yielded results that were difficult to interpret. 
ARFGAP2 variants were not associated with pustular psoriasis in the Malay population, but the 
analysis of European cases showed an enrichment for rare pathogenic variants among patients. 
While this was statistically significant, exome-wide significance levels were not reached. 
The result obtained in the Malay sample may reflect the extremely small size of the control 
cohort, which limited the power to detect a significant association. Of note, larger Malay 
datasets are now being generated (166). This will enable the group to investigate the role of 
ARGFAP2 variants in an adequately powered sample. 
While the European cohort was larger, reaching exome-wide significance would have required 
the screening of additional patients. For example, based on an analysis with the Genetic Power 
Calculator (125,167), a further 120 cases would be needed for an allele with a MAF of 0.005 and 
a genotype relative risk (GRR) of 5, similar to the GRR reported for IL36RN (44). Alternatively, 
the variant would need to have a larger effect (e.g. a GRR of 7). 
It is also possible that the P value observed among European patients may represent a spurious 
association, with the genuine disease allele erroneously removed during the filtering process. In 
this context, relaxing the MAF or pathogenicity cut-offs may reveal additional candidate genes 
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for follow-up. It should also be remembered that the use of WES reduces the likelihood of 
detecting large duplications or deletions, which are better identified by whole genome 
sequencing. Finally, although it is certainly plausible that the causative variants could 
demonstrate a digenic pattern of inheritance, a digenic analysis was not carried out here. With 
data from only 8 patients, it is likely that the study would have lacked power. Additionally, an 
extremely stringent significance threshold would have been necessary to compensate for the 
degree of multiple testing present in this type of analysis.  
5.3.1.1 The function of ARFGAP2 
While it is as yet unclear whether the association between ARFGAP2 alleles and pustular 
psoriasis is genuine, it is interesting to note the overlap in function with a known disease 
associated protein, APσ1C, a subunit of the AP-1 complex. This is recruited by Arf1-GTP during 
the formation of a clathrin-coated vesicle. Before the vesicle can fuse with its target membrane, 
ARf1 must hydrolyse GTP to GDP in order for the coat to dissociate. ADP Ribosylation Factor 
GTPase Activating Protein 2 (ARFGAP2) is required for the hydrolysis of GTP by Arf1, which has 
very low intrinsic GTPase activity (168). Therefore, if the function of ARFGAP2 is disrupted, so to 
would be aspects of AP-1 dependent intracellular trafficking, providing a possible role for 
ARFGAP2 in disease aetiology. 
5.3.2 Analysis of paediatric case 
5.3.2.1 Association with pustular psoriasis 
Stepwise filtering of a whole exome profile identified a rare and damaging homozygous variant 
(c.1076G>A; p.Cys359Tyr), lying within ZNF33A. This gene is highly expressed in a disease 
relevant cell type and was located in a large region of homozygosity (25.8Mb).  
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Examination of additional exome profiles revealed two recurring low frequency variants 
(c.720G>C; p.Glu240Asp and c.806C>T; p.Pro269Leu), which were found in a number of 
unrelated individuals. Although these changes were only observed in the heterozygous state, 
the results obtained in the IL36RN analysis show that a disease locus can harbour bi-allelic 
variants in some patients and mono-allelic defects in others (44).  
Further patient screening demonstrated that c.720G>C (p.Glu240Asp) is associated  with 
pustular psoriasis at a level approaching exome wide significance. The study has therefore 
identified a set of disease alleles with varying effect sizes. These include an extremely rare 
change with strong indicators of pathogenicity (p.Cys359Tyr) and a low frequency variant  
(p.Glu240Asp) with a more subtle effect on protein function, indicated by a moderately sized 
odds ratio. 
In this context, it is important to note that the pathogenicity predictions for c.720G>C 
(p.Glu240Asp) are weak, as the damaging effect of the variant is supported by a single algorithm 
(CADD). However, pathogenicity predictions are likely to be less reliable for recently evolved 
genes. And indeed, this is the case for ZNF33A, which only has orthologues in primates 
(106,169). Of interest, Itan et al demonstrated that the correct CADD, SIFT and PolyPhen-2 
thresholds for pathogenicity vary on a gene-to-gene basis, indicating that, where possible, a 
gene-specific approach to variant assessment is more appropriate (99).  
While the recent evolution of ZNF33A, and the resulting impact on the effectiveness of 
pathogenicity tools, may explain the weaker predictions, there is a heightened need for in-vitro 
confirmation of a damaging effect caused by the c.720G>C (p.Glu240Asp) allele. Mutagenised 
constructs are being generated so that the expression, stability and intracellular localisation of 
wild-type and variant proteins can be compared.  
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5.3.2.2 The function of ZNF33A 
ZNF33A encodes a zinc-finger transcription factor of the KRAB (Krüppel-associated box) domain-
containing family. These proteins bind DNA via multiple C2H2 zinc-finger motifs, while their 
KRAB domain associated with the universal repressor known as KRAB Associated Protein 1 
(KAP1) (170). Thus, KRAB zinc fingers confer target specificity to the silencing activity of KAP1.  
The consensus sequence for the C2H2 motif is φ-X-Cys-X(2-4)-Cys-X3-φ-X5-φX2-His-X(3,4)-His 
(where φ is a hydrophobic residue and X can be any residue), with the key cysteine and histidine 
residues binding a zinc ion, which stabilises the structure of the finger (170). ZNF33A 
encompasses 16 C2H2 motifs, encoded by exon 5. Notably, the homozygous p.Cys359Tyr 
change, identified in the original paediatric case, affects the first key cysteine residue within the 
second C2H2 motif. It is therefore likely to affect formation of this zinc finger structure. Three 
additional changes (p.Gly615Arg, p.Ser678Leu and p.Thr709Ile) also map to C2H2 motifs, 
altering broadly conserved residues. The remaining variants are mostly found in the linker region 
between the KRAB domain and the C2H2 zinc fingers, where they may affect protein folding and 
stability (Figure 5.11). 
There are over 700 KRAB-ZNFs within the human genome, with a wide range of transcriptional 
targets (171). While the specific function of ZNF33A is currently unknown, it is noteworthy that 
other KRAB proteins have been involved in various aspects of immune function, most notably 
antiviral defence and NF-κB signalling. Thus, it is tempting to speculate that loss-of-function 
ZNF33A alleles may cause excessive inflammatory signalling.  
Efforts are ongoing within the Capon group to elucidate the mechanisms whereby ZNF33A 
contributes to disease pathogenesis. As the protein binds DNA, it would be particularly 
informative to identify its targets. Of note, a systematic ChIP-Seq study of 39 KRAB proteins 
(including ZNF33A) has been published and the raw data is publicly available (172). The analysis 
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of this dataset may provide insights into the genes that are regulated by ZNF33A and the 





Figure 5.11 Schematic of ZNF33A variants seen in exomes 
Four of the eight variants identified in patients map to C2H2 motifs within the zinc finger domain, with p.Cys359Tyr affecting a key residue within the second 
of sixteen motifs. The remaining four variants lie within a region without annotated function but may affect the overall folding of the protein. Location of 
domains taken from Uniprot (173,174). 
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6 Final discussion 
6.1 Genetic advances 
A pustular form of psoriasis was first described in 1910 (175), but over 100 years later our 
understanding of disease aetiology is still incomplete, and available treatments are often 
ineffective (8). This contrasts with plaque psoriasis, where a more extensive knowledge of the 
immunopathogenesis has transformed treatment efficacy, particularly for severe disease  
(22,176).  
The first genetic determinants of plaque psoriasis were identified in the 1990s (177), whereas 
IL36RN alleles were only uncovered in 2011 (28,29). Work reported here (section 3.3.2) and 
published by others has shown that a small number of recurrent and well-characterised variants 
(p.Leu27Pro, p.Arg48Trp, p.Ser113Leu, c.115+6T>C) account for the majority of IL36RN disease 
alleles in northern Europe, north Africa and East Asia (2,15,28,29). 
However, as IL36RN screening is extended to further populations, the incidence of private 
variants will increase. Of note, IL36RN is now included on diagnostic gene panels for 
autoinflammatory syndromes (85), so new sequence changes will likely be identified in patients 
without a pre-existing GPP diagnosis. This will further complicate the interpretation of genetic 
findings. 
It is therefore clear that reliable in-silico predictions will be needed for IL36RN alleles which have 
not been functionally characterised. This study has demonstrated that currently available 
algorithms have their limitations, particularly in the case of variants that do not alter protein 
expression. However, databases such as ClinVar (178) or Infevers (179) may provide important 
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guidance – a rare sequence change that has already been seen in an individual with a similar 
phenotype is more likely to be pathogenic. 
Following the identification of IL36RN variants, disease-associated alleles have been identified 
in two additional genes (AP1S3 and CARD14) (46,48). However, the majority of cases remain 
unaccounted for (41).  
This study has demonstrated that genetic heterogeneity is present even in cohorts of robustly 
phenotyped patients. One notable example is that Malay subjects had much higher rates of 
plaque psoriasis. It would therefore be interesting to explore whether this can be linked to a 
variant that is both Malay specific and associated with plaque psoriasis.  
While IL36RN and AP1S3 alleles accounted for a sizeable minority of generalised pustular 
psoriasis (GPP) and acrodermatitis of Hallopeau (ACH) cases, their frequency in PPP was 
significantly lower. It therefore seems likely that the genetic architecture of PPP is distinct from 
that of GPP, a hypothesis which is reflected in contrasting demographic and phenotypic data.  
Here, genetic heterogeneity has also affected attempts to identify further disease genes by 
whole exome sequencing (WES). While a promising ZNF33A change (c.1076G>A; p.Cys359Tyr) 
was uncovered in a GPP subject who was the offspring of first cousins, the ZNF33A variants 
found in the broader patient cohort are relatively common in the general population (minor 
allele frequency >1%) and seem to have a modest impact on protein function. As such, these 
ZNF33A alleles are more likely to act as modifiers than major genetic determinants of the 
disease. 
Therefore, it appears increasingly probable that the genetics of pustular psoriasis is more 
complex than initially thought and that the ‘low-hanging fruits’ have already been discovered. 
In this context, it seems likely that future advances will come from alternative investigative 
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routes. If further analyses of WES data do take place, it would be interesting to utilise the 
recently published technique of ‘blacklisting’ variants seen frequently in private exome cohorts 
but not public databases, which has been shown to be effective at removing non-pathogenic 
variants (80). 
In pulmonary arterial hypertension (PAH), a rare condition with an autoinflammatory 
component, epigenetic dysregulation has been found to play a role in disease development 
(180). It is possible that changes affecting non-coding RNAs, histone modifications and DNA 
methylation may also underlie some cases of pustular psoriasis, especially given the marked 
association between palmoplantar pustulosis and smoking.  
In amyotrophic lateral sclerosis (ALS) which, like PPP, is rare and genetically heterogeneous, a  
disease-associated locus (C21orf2) has been identified by undertaking a genome-wide 
association scan (GWAS) (181,182).  
Classical GWAS, which are intended to detect common variants with small effect sizes, typically 
require several thousand cases. However, if the underlying disease alleles have a moderate 
effect then smaller datasets can still yield positive results. In fact, a new PAH gene was recently 
identified through the analysis of only 256 affected individuals (183).  
As the underlying genetic architecture could be similar in palmoplantar pustulosis, a GWAS (or 
exome-wide association study (EWAS)) may be feasible through the involvement of an 
international consortium such as ERASPEN. Patients are being actively ascertained to this 
project, as well as the PLUM study, and so the size of patient cohorts continues to grow. 
By utilising the common CRF described in this study, it may also be possible to stratify affected 
individuals into more homogenous groups. This would be of particular interest in palmoplantar 
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pustulosis, where in-depth phenotyping could identify further correlations between genotypic 
and clinical features, leading to an improved understanding of the disease.  
6.2 Interaction with environmental factors 
It is clear that pustular psoriasis develops as a result of both genetic and environmental factors, 
not least because of the wide range of phenotypes that can be observed in individuals who carry 
the same disease allele. One way to explain this is that genetic disrupt the balance between pro- 
and anti-inflammatory factors, such as the IL-36 receptor agonists and antagonist, or the levels 
of NF-κB mediated gene expression. However, these deviations are generally small enough that 
individuals remain apparently unaffected until they are exposed to an environmental trigger 
which further tips the balance. Following the same logic, the more damaging the alleles carried, 
the smaller the environmental trigger need be. In the mouse model with complete knock-out of 
IL-36Ra, pups generally die young with significant skin abnormalities (38). In humans the effect 
of carrying homozygous disease alleles is not so severe, but is significantly associated with earlier 
onset (15). 
As described in section 1.1.4, the IL-36 pathway can drive pro-inflammatory feedback loops that 
lead to increased neutrophil infiltration, pustule formation and, in some GPP cases, systemic 
involvement. The age at which a trigger is encountered, or the degree to which one is exposed, 
could then help to explain the range of clinical presentations that are seen. 
One aspect of pustular psoriasis pathogenesis that remains poorly understood is the systemic 
nature of some disease triggers, such as upper respiratory tract infections, stress or vaccination. 
Presumably some individuals possess a genetic or epigenetic background that leaves them 
predisposed to systemic effects; if this could be better understood then it would allow for 
identification of patients at greater risk of extracutaneous involvement. Ongoing work carried 
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out in the Capon group indicates that IL-36 has systemic effects on plasmacytoid dendritic cells 
(pDC), which may amplify the response to infections. 
Women are more likely to develop pustular psoriasis than men and disease onset is generally 
pre/peri-menopausal (mean age of onset for women within the cohort described here was 
41.2yrs). In addition, cases of pustular psoriasis during pregnancy usually resolve after delivery 
(6). The implication is therefore that changes in female hormones may be one of the more 
common disease triggers. The finding that almost all subjects who carried an AP1S3 variant were 
female (section 3.3.3) may reveal a route into understanding the female bias seen in pustular 
psoriasis. 
6.3 Translational implications 
The most recent and exciting development in pustular psoriasis research has been the 
emergence of a new class of biologics that act by blocking IL-36 signal transduction. The 
potential of this therapeutic approach was initially shown by Mahil et al (25), who reported that 
IL-36 receptor deficiency does not adversely affect human immune function. This observation 
led the authors to suggest that pharmaceutical blockade of the same receptor would be, in all 
likelihood, safely tolerated. 
This prediction was borne out by the results of an open label, phase I trial (NCT02978690), 
conducted by Boehringer Ingelheim in generalised pustular psoriasis patients. Seven affected 
individuals (flaring at the time of treatment) received a single dose of BI 655130, an anti-IL-36 
receptor antibody. The primary endpoint of safety and tolerability was successfully met, with no 
severe adverse events or infections reported. In addition, all seven patients achieved a clear or 
nearly clear status within four weeks, with five maintaining it until the conclusion of the trial (20 
weeks) (184,185). Notably, only three of the seven patients carried an IL36RN variant. This 
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reinforces the notion, also supported by transcriptomic studies (25,56), that IL-36 is a key driver 
in GPP, regardless of the patient variant status.  
 A second IL-36 receptor neutralising antibody, ANB019, has been produced by AnaptysBio (27) 
and will soon be tested in a multi-centre trial, led by St John’s Institute of Dermatology 
(NCT03619902). This will involve 10 affected individuals and will include genetic and 
transcriptomic studies of patient material. 
Both Boehringer Ingelheim and AnaptysBio plan to further test their molecules in PPP patients 
(NCT03135548 and NCT03633396 studies, respectively). However, IL-36 blockade may be less 
beneficial in these individuals, due to the differences between GPP and PPP. In fact, the data 
obtained in this study indicate that IL36RN alleles are found in less than 5% of PPP cases.  
The Capon group have also exome sequenced 100 unrelated PPP patients and have seen very 
little evidence for involvement of genes related to IL-36 signal transduction. Further 
transcriptomic studies are needed to complement these genetic observations and clarify to what 
extent IL-36 de-regulation is a feature of PPP. 
6.4 Conclusions 
The future for pustular psoriasis patients seems brighter than just a decade ago. In particular, 
significant progress has been made in the understanding of GPP. This demonstrates the 
translational potential of genetic studies and how a single breakthrough can, within just a few 
years, lead to exciting new drugs entering clinical trials. 
Although more frequent, PPP remains poorly understood at the genetic level. Whole exome data 
generated by the Capon group suggest that this form of pustular psoriasis is particularly 
heterogeneous. The ascertainment of large patient samples through multi-centre studies may 
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help overcome this barrier. Thus, the progress that has been made in forming international 
collaborations holds the promise of facilitating the identification of new disease genes and 
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IL36RN Exon 2 
IL36RN_1F GCTCCGTGGAGGCTGTTC 
62 PCR and Sanger sequencing 
IL36RN_1R CACAATTTCCCAGCTGCAAT 
IL36RN Exon 3 
IL36RN_2F GGAGACAAGGCTGTGCTGTT 
59 PCR and Sanger sequencing 
IL36RN_2R GCTTAGAGCCTGGTTTGTGC 
IL36RN Exon 4 
IL36RN_3F CTGCTGAGAAGCCTCCCTTC 
62 PCR and Sanger sequencing 
IL36RN_3R CAAAGCTGCCATCAACAGAA 
IL36RN Exon 5 
IL36RN_4F TTCTGTTGATGGCAGCTTTG 
59 PCR and Sanger sequencing 
IL36RN_4R GGTCAGGTGCCCACTAAGTC 
AP1S3 Exon 2 
AP1S3_2F TTTCAGTGTCTTTGCAGAACG 
59 PCR and Sanger sequencing 
AP1S3_2R CCCCAGCCTTCAAAGATTTC 
CARD14 Exon 3 
CARD14_3F ACCCAGCAGAACCCAGAAA 
64 PCR and Sanger sequencing 
CARD14_3R AAGGGGGAGTAGGGCAAAT 
CARD14 Exon 4 
CARD14_4F TGCTCACCTGCTCACCTAC 




ARFGAP2 Exon 1+2 
ARFGAP2 Ex1+2F AGATCGGACTCCAATCACCC 
66 PCR and Sanger sequencing 
 
ARFGAP2 Ex1+2R CTTCCCACCGAATTCAGAGC 
ARFGAP2 Exon 3 
ARFGAP2_3F GACAGGTATCCGGGTTGC 
59 PCR and Sanger sequencing 
ARFGAP2_3R TGACCAGTTTCGAAGTTTTCAG 
ARFGAP2 Exon 4+5 
ARFGAP2_4-5F AACCGGTGTCAGTAGCGTGT 
62 PCR and Sanger sequencing 
ARFGAP2_4-5R CTAGGCCTACCCAGCAGGA 
ARFGAP2 Exon 6+7 
ARFGAP2_6-7F TGATTTCTTGTCCACAAGGTG 
59 PCR and Sanger sequencing 
ARFGAP2_6-7R CAGGCAGTAGGACCTCTGAA 
ARFGAP2 Exon 8 
ARFGAP2_8F CCTTGCCTGAAGCTGTTCTT 





59 PCR and Sanger sequencing 
ARFGAP2_9-10R GCATCCCAAACTGCTAGGAA 
ARGAP2 Exon 10 ARFGAP2_10F_INT ATGTAAGTGTTTGCTGCCGG n/a Sanger sequencing 
ARFGAP2 Exon 11 
ARFGAP2_11F TGGGTAAGGACAGAAGGCTC 
60 PCR and Sanger sequencing 
ARFGAP2_11R TTGTCCTTGTACCTAGGGAGA 
ARFGAP2 Exon 12 
ARFGAP2_12F TTGGTACTTTCGCCTCTGGA 





ARFGAP2 Exon 13 
ARFGAP2_13F AATGCTGACGAAGCTGTGTG 








ARFGAP2 Exon 14 ARFGAP2_14R_INT CCTGTAAAACAAGAGCAGGGT n/a Sanger sequencing 
ARFGAP2 Exon 15 ARFGAP2_15F_INT ATGGATGGAGCTCACGGAG n/a Sanger sequencing 
ARFGAP2 Exon 16 
ARFGAP2_16F CAGCTCTCACCGTGGACTC 
62 PCR and Sanger sequencing 
ARFGAP2_163R CAAGGGCTGGTACTGACCAT 
ZNF33A Exon 2 
ZNF334_Ex2F CCATTTCTACCGCCTATTCCG 
67 PCR and Sanger sequencing 
ZNF334_Ex2R ACCGAGATGGGGACATTGTA 
ZNF33A Exon 3 
ZNF334_Ex3F TCCAGCAGTGATGATAGTTCCAG 
60 PCR and Sanger sequencing 
ZNF334_Ex3R TCTTCTGGTACTCAGAGGTG 
ZNF33A Exon 4 
ZNF334_Ex4F GTGTTGATTGATCACCTCTG 
62 PCR and Sanger sequencing 
ZNF334_Ex4R_v2 AGGACACTGAAAGTGCTTG 
ZNF33A Exon 5 
ZNF334_Ex5_P1F CATGGGGCATTTGTTTAGC 





ZNF33A Exon 5 
ZNF334_Ex5_P2F GTTCTGTCAGTGTGATTCAT 
56 PCR and Sanger sequencing 
 
ZNF334_Ex5_P2R TTCATAGATACCCCATGAG 
ZNF33A Exon 5 
ZNF334_Ex5_P3F GTTCCATCAGATATCTCCGTCAAG 
62 PCR and Sanger sequencing 
ZNF334_Ex5_P3R CTCTGGTGTACTTTAAGGTGC 
ZNF33A Exon 5 
ZNF334_Ex5_P4F GAAACCCTATCAATGTAATGCG 
64 PCR and Sanger sequencing 
ZNF334_Ex5_P4R CTGTGTGTGTTCTCTGATGTAC 
ZNF33A Exon 5 
ZNF334_Ex5_P5F CTCACAGTACATCAGAGAACA 
64 PCR and Sanger sequencing 
ZNF334_Ex5_P5R CTCTGATGTTGAGCAAGTTCC 
ZNF33A Exon 5 
ZNF334_Ex5_P6F GAATGTGGGAAATTCTTCAGG 
58 PCR and Sanger sequencing 
ZNF334_Ex5_P6R CTTTGGAGTAACATAAGGTG 
ZNF33A Exon 5 ZNF33Aint TGTGACTTCTGGTAGAAGGC n/a Sanger sequencing 
IL36RN V2F 
Mut_V2F_F CGCGATCGCCATGTTCCTGAGTGGGGC 





























































































n/a Plasmid mutagenesis 
 
Mut_Q153R_R GTTGCCCTAGTCACACCGCTGGAAGTAGAAGTC 
CMV RB_CMV_F CGGGGTCATTAGTTCATAGCC n/a Sanger sequencing 
T7 promoter T7F TAATACGACTCACTATAGGG n/a Sanger sequencing 
hGH poly(A) region hGH rev CAACTCAAATGTCCCACCGG n/a Sanger sequencing 
bGH poly(A) region BGHextra1 CTTCTAGTTGCCAGCCATC n/a Sanger sequencing 
ARFGAP2 full 
length cDNA 
ARFGAP2 Q F main TCACTCCCCAGAGAAGAAGG 
n/a Real-time qPCR 
ARFGAP2 Q R main CAGGCCACTGCTCTCTGTAGA 
ARFGAP2 cDNA 
lacking exon 5 
ARFGAP2 Q F 2nd ATGGCACTGATCCCCCTGC 
n/a Real-time qPCR 
ARFGAP2 Q R 2nd TCTGTGTTGGGGCCATGCT 
IL8 cDNA 
IL8_Fwd TTGGCAGCCTTCCTGATTTC 
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Background: The term pustular psoriasis indicates a group of
severe skin disorders characterized by eruptions of neutrophil-
filled pustules. The disease, which often manifests with
concurrent psoriasis vulgaris, can have an acute systemic
(generalized pustular psoriasis [GPP]) or chronic localized
(palmoplantar pustulosis [PPP] and acrodermatitis continua of
Hallopeau [ACH]) presentation. Although mutations have been
uncovered in IL36RN and AP1S3, the rarity of the disease has
hindered the study of genotype-phenotype correlations.
Objective: We sought to characterize the clinical and genetic
features of pustular psoriasis through the analysis of an
extended patient cohort.
Methods: We ascertained a data set of unprecedented size,
including 863 unrelated patients (251 with GPP, 560 with PPP,
28 with ACH, and 24 with multiple diagnoses). We undertook
mutation screening in 473 cases.
Results: Psoriasis vulgaris concurrence was lowest in PPP (15.8%
vs 54.4% in GPP and 46.2% in ACH, P < .0005 for both), whereas
themean age of onset was earliest inGPP (31.0 vs 43.7 years in PPP
and51.8 years inACH,P<.0001 forboth).Thepercentage of female
patients was greater in PPP (77.0%) than in GPP (62.5%;
P5 5.83 1025). The same applied to the prevalence of smokers
(79.8% vs 28.3%, P < 10215). Although AP1S3 alleles had similar
frequency (0.03-0.05) across disease subtypes, IL36RNmutations
were less common in patients with PPP (0.03) than in those with
GPP (0.19) andACH (0.16; P5 1.93 10214 and .002, respectively).
Importantly, IL36RN disease alleles had a dose-dependent effect on
age of onset in all forms of pustular psoriasis (P5 .003).
Conclusions: The analysis of an unparalleled resource revealed
key clinical and genetic differences between patients with PPP and
those with GPP. (J Allergy Clin Immunol 2018;nnn:nnn-nnn.)
Key words: Generalized pustular psoriasis, palmoplantar pustulo-
sis, acrodermatitis continua of Hallopeau, IL36RN, AP1S3, geno-
type-phenotype correlation
The term pustular psoriasis refers to a group of severe
inflammatory skin disorders manifesting with repeated eruptions
of painful neutrophil-filled pustules. These conditions can present
with acute episodes of skin pustulation and systemic upset
(generalized pustular psoriasis [GPP]) or chronic pustular
eruptions that affect the palms and soles (palmoplantar pustulosis
[PPP]) or the tips of fingers and toes (acrodermatitis continua of
Hallopeau [ACH]). Of note, all forms of the disease can be
complicated by concurrent psoriasis vulgaris (PV).1
We and others have shown that mutations of the gene encoding
the IL-36 receptor antagonist (IL36RN) are associated with GPP.2,3
Although these defects are observed mostly in the homozygous or
compound heterozygous state, a number of patients carrying single
heterozygous changes have also been reported.4
Disease alleles associated with GPP have been identified
subsequently in AP1S3 (encoding a subunit of the adaptor protein
1 complex)5 and CARD14 (encoding a keratinocyte nuclear factor
kB adaptor protein).6 Of note, IL36RN, CARD14, and AP1S3
mutations have also been described in patients with PPP and those
with ACH, demonstrating a shared genetic basis for pustular forms
of psoriasis.5,7,8 Patients harboring disease alleles at 2 distinct loci
(IL36RN and AP1S3; IL36RN and CARD14) have also been
reported.9,10 Thus an increasingly complex picture is emerging
with evidence of substantial genetic heterogeneity, pleiotropy (the
phenomenonwhereby a single gene can influencemore than 1 trait),
and digenic inheritance.
In this context analysis of genotype-phenotype correlations
would facilitate stratification of patient cohorts and streamline the
genetic diagnosis of disease subtypes. However, rigorous studies
have been hindered by the rarity of pustular psoriasis, which has
prevented the ascertainment and standardized phenotyping of
sizeable patient resources.
Here we sought to address this issue through formation of a
multicenter consortium. We brought together 8 tightly pheno-
typed patient cohorts through a collaboration with the European
Rare and Severe Psoriasis Expert Network (ERASPEN). This
enabled us to ascertain a unique clinical resource, including 863
unrelated cases and exceeding by nearly 3-fold the size of any
published data set. Analysis of this extended cohort revealed very
significant differences in the clinical and genetic features of
pustular psoriasis subtypes. Specifically, it demonstrated that PPP
differs from ACH and GPP in terms of patients’ demographics,
disease presentation, and underlying genetic abnormalities.
METHODS
Patient ascertainment
This research was carried out in accordance with the principles of the
Declaration of Helsinki and was approved by the ethics committees of
Abbreviations used
ACH: Acrodermatitis continua of Hallopeau
ERASPEN: European Rare and Severe Psoriasis Expert Network
GPP: Generalized pustular psoriasis
PPP: Palmoplantar pustulosis
PV: Psoriasis vulgaris
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participating institutions. Written informed consent was also obtained from all
participants. The study aligned 8 patient cohorts (n 5 863) recruited in the
reference centers listed in Table E1 in this article’s Online Repository at
www.jacionline.org. The largest resource (n 5 255 British and Irish cases)
was provided by St John’s Institute of Dermatology (London, United Kingdom)
and combined a historical data set (n 5 177) with patients ascertained
prospectively (n 5 78) through the Anakinra in Pustular Psoriasis,
Response in a Controlled Trial (APRICOT) clinical trial (EudraCT no.
2015-003600-23) and its sister mechanistic study, Pustular Psoriasis,
Elucidating Underlying Mechanisms (PLUM). An additional 40 affected
subjects (listed as ‘‘others’’ in Table E1) were recruited outside the main
reference centers by clinicians who sent individual samples to the ERASPEN
Consortium or St John’s Institute of Dermatology.
Pustular psoriasis was diagnosed by expert dermatologists based on direct
clinical examination, with the ERASPEN consensus criteria1 used in at least
506 cases. The observation of primary, sterile, macroscopically visible
pustules affecting nonacral skin (GPP), palms/soles (PPP), or the nail
apparatus (ACH) was the main inclusion criterion. Conversely, the occurrence
of pustules restricted to the edges of psoriatic plaques represented an exclusion
criterion.
Mutation screening
IL36RN, AP1S3, and CARD14 mutations were screened by using Sanger
sequencing in 473 patients for whom DNAwas available. Primer sequences and
cycling conditions have been described elsewhere.3,5,6 Nucleotide substitutions
were identified by using Sequencher 4.9 (Gene Codes, Ann Arbor, Mich). The
deleterious effect of the newly identified c.11515G>A mutation was confirmed
by using Spliceman and MaxEntScan,11,12 whereas the pathogenic potential of
CARD14 alleles was assessed with Combined Annotation Dependent Depletion
(CADD).13
Statistics
The clinical and demographic characteristics of study participants were
analyzed by using a binomial test (to establish the presence of a sex bias
among patients with pustular psoriasis), the x2 test with the Yates correction
(to analyze differences in the prevalence of PV and proportion of affected
female subjects across disease types), and a Kruskal-Wallis test followed by
the Dunn multiple comparison test (to analyze differences in age of onset
between PPP, ACH, and GPP cases). Analysis of genetic data was based on
a x2 test with the Yates correction (to compare the frequency of disease alleles
in PPP, ACH, and GPP cases and the combined prevalence of IL36RN
mutations across ethnic groups) and a 1-tailed Fisher exact test (for association
between the IL36RN p.Ser113Leu allele and PPP). Genotype-phenotype
correlations were investigated by implementing logistic (for PV concurrence
and sex ratios) and linear (for age of onset) regression analysis with disease
subtype as a covariate. All tests were implemented in R software.14
Patients with multiple diagnoses were excluded from all statistical analyses
because they could not be assigned to a single disease group.
RESULTS
Age of onset and PV concurrence rates vary
significantly among disease subtypes
As members of the ERASPEN network, we previously defined
consensus criteria for the diagnosis of pustular psoriasis.1 Herewe
build on this work to describe the presentation of key disease
features, as observed in clinical practice. We analyzed 863
unrelated patients, the majority of whom (823/863 [95.4%])
were recruited through 6 European, 1 North African, and 1 Asian
reference center (Table I and see Table E1). Of note, key patients’
demographics (male/female ratios and mean age of onset for
various disease types) were comparable across these
cohorts (see Table E2 in this article’s Online Repository at
www.jacionline.org).
While patients with GPP (251/863 [29.1%]) and PPP (560/863
[64.9%]) accounted for most of the data set, the ACH sample was
substantially smaller (28/863 [3.2%]), reflecting the extreme
rarity of this condition. Of note, the concurrence of multiple
disease forms (most notably GPP with ACH and GPP with PPP)
was reported in a small percentage of affected patients (24/863
[2.8%]).
A number of comorbidities were observed, with diabetes and
hypertension figuring most prominently, regardless of the
patient’s ethnicity (see Table E3 in this article’s Online
Repository at www.jacionline.org). In keeping with published
associations,15 we also found that 11 (3.9%) of 281 European
patients with PPP had autoimmune thyroid disease.
Mean age of onset differed considerably across disease types
and was lower in patients with GPP (31.0 6 19.7 years) than in
those with PPP (43.7 6 14.4, P 5 9.3 3 10219) and those
with ACH (51.8 6 20.4, P 5 1.2 3 1027; Fig 1, A, and see
Table E2). Despite these marked differences, there was
substantial heterogeneity within the individual disease cohorts,
with very early-onset (<10 years) and very late-onset
(>70 years) cases observed in all forms of pustular psoriasis.
Although the prevalence of PV in the overall data set (29.1%)
was much greater than that reported for the general population
(2% to 3%), concurrence rates varied among disease variants. In
particular, the frequency of PV among patients affected by PPP
(15.8%) was significantly lower than that seen in the ACH
(46.2%, P 5 .0004) and GPP (54.4%, P 5 2.2 3 10216) groups
(Fig 1, B). Although the latter result was driven in part by a
very high prevalence of PV among Malaysian patients with
GPP (see Table E2), the difference remained significant
(P 5 .01) when the sizeable Malaysian cohort (n 5 138) was
removed from the analysis. Thus our investigations have
demonstrated key differences between disease subtypes,
highlighting PPP as a late-onset condition with low PV
concurrence.
PPP is the form of pustular psoriasis most
influenced by sex and smoking status
It has been reported that female patients and smokers are at
greater risk of PPP than male patients and nonsmokers.16 Here we
observed a degree of sex bias in all forms of pustular psoriasis as
the female/male ratiowas 1.5 in patients with ACH, 1.7 in patients
with GPP, and 3.5 in patients with PPP. The distortion in sex ratios
TABLE I. Summary description of the patient cohort
Ethnicity Sex Clinical diagnosis
TotalEuropean Asian African Other* Female Male Unknown ACH PPP GPP ACH 1 GPP ACH 1 PPP GPP 1 PPP
Total 591 161 78 33 620 233 10 28 560 251 9 4 11 863
*Includes unknown ethnicity (n 5 19), mixed ethnicity (n 5 4), and Middle Eastern (n 5 4), Finnish (n 5 2), Filipino (n 5 1), Hispanic (n 5 1), Jamaican (n 5 1), and Romani
(n 5 1) ethnicity.
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observed in GPP and PPP was statistically significant (P < 1025
and P < 10215, respectively) and readily recognizable in
individual cohorts (see Table E2). Of note, the difference between
the PPP and GPP female/male ratios was also significant
(P 5 5.8 3 1025), highlighting PPP as the condition most
influenced by sex-related factors (Fig 1, C).
In our data set 79.8% (249/312) of patients with PPP for whom
data were available were current or past smokers. Of interest, the
rate of PV concurrence was much greater in patients with PPP
who smoked (or had done so in the past) compared with thosewho
did not (12.4% vs 1.6%, P 5 .009), suggesting that cigarette
smoking can modulate disease manifestations. In fact, smoking
has a well-documented effect on aryl hydrocarbon
receptor signaling,17 a pathway that modulates the severity of
inflammation in psoriatic skin.18
Although the ACH sample was too small for analysis, the
percentage of smokers in the GPP data set (26/96 [28.3%]) was
significantly less than that observed in patients with PPP
(P < 10215), indicating that the adverse effect of cigarette
smoking is specific to the latter condition.
Definition of a patient subset for genetic analysis
Having investigated the key clinical manifestations of pustular
psoriasis, we sought to define their relationship with the patient’s
genotype. For this purpose, we examined the mutation status
of 473 affected subjects for whom DNA was available (see
Table E1). We collated genetic data previously generated by our
group (n 5 358)4-6,9 while also examining 115 newly recruited
cases. Importantly, Table E4 in this article’s Online Repository
at www.jacionline.org shows that the patient subset screened for
mutations is representative of the broader data set, suggesting
that the findings obtained in this sample can be generalized to
the whole resource.
Frequency of IL36RN mutations differentiates PPP
from ACH and GPP
The IL36RN coding sequence and exon/intron junctions were
screened in the entire patient resource, uncovering 66 patients
(4 with ACH, 45 with GPP, 12 with PPP, and 5 with multiple
diagnoses) with disease alleles (Table II and see Table E5
in this article’s Online Repository at www.jacionline.org).
Thirty-six of these subjects harbored biallelic (homozygous/
compound heterozygous) changes, with the remaining 30
carrying monoallelic (single heterozygous) variants. All the
observed mutations had been described previously, except for a
c.11515G>A splicing variant uncovered in a North American
patient with GPP (see Table E5).
IL36RN disease alleles were present in a variety of ethnic
groups, with the greatest prevalence observed among patients of
European (34.7%) and East Asian (28.8%) descent (Fig 1, D).
Althoughwe did not detect any rare changes in the 21 South Asian
cases we examined, a homozygous p.Leu21Promutation has been
described in a Pakistani GPP pedigree,19 suggesting that
deleterious IL36RN alleles can also be found within the Indian
subcontinent.
The proportion of subjects harboring IL36RN disease alleles
was greater in GPP and ACH (23.7% and 18.2%, respectively)
compared to PPP (5.2%). Patients with GPP and those with
ACH were also more likely to carry biallelic mutations compared
to individuals affected by PPP (see Table E5). As a result, the
prevalence of IL36RN mutations was significantly increased in
patients with GPP (0.19) and ACH (0.16) compared with that in
patients with PPP (0.03;P5 1.93 10214 and .0018, respectively;
Table II). Nonetheless, the association between IL36RN
mutations and PPP, which has been recently questioned,10 was
statistically significant. In fact, an analysis of the recurrent
p.Ser113Leu variant showed that its frequency in British
patients was almost 10 times greater than that observed in
population-matched control subjects (P5 9.33 1028; odds ratio,






























































































































FIG 1. Features of pustular psoriasis observed in the disease cohort.
A, Mean age of onset was compared across disease groups by using
a Kruskal-Wallis test followed by the Dunn multiple comparison test.
B, Differences in PV concurrence were analyzedwith a x2 test. C, Differences
in the proportion of affected female subjects were assessed by using a x2
test. The dashed line indicates the percentage of female subjects in the
general population. D, Differences in combined frequency of IL36RN
mutations were assessed across ethnic groups by using a x2 test. Pairwise
comparisons were undertaken with the Fisher exact test. The analysis was
restricted to patients with GPP because this is the only group for which data
were available for multiple ethnicities. Other mutations indicates alleles
seen only once in the cohort. The notation c.11516T>C; p.Pro76Leu refers
to patients carrying the 2 variants on the same haplotype. E, Effects of
IL36RN mutations on age of onset were assessed by using linear
regression. **P < .01, ***P < .001, and ****P < .0001.
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We next sought to determine whether IL36RN alleles were
associated with key features of pustular psoriasis across
disease subtypes. Therefore we implemented a regression
analysis using clinical diagnosis as a covariate. Although we
did not observe a consistent effect of IL36RN mutations on
PV concurrence (see Table E6 in this article’s Online
Repository at www.jacionline.org), we found a significant
association with early age of onset (P 5 .003; Fig 1, E), which
was observed in all 3 forms of the disease (see Table E6). Thus
IL36RN alleles have shared genetic effects across pustular
psoriasis subtypes but occur at a very low frequency among
patients with PPP.
CARD14 mutations are observed in only a small
minority of cases
Although a sizeable patient subset (n 5 106/473) was
sequenced for the entire CARD14 coding region, a targeted
screening of exons 3 and 4 was undertaken in the rest of the
sample, given that the only disease alleles associated with
pustular (p.Asp176His) or plaque (p.Gly117Ser) psoriasis map
to this mutation hotspot.6,20,21
We found 3 previously described6 GPP patients of Chinese
descent bearing the p.Asp176His variant. We did not detect any
CARD14 substitutions among European patients with GPP
but observed 5 British patients with PPP harboring rare
nonsynonymous changes with deleterious potential (see Table
E7 in this article’s Online Repository at www.jacionline.org).
Although most of the above subjects (6/8 [75%]) had concurrent
PV, the small size of the data set prevented us from establishing
genotype-phenotype correlations.
AP1S3 mutations occur with comparable frequency
across disease types
Although a substantial patient subset (n5 249)was screened for
the entire coding region, the rest were sequenced only for exon 2,
given that the only known AP1S3 mutations (p.Phe4Cys,
p.Arg33Trp) map to this genomic segment 2.5,9 This revealed 24
European cases (2 patients with ACH, 4 with GPP, 14 with PPP,
and 4 with multiple diagnoses) bearing the p.Phe4Cys or
p.Arg33Trp changes (see Table E8 in this article’s Online
Repository at www.jacionline.org). No additional mutations were
observed in the subjects who were screened for the entire coding
region. Of note, 3 patients (2 with GPP and 1 with PPP) carried
both AP1S3 and IL36RN disease alleles (see Table E9 in this
article’s Online Repository at www.jacionline.org).
The prevalence of AP1S3 mutations was not significantly
different across disease types (Table II) and did not seem to
influence PV concurrence or age of onset (see Table E10 in this
article’s Online Repository at www.jacionline.org). However, it
was noteworthy that almost all patients with AP1S3 disease
alleles (23/24 [95.8%]) were female. Although this observation
was not statistically significant (P 5 .06), a trend toward female
overrepresentation was apparent in all clinical variants
(see Table E10), suggesting that the penetrance of AP1S3
mutations might be modified by sex-specific factors, such as
hormone levels or X-linked modifiers.
DISCUSSION
The purpose of our study was to robustly define clinical and
genetic features of pustular psoriasis by investigating a patient
cohort of unprecedented size.
Initially, we sought to define the presentation of the various
clinical variants through a rigorous statistical analysis of key
phenotypic features. This work, which builds on the definition of
consensus diagnostic criteria by ERASPEN,1 underscores the
importance of collaborative efforts in the analysis of rare diseases.
Here a common case report form was used in all prospectively
recruited cases, enabling standardized patient phenotyping and
robust data collection. The participation of multiple centers also
allowed us to monitor the effects of ascertainment bias and
show that key patients’ demographics were comparable across
the various data sets.
Our analysis demonstrated novel and significant differences
between disease subtypes. Specifically, it showed that PPP is
associated with patients’ demographics (very high prevalence of
female subjects and smokers), clinical (low rates of PV) and
genetic features (low prevalence of IL36RN mutations) that are
clearly distinct from those observed in ACH and GPP. Given
that abnormal IL-36 signaling has now been implicated in the
pathogenesis of plaque psoriasis,22 it is tempting to speculate
that these observations might be correlated with each other and
that the decreased prevalence of PV in PPP might be linked to
the low frequency of deleterious IL36RN alleles in this patient
group.
We also found that IL36RN mutations are associated with an
earlier age of onset across all variants of pustular psoriasis. This
validates the results we obtained originally in patients with
GPP4 and indicates that IL36RN should be prioritized for
mutation screening when patients have disease symptoms before
TABLE II. IL36RN and AP1S3 mutation frequencies across disease types
ACH GPP PPP Multiple diagnoses
No. of IL36RN-positive patients* 4/23 (17.4%) 45/190 (23.7%) 12/234 (5.1%) 5/18 (27.8%)
IL36RN mutation count (frequency) 7/46 (0.15) 72/380 (0.19) 15/468 (0.03) 8/36 (0.22)
No. of AP1S3-positive patients* 2/19 (10.5%) 4/37 (10.8%) 14/212 (6.6%) 4/11 (36.4%)
AP1S3 mutation count (frequency) 2/38 (0.05) 4/74 (0.05) 14/424 (0.03) 4/22 (0.18)
*Patients were classified as ‘‘positive’’ if they were carrying at least 1 mutation at the examined locus.
p.Phe4Cys and p.Arg33Trp mutations have no frequency in East Asian populations and therefore were not screened in patients from this ethnic group.
TABLE III. Association between IL36RN p.Ser113Leu and PPP
p.Ser113Leu WT
Cases* 11 (3.6%) 291 (96.4%)
Control subjects 26 (0.4%) 7402 (99.6%)
WT, Wild-type.
*British patients only.
Control subjects from publicly accessible cohorts (TWINSUK and ALSPAC).
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the age of 30 years (40 years in the case of ACH/PPP). Given that
biologics that counter the effect of IL36RNmutations by blocking
IL-36 signaling are now under development,23 such targeted
screening could have important implications for patient
management.
Our study showed that IL36RNmutations are the most frequent
genetic abnormality observed in pustular psoriasis. In fact,
deleterious AP1S3 alleles were found in only 7% to 10% of
patients, and CARD14 variants were observed in a very small
number of affected subjects. Importantly, our analysis
demonstrated that known genes account only for a minority of
disease cases. This is especially the case in patients with PPP,
in whom the combined frequency of AP1S3 and IL36RN
mutations is less than 10%. Therefore additional studies will be
needed to illuminate the genetic landscape of this condition,
facilitate its diagnosis, and better understand the correlation
between genotype and clinical phenotype. Although the
discovery of novel genetic determinants has thus far been
hindered by the rarity and heterogeneous nature of the disease,
the ascertainment and rigorous phenotyping of our clinical
resource lays a robust foundation for future gene identification
studies.
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Clinical implications: The association between IL36RN
mutations and early-onset pustular psoriasis defines a patient
group that should be prioritized for IL36RN screening and
might benefit from the development of IL-36 inhibitors.
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